

This is a repository copy of *Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients:the CAFE scoping review and database analyses*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/181090/>

Version: Published Version

---

**Article:**

Bedford, Jonathan, Drikite, Laura, Corbett, Mark Stephen orcid.org/0000-0002-5937-1493 et al. (9 more authors) (2021) Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients:the CAFE scoping review and database analyses. Health Technology Assessment. pp. 1-204. ISSN 2046-4924

<https://doi.org/10.3310/hta25710>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.


## Health Technology Assessment

Volume 25 • Issue 71 • November 2021

ISSN 1366-5278

# Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses

*Jonathan Bedford, Laura Drikite, Mark Corbett, James Doidge, Paloma Ferrando-Vivas, Alistair Johnson, Kim Rajappan, Paul Mouncey, David Harrison, Duncan Young, Kathryn Rowan and Peter Watkinson*





# Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses

Jonathan Bedford<sup>id,1\*</sup> Laura Drikite<sup>id,2</sup> Mark Corbett<sup>id,3</sup>  
James Doidge<sup>id,2</sup> Paloma Ferrando-Vivas<sup>id,2</sup>  
Alistair Johnson<sup>id,4</sup> Kim Rajappan<sup>id,5</sup> Paul Mouncey<sup>id,2</sup>  
David Harrison<sup>id,2</sup> Duncan Young<sup>id,1</sup> Kathryn Rowan<sup>id,2</sup>  
and Peter Watkinson<sup>id,1,6</sup>

<sup>1</sup>Kadoorie Centre for Critical Care Research and Education, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

<sup>2</sup>Intensive Care National Audit and Research Centre, London, UK

<sup>3</sup>Centre for Reviews and Dissemination, University of York, York, UK

<sup>4</sup>Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA

<sup>5</sup>Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

<sup>6</sup>Adult Intensive Care Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

\*Corresponding author

**Declared competing interests of authors:** Peter Watkinson worked part time for Sensyne Health (Oxford, UK); has received grant funding from the National Institute for Health Research (NIHR) and Sensyne Health outside the submitted work; was a member of the Health Technology Assessment (HTA) Elective and Emergency Specialist Care (EESC) Methods Group (2014–17), HTA EESC Panel (2013–18), HTA Prioritisation Committee B (in hospital) (2018–19) and NIHR Invention for Innovation (i4i) Programme for Product Development Awards Committee (2018 to present); and is supported by the NIHR Biomedical Research Centre, Oxford. Kathryn Rowan was a member of the Department of Health and Social Care/UK Research and Innovation COVID-19 Rapid Response Research Initiative and the College of Experts 2020, and was a Health Services and Delivery Research (HSDR) Programme Funding Committee Member (2014–19), HSDR Rapid Service Evaluation Themed Call Committee Member (2017), HSDR Commissioned Board Member (2016) and HTA Trauma Themed Call Board Member (2007–8). Duncan Young received a salary from the University of Oxford (Oxford, UK) during the duration of the work. Jonathan Bedford is funded by an award to the University of Oxford, NIHR Doctoral Research Fellowship 300224.

Published November 2021

DOI: 10.3310/hta25710



This report should be referenced as follows:

Bedford J, Drikite L, Corbett M, Doidge J, Ferrando-Vivas P, Johnson A, *et al.* Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses. *Health Technol Assess* 2021;**25**(71).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus*/MEDLINE, *Excerpta Medica*/EMBASE, *Science Citation Index Expanded* (SciSearch®) and *Current Contents*®/Clinical Medicine.



# Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 17/71/04. The contractual start date was in February 2019. The draft report began editorial review in December 2020 and was accepted for publication in April 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

Copyright © 2021 Bedford *et al.* This work was produced by Bedford *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses

Jonathan Bedford<sup>1\*</sup>, Laura Drikite<sup>2</sup>, Mark Corbett<sup>3</sup>, James Doidge<sup>2</sup>, Paloma Ferrando-Vivas<sup>2</sup>, Alistair Johnson<sup>4</sup>, Kim Rajappan<sup>5</sup>, Paul Mouncey<sup>2</sup>, David Harrison<sup>2</sup>, Duncan Young<sup>1</sup>, Kathryn Rowan<sup>2</sup> and Peter Watkinson<sup>1,6</sup>

<sup>1</sup>Kadoorie Centre for Critical Care Research and Education, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

<sup>2</sup>Intensive Care National Audit and Research Centre, London, UK

<sup>3</sup>Centre for Reviews and Dissemination, University of York, York, UK

<sup>4</sup>Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA

<sup>5</sup>Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

<sup>6</sup>Adult Intensive Care Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

\*Corresponding author [Jonathan.bedford@ndcn.ox.ac.uk](mailto:Jonathan.bedford@ndcn.ox.ac.uk)

**Background:** New-onset atrial fibrillation occurs in around 10% of adults treated in an intensive care unit. New-onset atrial fibrillation may lead to cardiovascular instability and thromboembolism, and has been independently associated with increased length of hospital stay and mortality. The long-term consequences are unclear. Current practice guidance is based on patients outside the intensive care unit; however, new-onset atrial fibrillation that develops while in an intensive care unit differs in its causes and the risks and clinical effectiveness of treatments. The lack of evidence on new-onset atrial fibrillation treatment or long-term outcomes in intensive care units means that practice varies. Identifying optimal treatment strategies and defining long-term outcomes are critical to improving care.

**Objectives:** In patients treated in an intensive care unit, the objectives were to (1) evaluate existing evidence for the clinical effectiveness and safety of pharmacological and non-pharmacological new-onset atrial fibrillation treatments, (2) compare the use and clinical effectiveness of pharmacological and non-pharmacological new-onset atrial fibrillation treatments, and (3) determine outcomes associated with new-onset atrial fibrillation.

**Methods:** We undertook a scoping review that included studies of interventions for treatment or prevention of new-onset atrial fibrillation involving adults in general intensive care units. To investigate the long-term outcomes associated with new-onset atrial fibrillation, we carried out a retrospective cohort study using English national intensive care audit data linked to national hospital episode and outcome data. To analyse the clinical effectiveness of different new-onset atrial fibrillation treatments, we undertook a retrospective cohort study of two large intensive care unit databases in the USA and the UK.

**Results:** Existing evidence was generally of low quality, with limited data suggesting that beta-blockers might be more effective than amiodarone for converting new-onset atrial fibrillation to sinus rhythm and for reducing mortality. Using linked audit data, we showed that patients developing new-onset atrial fibrillation have more comorbidities than those who do not. After controlling for these differences,

patients with new-onset atrial fibrillation had substantially higher mortality in hospital and during the first 90 days after discharge (adjusted odds ratio 2.32, 95% confidence interval 2.16 to 2.48; adjusted hazard ratio 1.46, 95% confidence interval 1.26 to 1.70, respectively), and higher rates of subsequent hospitalisation with atrial fibrillation, stroke and heart failure (adjusted cause-specific hazard ratio 5.86, 95% confidence interval 5.33 to 6.44; adjusted cause-specific hazard ratio 1.47, 95% confidence interval 1.12 to 1.93; and adjusted cause-specific hazard ratio 1.28, 95% confidence interval 1.14 to 1.44, respectively), than patients who did not have new-onset atrial fibrillation. From intensive care unit data, we found that new-onset atrial fibrillation occurred in 952 out of 8367 (11.4%) UK and 1065 out of 18,559 (5.7%) US intensive care unit patients in our study. The median time to onset of new-onset atrial fibrillation in patients who received treatment was 40 hours, with a median duration of 14.4 hours. The clinical characteristics of patients developing new-onset atrial fibrillation were similar in both databases. New-onset atrial fibrillation was associated with significant average reductions in systolic blood pressure of 5 mmHg, despite significant increases in vasoactive medication (vasoactive-inotropic score increase of 2.3;  $p < 0.001$ ). After adjustment, intravenous beta-blockers were not more effective than amiodarone in achieving rate control (adjusted hazard ratio 1.14, 95% confidence interval 0.91 to 1.44) or rhythm control (adjusted hazard ratio 0.86, 95% confidence interval 0.67 to 1.11). Digoxin therapy was associated with a lower probability of achieving rate control (adjusted hazard ratio 0.52, 95% confidence interval 0.32 to 0.86) and calcium channel blocker therapy was associated with a lower probability of achieving rhythm control (adjusted hazard ratio 0.56, 95% confidence interval 0.39 to 0.79) than amiodarone. Findings were consistent across both the combined and the individual database analyses.

**Conclusions:** Existing evidence for new-onset atrial fibrillation management in intensive care unit patients is limited. New-onset atrial fibrillation in these patients is common and is associated with significant short- and long-term complications. Beta-blockers and amiodarone appear to be similarly effective in achieving cardiovascular control, but digoxin and calcium channel blockers appear to be inferior.

**Future work:** Our findings suggest that a randomised controlled trial of amiodarone and beta-blockers for management of new-onset atrial fibrillation in critically ill patients should be undertaken. Studies should also be undertaken to provide evidence for or against anticoagulation for patients who develop new-onset atrial fibrillation in intensive care units. Finally, given that readmission with heart failure and thromboembolism increases following an episode of new-onset atrial fibrillation while in an intensive care unit, a prospective cohort study to demonstrate the incidence of atrial fibrillation and/or left ventricular dysfunction at hospital discharge and at 3 months following the development of new-onset atrial fibrillation should be undertaken.

**Trial registration:** Current Controlled Trials ISRCTN13252515.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 71. See the NIHR Journals Library website for further project information.

# Contents

List of tables	xiii
List of figures	xv
List of abbreviations	xvii
Plain English summary	xix
Scientific summary	xxi
<b>Chapter 1</b> Background	<b>1</b>
Description of the health problem	1
Overall aims and objectives of the study	1
<i>Scoping review</i>	1
<i>Database analysis: RISK-II</i>	2
<i>Database analysis: MIMIC-III and PICRAM</i>	2
Patient and public involvement	2
<b>Chapter 2</b> Scoping review of treatments for new-onset atrial fibrillation	<b>3</b>
Scoping review methods	3
<i>Literature searches</i>	3
<i>Eligibility criteria</i>	3
<i>Data charting</i>	5
<i>Critical appraisal</i>	5
<i>Collating and summarising the results</i>	5
<i>Expert panel review</i>	5
Scoping review results	7
<i>Quantity and quality of the research available</i>	7
<i>Primary studies of clinical effectiveness and safety</i>	8
<i>Reviews and guidelines</i>	34
<i>Surveys and opinion pieces</i>	35
<i>Definitions used for new-onset atrial fibrillation</i>	36
<i>Recommendations for and barriers to future research</i>	36
<i>Expert panel review</i>	37
<b>Chapter 3</b> Database analysis part 1: RISK-II database	<b>39</b>
Database analysis part 1: methods	39
<i>Data sources</i>	39
<i>Inclusion and exclusion criteria</i>	39
<i>Identification of new-onset atrial fibrillation</i>	39
<i>Identification of comorbidities and outcomes</i>	41
<i>Selection of matched comparators</i>	41
<i>Statistical analysis</i>	42
Database analysis part 1: results	42
<i>Data linkage and matching</i>	42
<i>How common is new-onset atrial fibrillation in critical care?</i>	42
<i>What are the typical characteristics of patients with new-onset atrial fibrillation in critical care and how to do these compare with other patients in critical care?</i>	44

<i>What are the outcomes for patients with new-onset atrial fibrillation in critical care and how do these compare with those for other patients in critical care?</i>	44
<i>How much of the difference in outcomes is explained by differences in patient characteristics and comorbidities?</i>	44
<i>Sensitivity analysis</i>	48
<b>Chapter 4 Database analysis part 2: intensive care unit databases</b>	<b>49</b>
Database analysis part 2: methods	49
<i>Study design</i>	49
<i>Study population</i>	49
<i>Exposure and outcomes</i>	50
<i>Adjustment for confounding</i>	50
<i>Critical Care Health Informatics Collaborative database analysis</i>	51
Database analysis part 2: results	51
<i>Study population</i>	51
<i>Characteristics of new-onset atrial fibrillation in treated patients</i>	55
<i>Association of new-onset atrial fibrillation with hospital mortality</i>	56
<i>New-onset atrial fibrillation treatments</i>	56
<i>Adjustment for confounding</i>	56
<i>Rate control</i>	56
<i>Rhythm control</i>	57
<i>Hospital survival</i>	60
<i>Haemodynamic changes associated with atrial fibrillation onset</i>	60
Summary	60
<b>Chapter 5 Expert panel</b>	<b>65</b>
<b>Chapter 6 Discussion</b>	<b>67</b>
Statement of principal findings	67
<i>Scoping review</i>	67
<i>The RISK-II database analysis</i>	69
<i>The MIMIC-III and PICRAM database analysis</i>	69
Strengths and limitations	70
Uncertainties	71
<b>Chapter 7 Conclusions</b>	<b>73</b>
Implications for service provision	73
Suggested research priorities	73
<b>Acknowledgements</b>	<b>75</b>
<b>References</b>	<b>77</b>
<b>Appendix 1 Search strategy</b>	<b>85</b>
<b>Appendix 2 Risk-of-bias assessment</b>	<b>91</b>
<b>Appendix 3 Data extraction tables for single-group studies</b>	<b>111</b>
<b>Appendix 4 Excluded studies</b>	<b>129</b>
<b>Appendix 5 RISK-II supplementary material</b>	<b>141</b>

<b>Appendix 6</b> Intensive care unit databases supplementary material	<b>147</b>
<b>Appendix 7</b> Critical Care Health Informatics Collaborative database analysis	<b>167</b>
<b>Appendix 8</b> Expert panel details	<b>171</b>



# List of tables

<b>TABLE 1</b> Risk-of-bias assessments for large non-randomised studies	<b>6</b>
<b>TABLE 2</b> Overview of the primary study evidence by active intervention and study design	<b>9</b>
<b>TABLE 3</b> Methods and characteristics of RCTs	<b>11</b>
<b>TABLE 4</b> Results of RCTs	<b>14</b>
<b>TABLE 5</b> Methods and characteristics of prospective comparative studies (non-RCTs) of NOAF treatments	<b>16</b>
<b>TABLE 6</b> Results of prospective comparative studies (non-RCTs) of NOAF treatments	<b>19</b>
<b>TABLE 7</b> Methods and characteristics of retrospective comparative studies of NOAF treatments	<b>21</b>
<b>TABLE 8</b> Methods and characteristics of retrospective comparative studies of NOAF treatments (further information)	<b>28</b>
<b>TABLE 9</b> The ICD-10 diagnosis codes and OPCS-4 procedure codes	<b>40</b>
<b>TABLE 10</b> Classification of AF in the RISK-II database	<b>41</b>
<b>TABLE 11</b> Patient characteristics and comorbidities	<b>44</b>
<b>TABLE 12</b> Outcomes for patients with NOAF in critical care	<b>45</b>
<b>TABLE 13</b> Regression models: main results	<b>47</b>
<b>TABLE 14</b> Characteristics of included patients	<b>54</b>
<b>TABLE 15</b> Methods and characteristics of prospective single-group studies	<b>112</b>
<b>TABLE 16</b> Results of prospective single-group studies	<b>117</b>
<b>TABLE 17</b> Methods and characteristics of retrospective single-group studies	<b>119</b>
<b>TABLE 18</b> Results of retrospective single-group studies	<b>126</b>
<b>TABLE 19</b> Excluded studies on full text with reason for exclusion	<b>129</b>
<b>TABLE 20</b> Regression model coefficients for mortality after hospital discharge	<b>141</b>
<b>TABLE 21</b> Regression model coefficients for subsequent hospitalisation	<b>141</b>
<b>TABLE 22</b> Sensitivity analysis: patient characteristics and comorbidities	<b>142</b>
<b>TABLE 23</b> Sensitivity analysis: outcomes	<b>142</b>

<b>TABLE 24</b> Sensitivity analysis: regression models, main results	<b>145</b>
<b>TABLE 25</b> Characteristics of patients with NOAF vs. those without: MIMIC-III database	<b>147</b>
<b>TABLE 26</b> Characteristics of patients with NOAF vs. those without: PICRAM database	<b>147</b>
<b>TABLE 27</b> Characteristics of included patients by treatment group: MIMIC-III database	<b>148</b>
<b>TABLE 28</b> Characteristics of included patients by treatment group: PICRAM database	<b>150</b>
<b>TABLE 29</b> Unweighted and weighted covariate means by treatment group: MIMIC-III database	<b>151</b>
<b>TABLE 30</b> Unweighted and weighted covariate means by treatment group: PICRAM database	<b>153</b>
<b>TABLE 31</b> Unadjusted and adjusted HRs for each outcome and associated 95% CIs: MIMIC-III database	<b>155</b>
<b>TABLE 32</b> Unadjusted and adjusted HRs for each outcome and associated 95% CIs: PICRAM database	<b>155</b>
<b>TABLE 33</b> Unadjusted and adjusted HRs for each outcome and associated 95% CIs: combined databases	<b>156</b>
<b>TABLE 34</b> The CCHIC database analysis patient characteristics	<b>168</b>
<b>TABLE 35</b> Expert panel members and roles	<b>171</b>
<b>TABLE 36</b> Research recommendation 1: amiodarone vs. beta-blockers	<b>173</b>
<b>TABLE 37</b> Research recommendation 2: risk stratification tools for anticoagulation	<b>174</b>
<b>TABLE 38</b> Research recommendation 3: incidence of AF and left ventricular dysfunction	<b>174</b>

# List of figures

<b>FIGURE 1</b> Flow chart showing the number of studies identified, excluded and eligible for inclusion in the scoping review	7
<b>FIGURE 2</b> Record selection and matching	43
<b>FIGURE 3</b> Prevalence of AF in the RISK-II database	43
<b>FIGURE 4</b> Cumulative incidence of mortality from ICU admission, estimated using the Kaplan–Meier method	45
<b>FIGURE 5</b> Cumulative incidence of mortality and hospitalisation after hospital discharge	46
<b>FIGURE 6</b> Study CONSORT flow diagrams	52
<b>FIGURE 7</b> Time from ICU admission to AF onset in treated patients	55
<b>FIGURE 8</b> Total duration of AF per treated patient	56
<b>FIGURE 9</b> Unadjusted and adjusted HRs for rate and rhythm control	58
<b>FIGURE 10</b> Haemodynamic changes associated with AF onset	61
<b>FIGURE 11</b> Sensitivity analysis: mortality from ICU admission	143
<b>FIGURE 12</b> Sensitivity analysis: outcomes after hospital discharge	143
<b>FIGURE 13</b> Cumulative incidence plot of time from treatment to heart rate of < 110 b.p.m. for each treatment: MIMIC-III database	157
<b>FIGURE 14</b> Kaplan–Meier curves of time from achieving rate control to reversion to heart rate of $\geq 110$ b.p.m.: MIMIC-III database	158
<b>FIGURE 15</b> Cumulative incidence plot of time from treatment to heart rate of < 110 b.p.m. for each treatment: PICRAM database	159
<b>FIGURE 16</b> Kaplan–Meier curves of time from achieving rate control to reversion to heart rate of $\geq 110$ b.p.m.: PICRAM database	160
<b>FIGURE 17</b> Cumulative incidence plot of time from treatment to rhythm control for each treatment: MIMIC-III database	161
<b>FIGURE 18</b> Kaplan–Meier curves for each treatment of time from achieving rhythm control to reversion to AF: MIMIC-III database	162
<b>FIGURE 19</b> Cumulative incidence plot of time from treatment to rhythm control for each treatment: PICRAM database	163
<b>FIGURE 20</b> Kaplan–Meier curves for each treatment of time from achieving rhythm control to reversion to AF: PICRAM database	164

## LIST OF FIGURES

**FIGURE 21** Kaplan–Meier survival curves for each treatment group: MIMIC-III database **165**

**FIGURE 22** Kaplan–Meier survival curves for each treatment group: PICRAM database **166**

**FIGURE 23** The CCHIC database analysis flow chart **168**

# List of abbreviations

AF	atrial fibrillation	IQR	interquartile range
aHR	adjusted hazard ratio	i.v.	intravenous
APACHE	Acute Physiology and Chronic Health Evaluation	MgSO <sub>4</sub>	magnesium sulphate
b.p.m.	beats per minute	MIMIC-III	Medical Information Mart for Intensive Care III
CAFE	Critical care Atrial Fibrillation Evaluation	NOAF	new-onset atrial fibrillation
CCHIC	Critical Care Health Informatics Collaborative	OASIS	Oxford Acute Severity of Illness Score
CHR	cause-specific hazard ratio	ONS	Office for National Statistics
CI	confidence interval	OPCS-4	Office of Population Censuses and Surveys <i>Classification of Surgical Operations and Procedures</i>
CMP	Case Mix Programme	OR	odds ratio
COPD	chronic obstructive pulmonary disease	PICRAM	Post Intensive Care Risk-adjusted Alerting and Monitoring
DCC	direct current cardioversion	PPI	patient and public involvement
HES	Hospital Episode Statistics	RCT	randomised controlled trial
HR	hazard ratio	ROBINS-I	Risk Of Bias In Non-randomized Studies – of Interventions
ICD-10	<i>International Classification of Diseases and Related Health Problems, Tenth Revision</i>	RR	relative risk
ICNARC	Intensive Care National Audit & Research Centre	SBP	systolic blood pressure
ICU	intensive care unit	SMD	standardised mean difference



# Plain English summary

## Background

Atrial fibrillation can cause heart failure and stroke. It can also affect heart rate in different ways. It is common for patients admitted to intensive care units to develop atrial fibrillation. When patients have never had atrial fibrillation before, this is called 'new-onset atrial fibrillation'.

We do not know how new-onset atrial fibrillation in patients treated in an intensive care unit affects heart rate and blood pressure, what the best treatments are or how treatments affect how people recover.

## Methods

We looked at studies of new-onset atrial fibrillation treatments in intensive care units to see if some treatments have been shown to work better.

We used a national database to see what happens to intensive care unit patients in the UK who develop new-onset atrial fibrillation. We also used two databases from intensive care units in the UK and the USA to see how many patients in the intensive care units have new-onset atrial fibrillation, how atrial fibrillation affects heart rate and blood pressure, and whether or not some treatments work better than others.

## Results

Between 6% and 11% of intensive care unit patients develop new-onset atrial fibrillation. These patients are more likely to die in hospital and in the first 90 days after discharge than those who do not. They are also more likely to be readmitted to hospital with atrial fibrillation, stroke and heart failure. The evidence for new-onset atrial fibrillation treatments is limited, but suggests that beta-blockers or amiodarone may work better than calcium channel blockers or digoxin.

## Conclusions

New-onset atrial fibrillation in intensive care units is common, and outcomes are worse in patients who develop new-onset atrial fibrillation than in those who do not. Our research shows that some new-onset atrial fibrillation treatments work better than others. This information will help us to plan a study to improve health after new-onset atrial fibrillation.



# Scientific summary

## Background

Of the 170,000 adults treated on UK intensive care units (ICUs) annually, 10,000–20,000 develop new-onset atrial fibrillation (NOAF) and are clustered in subgroups, such as patients with sepsis. NOAF in patients on ICUs can cause cardiovascular instability and thromboembolism. It is independently associated with increases in length of hospital stay, mortality and health-care costs. It may also be associated with increased long-term morbidity and mortality in patients who survive until hospital discharge.

The current atrial fibrillation (AF) treatment guidelines are based on patients outside ICUs. NOAF in patients in an ICU differs in the causes of rhythm disturbance, and the risks and clinical effectiveness of treatments. There is little evidence to guide NOAF treatment on ICUs; consequently, practice varies. It is unclear whether or not NOAF developed in an ICU results in future episodes of AF, heart failure or stroke. Optimal management strategies in ICUs and post ICU discharge are unknown.

## Objectives

### Scoping review

- To evaluate the evidence for the clinical effectiveness and safety of pharmacological and non-pharmacological NOAF treatments.
- To provide guidance for the database analysis on:
  - NOAF definitions used for patients in an ICU
  - patient subgroups who develop NOAF in an ICU
  - inclusion/exclusion of specific treatments and potential confounders
  - determining barriers to future research.

### Database analysis: RISK-II

- To determine how common NOAF is in critical care.
- To determine the typical characteristics of patients with NOAF in critical care and how they compare with those of other patients in critical care.
- To increase the understanding of the outcomes of patients with NOAF in critical care and how they compare with those of other patients in critical care.
- To investigate how much of the difference in outcomes is explained by differences in patient characteristics and comorbidities.

### Database analysis: MIMIC-III and PICRAM

- To compare the use and clinical effectiveness of pharmacological and non-pharmacological NOAF treatments.
- To determine the incidence of short- and long-term NOAF complications.

## Methods

### Scoping review

In March 2019, we searched 13 electronic databases and trial registries, including MEDLINE, EMBASE™ (Elsevier, Amsterdam, the Netherlands) and Cumulative Index to Nursing and Allied Health Literature (CINAHL), without date and language restrictions to identify published and unpublished studies.

Adults aged  $\geq 16$  years in general medical, surgical or mixed ICUs were eligible. We excluded studies of cohorts defined by a single disease or a narrow disease group that are not normally admitted to a general ICU, and studies based on service-specific ICUs. Pharmacological, electrical and other non-pharmacological treatment strategies for treatment or prevention of NOAF and the use of short- or long-term anticoagulation were eligible. Any eligible intervention could be a comparator, as could no treatment, standard care and placebo. Outcomes were rhythm and rate control, length of ICU and hospital stay, mortality (ICU, hospital, 30 days and long term), arterial thromboembolism and adverse treatment effects. Quantitative studies (randomised and non-randomised trials, cohort studies, case series with five or more patients reported, and trial protocols) were eligible. We included reviews, practitioner surveys and opinion pieces.

Two reviewers independently screened titles, abstracts and full-text articles. Discrepancies were resolved through discussion or via a third reviewer. Study details and findings were presented in structured tables and described and summarised narratively.

Included studies were quality assessed using version 2 of the Cochrane risk-of-bias tool for randomised trials and the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) tool for larger non-randomised comparative studies.

### Expert panel

We identified a list of variables from our scoping review that may affect the treatment choice for NOAF. We then circulated this list among our expert panel, who added to and refined the list. We collated a final list of these confounding variables, which was ratified by our expert panel. We repeated this process with definitions of NOAF, interventions of interest and outcomes of interest.

### Database analysis: RISK-II

To investigate the long-term outcomes associated with NOAF, we analysed patient records from the RISK-II database. RISK-II combines anonymised, linked, routinely collected data from the Case Mix Programme national clinical audit of adult intensive care, Hospital Episode Statistics (HES) for England and the Office for National Statistics (ONS) mortality databases. It includes patients admitted to ICUs in England between 1 April 2009 and 31 March 2016. We categorised admissions as involving NOAF, possible NOAF, pre-existing AF or no AF, in accordance with evidence available from the linked HES records.

To compare characteristics and outcomes, we selected a cohort of comparator patients who did not develop NOAF and who were matched on hospital and month/year of admission to an ICU. We identified comorbidities using the *International Classification of Diseases and Related Health Problems*, Tenth Revision, codes from linked HES records. We identified the date and cause of death from linked ONS records. We identified subsequent hospital admissions using linked HES records and classified these as involving AF, stroke or heart failure. We estimated associations between NOAF and outcomes before and after adjustment for patient characteristics and comorbidities using multivariable regression models adjusting for age, sex and comorbidities.

### Database analysis: PICRAM and MIMIC-III

We carried out a retrospective cohort study of two large within-ICU databases from the USA and the UK. We excluded patients with known pre-existing AF or an arrhythmia within 3 hours of ICU admission. We identified the occurrence of AF from observation chart data.

We compared patients who developed NOAF with patients who did not. We analysed the mortality associated with NOAF before and after adjusting for confounding variables. We then identified a cohort of patients who received treatment for their NOAF. We analysed the characteristics of treated NOAF, including time to onset and duration. We also analysed the changes in haemodynamic parameters and vasoactive medication use associated with NOAF onset.

We balanced treatment groups using propensity score weighting. We then investigated the efficacy of different NOAF treatments for rate control, rhythm control and mortality.

## Results

### Scoping review

We screened 3651 articles by title and abstract, identifying 198 articles of potential interest. After full-text screening, we included 25 group studies, 12 reviews, one survey and four opinion pieces.

A limited evidence base was available. Of 25 primary studies included in the review, two were randomised controlled trials (RCTs). Of 11 non-randomised comparative studies, three attempted to control for confounding factors. Where studies attempted to control for confounding, quality assessment still identified concerns that bias might affect results. Most studies were single-group studies lacking a comparator group. Studies used different treatment doses, administration methods and time points to assess the success of conversion to sinus rhythm. Six studies were available as conference abstracts only. Limited evidence from four studies suggested that beta-blockers might be more effective than amiodarone for conversion to sinus rhythm and in reducing mortality. It is unclear whether or not anticoagulant therapy results in a reduction in stroke risk and whether or not the potential benefits outweigh the increased risk of bleeding in ICU patients. No conclusive findings have been reported owing to the low quality of the reviewed evidence and the methodological differences between the included studies. Most studies and reviews concluded that further research is needed urgently.

### Expert panel

The expert panel ratified a list of treatments of interest and confounding variables. The scoping review highlighted that definitions of NOAF in patients on ICUs and definitions of treatment success varied. In the absence of any consensus definition of NOAF, we adopted the agreed definition of AF in patients outside an ICU, namely any AF lasting  $\geq 30$  seconds. We defined time to cardioversion as the time to first reversion of sinus rhythm, and time to rate control as the time to a heart rate of  $< 110$  beats per minute (b.p.m.).

### Database analysis: RISK-II

The analysis included 841,005 ICU admissions for 733,038 patients. We identified 4615 (0.6%) admissions as involving NOAF and a further 3548 (0.4%) as involving possible NOAF. Each admission involving NOAF was matched to six comparator admissions with no AF from the same month/year and ICU. Patients with NOAF were older (mean age 71.5 years vs. 59.1 years) and had higher levels of comorbidity, especially hypertension (66.1% vs. 47.2%), heart failure (24.8% vs. 10.1%) and valvular heart disease (12.5% vs. 6.2%), than the comparator patients. After controlling for these differences, patients with NOAF had substantially higher mortality in hospital and during the first 90 days after discharge than patients who did not [adjusted odds ratio (aOR) 2.32, 95% confidence interval (CI) 2.16 to 2.48; adjusted hazard ratio (aHR) 1.46, 95% CI 1.26 to 1.70, respectively], and higher rates of subsequent hospitalisation with AF, stroke and heart failure [adjusted cause-specific hazard ratio (CHR) 5.86, 95% CI 5.33 to 6.44; adjusted CHR 1.47, 95% CI 1.12 to 1.93; and adjusted CHR 1.28, 95% CI 1.14 to 1.44, respectively) than patients who did not.

**Database analysis: MIMIC-III and PICRAM**

New-onset atrial fibrillation was common in ICU patients, occurring in 1065 out of 18,559 (5.7%) eligible patients in US data and 952 out of 8367 (11.4%) eligible patients in UK data. In the study cohort (patients treated for NOAF), the median time to onset of NOAF was 40 hours, with a median duration of 14.4 hours.

In the combined database analysis, NOAF was associated with a significant increase in heart rate of 18 b.p.m., a reduction in systolic blood pressure of 5 mmHg and an increase in vasoactive-inotropic score of 2.3 (all  $p < 0.001$ ). NOAF was associated with a significantly increased risk of hospital mortality after adjusting for confounding factors (CHR 1.84, 95% CI 1.69 to 2.00; adjusted CHR 1.58, 95% CI 1.45 to 1.71).

In the combined database analysis, we found no differences between beta-blockers and amiodarone in rates of achieving rate control (aHR 1.14, 95% CI 0.91 to 1.44) or rhythm control (aHR 0.86, 95% CI 0.67 to 1.11). We found that digoxin therapy was associated with a lower rate of achieving rate control than amiodarone (aHR 0.52, 95% CI 0.32 to 0.86). We found that calcium channel blocker therapy was associated with a lower rate of achieving rhythm control than amiodarone (aHR 0.56, 95% CI 0.39 to 0.79). These findings were consistent with analyses of individual databases.

**Discussion**

Our scoping review revealed marked differences in the definitions of NOAF and the definitions of treatment success between studies. Limited evidence suggested that beta-blockers might be more effective than amiodarone for conversion to sinus rhythm and mortality outcomes. However, residual bias may explain these assertions. The available literature suggests that it is unclear whether or not the benefits of administering anticoagulants in critically ill patients with NOAF for stroke prevention outweigh the increased risk of bleeding. Reluctance to initiate anticoagulation demonstrated in surveys may be owing to the uncertainty of this risk-benefit balance.

The scoping review was performed using systematic, transparent and robust methods. The bibliographic database searches were comprehensive, maximising identification of relevant studies, while also minimising the possibility of publication or language biases affecting the review. The main limitation of the scoping review was the methodological shortcomings of the studies identified, preventing conclusive findings.

The scoping review allowed definitions of NOAF and treatment success for the database analyses to be agreed following the expert panel meeting, along with a long list of interventions and potential confounders.

Analysis of the RISK-II database identified a group of patients who develop NOAF in critical care who have substantially worse short- and long-term outcomes, including readmission with heart failure and thromboembolism, than similar patients without any record of AF during or prior to ICU admission. However, the group identified by hospital coding is much smaller than that found by analysis of ICU data. Whether or not the findings would be replicated in this larger group is unclear. The increased incidence of stroke suggests that there may be a role for anticoagulation in some patients who develop NOAF during an ICU stay; however, the appropriate patient group, timing and duration of anticoagulation are unknown.

Our within-ICU database analysis found that the treatment of NOAF with digoxin or calcium channel blockers as first-line therapy, compared with amiodarone, is associated with poorer rate control and rhythm control, respectively. Previous studies have suggested that beta-blocker therapy may be associated with better outcomes than amiodarone therapy. Our findings revealed that patients who received beta-blockers were less unwell at admission and more stable around AF onset. After comprehensive adjustment of these factors, there were no identifiable differences in outcomes

between these two treatments. To the best of our knowledge, our ICU database analysis provides the first comparative study of NOAF treatments, where differences between treatment groups around AF onset are adjusted for. The use of routine data provided a sample size large enough to detect differences between these treatment groups. However, it is limited by its retrospective nature and residual unmeasured confounding may contribute to any identified effects.

### Applicability

Our RISK II database analysis included national data and our results are, therefore, meaningful for most general adult ICUs in the UK. Our within-ICU database analysis included data from tertiary centres and district general hospitals in the UK, alongside data from the USA, suggesting that our findings are applicable elsewhere.

## Conclusions

Our scoping review highlighted the need for standardised definitions in future research into NOAF.

We found that NOAF during an ICU stay is common and is associated with substantially increased mortality, after correction for associated risk factors. Identifying optimal treatment strategies is a research priority, with the potential to improve patient outcomes. Both amiodarone and beta-blockers are commonly used but have significant side effects. Whether or not one is superior to the other is unknown. A RCT of amiodarone compared with beta-blockers for the management of NOAF in critically ill patients should be undertaken. Current evidence does not support the use of calcium channel blockers or digoxin as first-line therapy for undifferentiated patients who develop NOAF during an ICU stay.

There is little evidence for or against anticoagulation for patients who develop NOAF in an ICU. The risk of thromboembolism is increased compared with those who do not develop NOAF, even when corrected for known risk factors. However, current risk stratification tools have not been validated in the 'new-onset atrial fibrillation during intensive care unit population' and do not take account of within-ICU factors that may affect future outcome. Whether or not subgroups of patients who develop NOAF while in an ICU may benefit from long-term anticoagulation is unknown. Studies should be undertaken to create risk stratification tools or investigate whether or not current tools are applicable to the 'new-onset atrial fibrillation during intensive care unit population' to identify patients sufficiently at risk of future thromboembolism to merit consideration of anticoagulation.

Readmission with heart failure and thromboembolism increases over the 5 years following an episode of NOAF while in an ICU, particularly in the first year. Whether or not these events are driven by persistent left ventricular dysfunction and/or AF is unknown. A prospective cohort study to demonstrate the incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following development of NOAF should be undertaken.

## Trial registration

This trial is registered as ISRCTN13252515.

## Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 71. See the NIHR Journals Library website for further project information.



# Chapter 1 Background

## Description of the health problem

New-onset atrial fibrillation (NOAF) is defined as atrial fibrillation (AF) that occurs in a patient with no known history of chronic or paroxysmal AF.<sup>1</sup> It is a common arrhythmia in critically ill patients.<sup>2</sup> It occurs in 5–15% of all patients admitted to a general intensive care unit (ICU),<sup>3,4</sup> rising to 23% of patients with septic shock.<sup>5</sup>

Organised atrial activity is important for ventricular filling and cardiac output.<sup>6</sup> NOAF is temporally associated with a reduction in cardiac output in non-ICU patients.<sup>7</sup> The haemodynamic impact of NOAF in critically ill patients is poorly understood, but limited data suggest that NOAF may precede haemodynamic instability<sup>8</sup> and may be associated with increased rates of thromboembolism.<sup>9</sup> NOAF during critical illness is associated with an increased risk of death in an ICU and in hospital.<sup>10,11</sup> There is also a significant organisational impact of NOAF because it is associated with an increased length of ICU and hospital stay, and higher health-care costs.<sup>12</sup>

New-onset atrial fibrillation during critical illness may carry a long-term burden. Patients who develop NOAF during sepsis and survive to hospital discharge have an increased risk of heart failure and stroke, and poorer 1-year and 5-year survival.<sup>13,14</sup> The long-term outcomes for patients who develop NOAF in an ICU remains unclear.

It is not known whether NOAF in patients in an ICU is causally related to worse outcomes or whether NOAF may be solely a marker of disease severity. However, there is clear mechanistic plausibility behind a causal association. This demonstrates the need for optimal prevention, management and follow-up. Although a recent scoping review has broadly described studies of NOAF treatment in patients in an emergency department or an ICU, or after major surgery,<sup>10</sup> an in-depth review of NOAF in patients in an ICU focusing on treatment efficacy is required to put current treatment practices into context and to inform future comparative studies.

Clear guidelines exist for the management of AF in patients in the community.<sup>15</sup> However, there is a paucity of evidence for its management in the critical care setting, for which the balance of risks and benefits associated with different treatment options is unclear. Understandably, there is significant variation within and between units in the management of this common problem.<sup>16</sup> Many previous studies informing NOAF treatment in ICUs are small or inadequately adjusted for confounding factors. Well-conducted, multicentre, observational studies are required to highlight candidate interventions for clinical trials.

## Overall aims and objectives of the study

### Scoping review

- To evaluate the evidence for the clinical effectiveness and safety of pharmacological and non-pharmacological NOAF treatments.
- To provide guidance for the database analysis on:
  - NOAF definitions used for patients in an ICU
  - patient subgroups who develop NOAF in an ICU
  - inclusion/exclusion of specific treatments and potential confounders
- determining barriers to future research.

### *Database analysis: RISK-II*

- To determine how common NOAF is in critical care.
- To determine the typical characteristics of patients with NOAF in critical care and how they compare with other patients in critical care.
- To increase the understanding of the outcomes of patients with NOAF in critical care and how they compare with other patients in critical care.
- To investigate how much of the difference in outcomes is explained by differences in patient characteristics and comorbidities.

### *Database analysis: MIMIC-III and PICRAM*

- To compare the use and clinical effectiveness of pharmacological and non-pharmacological NOAF treatments.
- To determine the incidence of short- and long-term NOAF complications.

## **Patient and public involvement**

Patient and public involvement was vital throughout the study. Valerie Keston-Hole and Rob Lawrence helped to develop the application, which was also reviewed by the Oxford Critical Care Patient Forum. The group strongly supported the use of existing databases for the purposes of undertaking the work. Valerie Keston-Hole sits on the group, which assesses applications for the use of the Post Intensive Care Risk-adjusted Alerting and Monitoring (PICRAM) data used in this work. Ian and Cathy Taylor provided us with a clear patient perspective when working with the expert panel and also helped us to choose research recommendations. Meetings went well and easy access to the chief investigator meant that things that were unclear could be explained by e-mail afterward and further thoughts considered. In discussion with Ian and Cathy Taylor, we identified that an area that we would improve in the future was how to present large numbers of initial data in a more comprehensible manner to our patient and public involvement (PPI) colleagues. A suggestion for the future would be to provide supplementary information that avoided technical terminology to help the understanding of the data by our PPI colleagues prior to the meetings. This would allow more spontaneous comments and discussion during the meeting. Our PPI work is not complete. We discussed our findings at the ICU patient forum. This helped us to understand how to clearly communicate our findings.

## Chapter 2 Scoping review of treatments for new-onset atrial fibrillation

Parts of this chapter are adapted with permission from Drikite *et al.*<sup>17</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

### Scoping review methods

The scoping review followed the methodological framework described by Arksey and O'Malley,<sup>18</sup> Levac *et al.*<sup>19</sup> and Daudt *et al.*,<sup>20</sup> and the reporting complies with the recently published Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) reporting guidelines.<sup>21</sup>

### Literature searches

The search strategy was developed by an information specialist in MEDLINE (via Ovid®; Wolters Kluwer, Alphen aan den Rijn, the Netherlands) without any date or language restrictions. The search strategy included terms used to describe NOAF combined with a set of terms used for critical care.

An adapted MEDLINE search strategy was used to search the following databases in March 2019: MEDLINE, EMBASE™ (Elsevier, Amsterdam, the Netherlands), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science™ [Clarivate Analytics, Philadelphia, PA, USA; including Conference Proceedings Citation Index – Science (Clarivate Analytics)], OpenGrey, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE; searched from 1994 to 2015). We were not able to search the National Guideline Clearinghouse, as suggested in our protocol,<sup>22</sup> because this database was no longer available. The following clinical trial databases were searched for studies in progress or completed but not reported: International Standard Randomised Controlled Trial Number (ISRCTN), ClinicalTrials.gov, the EU Clinical Trials register, additional World Health Organization International Clinical Trials Registry Platform (ICTRP) trial databases and the National Institute for Health Research Clinical Trials Gateway.

The search results were imported into EPPI-Reviewer 4 software (Evidence for Policy and Practice Information and Co-ordinating Centre, University of London, London, UK) and duplicates were removed. The search strategies can be found in *Appendix 1*. The reference lists of included review articles and studies were also reviewed to identify any relevant studies.

### Eligibility criteria

The eligibility criteria used to screen titles, abstracts and full-text articles were as follows.

- Population:
  - Studies of adults (age  $\geq 16$  years) with NOAF (or without any history of AF, for prevention/prophylactic studies) admitted to general medical, surgical or mixed ICUs were included.
  - Studies of cohorts defined by a single disease or narrow disease group not normally admitted to a general ICU (e.g. myocardial infarction) and studies based on service-specific ICUs (e.g. cardiothoracic or neurosurgical) were excluded.

- Studies in which a majority (> 50%) of patients belonged to a single, specific disease or operative cohort (e.g. liver resections or lung surgery) and cohorts with a known history of chronic or paroxysmal AF were excluded.
- Studies of disease groups commonly admitted to an ICU, such as sepsis and septic shock, were included.
- Studies of patients with supraventricular arrhythmias if AF constituted at least 70% of arrhythmias were included. Where these data were unavailable, we included studies that grouped AF and atrial flutter together if no other arrhythmia types were included.
- Studies reporting on populations that were a mixture of NOAF and known AF were included only if data for the NOAF subgroup were reported separately.
- Studies that included both ICU and non-ICU patients, but which did not present results separately, were included only if > 50% of the total cohort were ICU patients and if a valid method for confounding adjustment was used with ICU status included as a covariate.
- Intervention:
  - Studies investigating pharmacological, electrical and other non-pharmacological (including electrolyte) treatment strategies for treatment or prevention of NOAF were included.
  - Studies of short- or long-term anticoagulation were included.
  - Studies of ablation or surgical interventions were excluded.
- Comparators:
  - Any eligible intervention could be a comparator, including no treatment or 'standard care'.
  - Placebo was also eligible.
- Outcomes – any of the following outcomes were eligible:
  - rhythm and rate control
  - length of ICU and hospital stay
  - mortality (ICU, hospital, 30 days and long term)
  - arterial thromboembolism and adverse treatment effects
  - in the case of studies of preventative/prophylactic treatments, the incidence of NOAF had to be reported.
- Study design – we included quantitative studies with the following designs:
  - randomised and non-randomised trials
  - cohort studies and case series containing five or more patients
  - practitioner surveys and opinion pieces (for research recommendations and interventions not otherwise identified) were also included.

Two reviewers independently screened titles and abstracts and potentially relevant full-text articles. Any discrepancies between the reviewers were resolved either through discussion or by a third reviewer if necessary. Titles, abstracts and full-text articles were screened using EPPI-Reviewer 4 software. The screening of titles and abstracts was facilitated by use of the highlighting function in EPPI-Reviewer 4 (which highlights keywords associated with inclusion or exclusion criteria). This function allowed more prompt decisions to be made. After screening the titles and abstracts, all potentially relevant full-text articles were uploaded on Mendeley Reference Manager Software (1.19.5; Elsevier, Amsterdam, the Netherlands) for easy access and sharing purposes.

Full-text articles that were not published in English included papers in French, German, Czech, Chinese and Spanish. These were screened by native speakers. None of the foreign language articles was eligible for the review.

### Data charting

Data-charting forms were developed for the following study designs:

- randomised controlled trials (RCTs)
- prospective comparative studies (non-RCTs)
- retrospective comparative studies
- single-group studies.

The extracted data included the following:

- details of the study (authors, country, setting, sample size and proportion of NOAF patients included in the study)
- population characteristics (primary diagnosis; mean age; proportion of males; severity of illness; proportion of patients on vasopressors; proportion of patients with cardiovascular disease, acute renal failure, acute respiratory failure and mechanical ventilation; mean serum potassium levels; and authors' definition of NOAF)
- description of intervention and comparator(s)
- methods to address confounding (for non-randomised studies)
- results
- any relevant recommendations for the future research.

The data-charting forms were piloted on a small number of studies and were adapted accordingly where necessary. Decisions about which population characteristics to extract were informed by a recent systematic review on risk factors for NOAF on the ICU<sup>23</sup> and a retrospective observational study on predictors for sustained NOAF in the critically ill.<sup>24</sup> All data were extracted by one reviewer and checked by another member of the team; any disagreements would be referred to a third member of the team.

### Critical appraisal

Randomised trials were evaluated using version 2 of the Cochrane risk-of-bias tool (see *Appendix 2*).<sup>25</sup> Non-randomised comparative studies that fulfilled the following criteria were evaluated for risk of bias using the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) tool:<sup>26</sup>

- reported as full papers
- included at least 100 patients per treatment arm
- reported on methods to adjust for confounding.

The ROBINS-I tool was adapted for use in this scoping review by including a stopping rule: the risk-of-bias assessment stopped if a serious or critical risk-of-bias judgement was made for the 'bias due to confounding' domain. For the confounding domain, decisions regarding which covariates should be reported as being controlled for in analyses were made by the clinical experts in the CAFE (Critical care Atrial Fibrillation Evaluation) study team, with supporting references where possible, and are reported in *Table 1*, along with the risk-of-bias judgements.

### Collating and summarising the results

The details of the primary studies were presented in structured tables categorised by study design. For each type of study design, the extent, range and nature of the identified research were described. Study parameters and results were then described and summarised narratively.

### Expert panel review

We convened a face-to-face meeting of expert panel members to review our scoping review results and to inform our subsequent database analysis. We created a list of variables identified from our scoping review that may affect NOAF treatment choice. We then circulated this list among our expert

TABLE 1 Risk-of-bias assessments for large non-randomised studies

Study <sup>a</sup>	Confounding domain		Review prespecified covariates to be controlled or adjusted for	Risk-of-bias judgement	Other domains
	Outcome	Results			
Launey 2019 <sup>27</sup>	Incidence of NOAF	RD 11.9% (95% CI -23.4% to -0.5%) RR 0.58 (95% CI 0.35 to 0.98)	Age, sex, preceding cardiovascular disease, acute renal failure, acute respiratory failure, APACHE score and the use of vasopressors <sup>23</sup>	Serious: <ul style="list-style-type: none"><li>Owing to missing covariates (sex, preceding cardiovascular disease and the use of vasopressors)</li></ul>	NA <sup>c</sup>
Walkey 2016 <sup>28</sup>	Mortality <sup>b</sup>	RR 0.99 (95% CI 0.86 to 1.15) RR 0.75 (95% CI 0.64 to 0.88) RR 0.67 (95% CI 0.59 to 0.77)	Sickness score (e.g. SOFA) or individual components of score	Serious: <ul style="list-style-type: none"><li>Although a comprehensive list of relevant covariates was used, it is unclear how many of the variables were measured at baseline (i.e. just prior to treatment). Acute organ failure was recorded at admission</li><li>Reliability or validity of covariate measurement was low enough to expect the possibility of serious residual confounding</li></ul>	NA <sup>c</sup>
Walkey 2016 <sup>29</sup>	Stroke and bleeding	Stroke: RR 0.85 (95% CI 0.57 to 1.27)  Bleeding: RR 0.97 (95% CI 0.83 to 1.14)	Stroke: age, sex, heart failure, hypertension, diabetes, carotid artery disease, hypercholesterolaemia  Bleeding: $\pm$ illness severity, systemic inflammation, type and location of surgery, nutritional status, invasive devices, and acute coagulopathy and thrombocytopenia	Serious for both outcomes: <ul style="list-style-type: none"><li>Stroke – owing to missing covariates (carotid artery disease and hypercholesterolaemia)</li><li>Bleeding – although a comprehensive list of relevant covariates was used, it is unclear how many of the variables were measured at baseline (i.e. just prior to treatment)</li><li>Reliability or validity of covariate measurement was low enough to expect the possibility of serious residual confounding</li></ul>	NA <sup>c</sup>

APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; NA, not applicable; RD, risk difference; RR, relative risk; SOFA, Sequential Organ Failure Assessment.

a For further details, see *Tables 5 and 7*.

b For groups receiving the following treatments: beta-blockers vs. calcium channel blockers, beta-blockers vs. digoxin and beta-blockers vs. amiodarone.

c Not applicable because a serious risk-of-bias judgement was made for the 'bias due to confounding' domain (see *Critical appraisal*).

panel where it was independently added to and refined. We collated a final list of these confounding variables, which was then ratified by our expert panel. We repeated this process with definitions of NOAF, interventions of interest and outcomes of interest.

## Scoping review results

### Quantity and quality of the research available

Following the removal of duplicates from the articles retrieved by database searches, 3651 articles were screened on their title and abstract. From those screened, 198 articles were identified as of potential interest and were screened on their full text. Two articles were unobtainable: a conference abstract published in 2000 and an old study from 1974 looking at amiodarone as a treatment of supraventricular tachyarrhythmias in critically ill patients. Therefore, copies of the 196 full-text articles were assessed for inclusion in the scoping review and 42 articles were included in the review. One eligible article was identified from checking the reference lists of included review articles. Figure 1 illustrates the flow of the articles throughout the review process and the number of included articles classified by study design. Studies excluded after full-text review are listed in Appendix 4, Table 19.




FIGURE 1 Flow chart showing the number of studies identified, excluded and eligible for inclusion in the scoping review.

## Risk-of-bias assessments

### **Randomised controlled trials**

Two RCTs were included. It was judged that the Balser *et al.*<sup>30</sup> trial gave rise to some concerns about possible bias, primarily owing to the lack of reporting of randomisation methods and the lack of blinding. The Delle Karth *et al.*<sup>31</sup> trial was judged to have a high risk of bias based on the lack of reporting of randomisation methods, coupled with baseline differences in sex and age. Moreover, the trial was not blinded with respect to investigators and caregivers.

### **Non-randomised comparative studies**

Three non-randomised studies<sup>27–29</sup> fulfilled the criteria (see *Critical appraisal*) to be evaluated using the ROBINS-I risk-of-bias tool.

All three of the large, non-randomised studies were judged to have a serious risk of bias owing to confounding. This was a result of either missing covariates in the propensity score matching or the risk of residual confounding as a result of the measurement of the covariates. The two studies by Walkey *et al.*<sup>28,29</sup> stated that some key data were recorded on admission, but that these studies used enhanced administrative data that lacked the detailed sequence of events. Some data relating to the admission time point may not be representative of the time point at which a treatment decision was made. The authors noted other limitations of these two studies, adding that the findings should be ‘considered hypothesis-generating and supportive of the need for future clinical trials to investigate optimal treatment of AF during sepsis’.<sup>28</sup>

### **Primary studies of clinical effectiveness and safety**

Table 2 presents an overview of the primary study evidence identified in the review. Further details are reported in the following sections, according to study design.

### **Randomised controlled trials**

Two small RCTs<sup>30,31</sup> were identified as eligible and were included in the review. Both trials investigated pharmacological treatment strategies for rate control in patients with NOAF. Details of the RCTs are presented in Tables 3 and 4. Two further RCTs<sup>51,52</sup> that studied supraventricular tachycardias were identified, but these were not eligible because < 70% of their study population were diagnosed with NOAF.

A RCT ( $n = 55$ )<sup>30</sup> set in the USA compared esmolol (a beta-blocker) with diltiazem (a calcium channel blocker) in a non-cardiac surgical population. The proportion of patients diagnosed with NOAF was 79% in the esmolol group and 80% in the diltiazem group. Both esmolol and diltiazem were second-line treatments for NOAF because adenosine had been administered before the study treatments. The authors reported that loading and infusion rates were adjusted to achieve a degree of ventricular rate control similar to that achieved with standard dosing regimens used in their surgical ICU. The primary outcome that was reported was the rate of conversion to sinus rhythm. There was no statistically significant difference in conversion rate between the study groups within 2 hours for patients with NOAF: 59% in those who received esmolol and 27% in those who received diltiazem ( $p = 0.067$ ). By 12 hours, 85% of patients who received esmolol had converted back to sinus rhythm, compared with 62% of patients who received diltiazem ( $p = 0.116$ ). No adverse events were reported.

Delle Karth *et al.*<sup>31</sup> conducted a small RCT in Austria comparing diltiazem, an amiodarone (an anti-arrhythmic medication with multiple mechanisms of action) bolus and an amiodarone bolus in combination with 24 hours of infusion in a mixed ICU population. Ninety-five per cent of patients enrolled in the trial ( $n = 57$ ) were diagnosed with NOAF. The first study group received a dose of 25 mg of diltiazem by an intravenous (i.v.) bolus infusion over 15 minutes, followed by a continuous infusion at a rate of 20 mg/hour for a total of 24 hours. The second study group was given a bolus dose of 300 mg of amiodarone, followed by an i.v. infusion over 15 minutes. The third study group was given a dose of 300 mg of amiodarone followed by an i.v. bolus infusion over 15 minutes, which was

TABLE 2 Overview of the primary study evidence by active intervention and study design

	Study details				
Intervention	RCT	Prospective comparative study	Retrospective comparative study	Prospective single-group study	Retrospective single-group study
Pharmacological treatments					
Amiodarone	Delle Karth 2001, <sup>31</sup> n = 60	Gerlach 2008, <sup>32</sup> n = 61	Walkey 2016, <sup>28</sup> n = 3174	Sleeswijk 2008, <sup>39</sup> n = 29	Liu 2016, <sup>41</sup> n = 240
			Cho 2017, <sup>33</sup> n = 448	Slavik 2003, <sup>40</sup> n = not reported	Mitrić 2016, <sup>42</sup> n = 177
			Matsumoto 2015, <sup>34</sup> n = 276		Kanji 2012, <sup>8</sup> n = 139
			Balik 2017, <sup>35</sup> n = 234		Mayr 2004, <sup>43</sup> n = 131
			Mieure 2011, <sup>36</sup> n = 126		Burris 2010, <sup>44</sup> n = 30
			Jaffer 2016, <sup>37</sup> n = 65		
			Brown 2018, <sup>38</sup> n = 33		
Beta-blockers	Balser 1998, <sup>30</sup> n = 55	No studies	Walkey 2016, <sup>28</sup> n = 3174	Nakamura 2016, <sup>45</sup> n = 16	Liu 2016, <sup>41</sup> n = 240
			Matsumoto 2015, <sup>34</sup> n = 276		Kanji 2012, <sup>8</sup> n = 139
			Balik 2017, <sup>35</sup> n = 234		Burris 2010, <sup>44</sup> n = 30
			Mieure 2011, <sup>36</sup> n = 126		
			Jaffer 2016, <sup>37</sup> n = 65		
			Brown 2018, <sup>38</sup> n = 33		
Calcium channel blockers	Delle Karth 2001, <sup>31</sup> n = 60  Balser 1998, <sup>30</sup> n = 55	Gerlach 2008, <sup>32</sup> n = 61	Walkey 2016, <sup>28</sup> n = 3174	No studies	Liu 2016, <sup>41</sup> n = 240
			Mieure 2011, <sup>36</sup> n = 126		Burris 2010, <sup>44</sup> n = 30
			Jaffer 2016, <sup>37</sup> n = 65		
			Brown 2018, <sup>38</sup> n = 33		

continued

Copyright © 2021 Bedford et al. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

TABLE 2 Overview of the primary study evidence by active intervention and study design (*continued*)

Intervention	Study details				
	RCT	Prospective comparative study	Retrospective comparative study	Prospective single-group study	Retrospective single-group study
Propafenone	No studies	No studies	Balik 2017, <sup>35</sup> <i>n</i> = 234	No studies	No studies
Digoxin	No studies	No studies	Walkey 2016, <sup>28</sup> <i>n</i> = 3174	No studies	Liu 2016, <sup>41</sup> <i>n</i> = 240 Burris 2010, <sup>44</sup> <i>n</i> = 30
Ibutilide	No studies	No studies	No studies	Hennersdorf 2002, <sup>46</sup> <i>n</i> = 26 Delle Karth 2005, <sup>47</sup> <i>n</i> = 17	No studies
Magnesium sulphate infusion	No studies	No studies	No studies	Sleeswijk 2008, <sup>39</sup> <i>n</i> = 29	No studies
<b>Prophylactic treatments</b>					
Hydrocortisone	No studies	Launey 2019, <sup>27</sup> <i>n</i> = 261	Kane 2014, <sup>48</sup> <i>n</i> = 109	No studies	No studies
<b>Electrical treatments</b>					
Direct-current cardioversion	No studies	No studies	No studies	Mayr 2003, <sup>49</sup> <i>n</i> = 37	No studies
Electrical cardioversion	No studies	No studies	No studies	No studies	Liu 2016, <sup>41</sup> <i>n</i> = 240 Kyo 2019, <sup>50</sup> <i>n</i> = 85
<b>Anticoagulants</b>					
Anticoagulants	No studies	No studies	Walkey 2016, <sup>29</sup> <i>n</i> = 7522	Slavik 2003, <sup>40</sup> <i>n</i> = not reported	No studies

TABLE 3 Methods and characteristics of RCTs

Study details	Population characteristics			Intervention	Comparator		
First author and year: Balser 1998 <sup>30</sup>	Primary diagnosis: non-cardiac surgical patients			Esmolol: 12.5-mg i.v. bolus, followed by additional 25- to 50-mg boluses every 3–5 minutes until the heart rate was < 110 b.p.m. or a total loading dose of 250 mg was attained. The maintenance infusion was 50 µg/kg/minute for patients receiving > 30 mg. After 15 minutes, patients whose heart rate exceeded 110 b.p.m. received 1–4 boluses of 25 mg, followed by a 50 µg/kg/minute increment in their maintenance infusion. The authors reported that this was repeated after 30 minutes for patients whose heart rate was > 100 b.p.m. Beyond 30 minutes, infusion rates were adjusted by the treating physician to maintain heart rates between 80 and 100 b.p.m. If at any time a patient had symptomatic hypotension or their systolic blood pressure was < 80 mmHg, the infusion rate was decreased by 50% or a phenylephrine infusion was administered, or both	Diltiazem: loading infusion of 20 mg over 2 minutes, immediately followed by a 10 mg/hour maintenance infusion. After 15 minutes, patients whose heart rate was > 110 b.p.m. received an additional loading infusion of 25 mg and a 5 mg/hour increment in their maintenance infusion. After 30 minutes, patients receiving a maintenance infusion of < 15 mg/hour with a heart rate of > 100 b.p.m. received an additional 5 mg/hour increment in their infusion rate. Beyond 30 minutes, infusion rates were adjusted by the treating physician to maintain heart rates between 80 and 100 b.p.m. If at any time a patient had symptomatic hypotension or their systolic blood pressure was < 80 mmHg, the infusion rate was decreased by 50% or a phenylephrine infusion was administered, or both		
Setting: ICU	Primary diagnosis	Esmolol (n)	Diltiazem (n)				
Country: USA	GI/GU	7	13				
Sample size: n = 55 (esmolol, n = 28; diltiazem, n = 27)	Thoracic	9	6				
	Nonthoracic vascular	4	3				
	Neurosurgery	2	3				
NOAF patients: n = 44 (80%) (esmolol, n = 22, 79%; diltiazem, n = 22, 81%)	Other	4	2				
	No surgery	2	0				
	Mean age: esmolol, 66 ± 15 years; diltiazem, 69 ± 11 years						
	Male: esmolol, n = 14 (50%); diltiazem, n = 16 (59%)						
	Severity of illness: APACHE III reported – esmolol, 59 ± 31; diltiazem, 65 ± 24						
	Patients on vasopressors: esmolol, n = 1 (3.57%); diltiazem, n = 3 (11%)						
	Cardiovascular disease	Esmolol, n (%)	Diltiazem, n (%)	Line of NOAF treatment: second line – adenosine given before the study treatment	Line of NOAF treatment: second line – adenosine given before the study treatment		
	Coronary artery disease	10 (36)	13 (48)				
	Recent MI or ischaemia	1 (3.57)	2 (7)				
	Left ventricular hypertrophy	3 (11)	1 (3.7)				
	Patients with acute renal failure: NR						
	Patients with acute respiratory failure: NR						
	Mechanical ventilation at NOAF onset: NR						
	Serum potassium: NR						
	Definition of NOAF: ‘SVT present for as long as 24 hours’						

continued

continued

TABLE 3 Methods and characteristics of RCTs (continued)

Study details	Population characteristics				Intervention	Comparator
First author and year: Delle Karth 2001 <sup>31</sup>	Primary diagnosis:				Diltiazem: 25 mg of diltiazem by i.v. bolus infusion over 15 minutes followed by a continuous infusion at a rate of 20 mg/hour for 24 hours	Amiodarone bolus: a bolus dose of 300 mg of amiodarone followed by i.v. infusion over 15 minutes
Setting: ICU	<b>Primary diagnosis</b>	<b>Diltiazem (n)</b>	<b>Amiodarone bolus (n)</b>	<b>Amiodaron bolus + 24 hours (n)</b>		
Country: Austria	Congestive heart failure	5	4	4	Line of NOAF treatment: first line	Line of NOAF treatment: first line
Sample size: n = 60 (diltiazem, n = 20; amiodarone bolus, n = 20; amiodarone bolus + 24 hours, n = 20)	Coronary artery disease	2	2	–		Amiodarone bolus + 24 hours: a dose of 300 mg of amiodarone followed by an i.v. bolus infusion over 15 minutes followed by a continuous infusion at a rate of 45 mg/hour over 24 hours
	Cardiac surgery	6	9	14		
	Respiratory failure	6	2	1		
	Others	1	3	1		
NOAF patients: n = 57 (95%)	Mean age: diltiazem, 64.8 ± 10 years; amiodarone bolus, 67.8 ± 9 years; amiodarone bolus + 24 hours, 71.2 ± 9 years					Line of NOAF treatment: first line
	Male: diltiazem, n = 15 (75%); amiodarone bolus, n = 17 (85%); amiodarone bolus + 24 hours, n = 11 (55%)					
	Severity of illness: APACHE III score reported – diltiazem, 75.1 ± 35; amiodarone bolus, 76.7 ± 38; amiodarone bolus + 24 hours, 59.7 ± 8					
	Patients on vasopressors at the time of onset: diltiazem, n = 14 (70%); amiodarone bolus, n = 15 (75%); amiodarone bolus + 24 hours, n = 15 (75%)					
	Patients with CVD: diltiazem, n = 13 (65%); amiodarone bolus, n = 15 (75%); amiodarone bolus + 24 hours, n = 18 (90%)					
	Patients with acute renal failure: NR					

Study details	Population characteristics	Intervention	Comparator
	<p>Patients with acute respiratory failure: diltiazem, <math>n = 6</math> (30%); amiodarone bolus, <math>n = 2</math> (10%); amiodarone bolus + 24 hours, <math>n = 1</math> (5%)</p> <p>Mechanical ventilation at NOAF onset: diltiazem, <math>n = 15</math> (75%); amiodarone bolus, <math>n = 17</math> (85%); amiodarone bolus + 24 hours, <math>n = 14</math> (70%)</p> <p>Serum potassium level: NR</p> <p>Definition of NOAF: recent-onset tachycardic AF was defined as 'atrial fibrillation with a rate consistently &gt; 120 beats/minute over a 30-minute period'</p>		
<p>APACHE, Acute Physiology and Chronic Health Evaluation; b.p.m., beats per minute; CVD, cardiovascular disease; GI, gastrointestinal; GU, genitourinary; MI, myocardial infarction; NR, not reported; SVT, supraventricular tachycardia.</p>			

TABLE 4 Results of RCTs

Study	Results	Adverse effects	Recommendations for/barriers to future research
Balser 1998 <sup>30</sup>	<ul style="list-style-type: none"> <li>A total of 59% of patients receiving esmolol converted to sinus rhythm within 2 hours vs. 33% of patients who received diltiazem (intention to treat; <math>p = 0.049</math>)</li> <li>The authors reported conversion rates within 2 hours for patients with NOAF: 59% (esmolol group) vs. 27% (diltiazem group) (<math>p = 0.067</math>)</li> <li>By 12 hours, 85% of patients who received esmolol had converted to sinus rhythm, compared with 62% of patients who received diltiazem (<math>p = 0.116</math>). About 40% of the patients in both groups received magnesium between 2 and 12 hours, and the authors reported that this could have potentially contributed to enhanced rate control and an increased rate of conversion at 12 hours</li> <li>The authors compared the length of ICU stay (days) between the groups and did not find it to differ significantly: esmolol group <math>8.4 \pm 9.5</math> vs. diltiazem group <math>10.6 \pm 13.4</math> days</li> <li>In-hospital mortality was also reported to be not significantly different: 31% in the esmolol group compared with 38% in the diltiazem group</li> </ul>	No adverse effects	<i>Although intuition suggests that ICU patients may benefit from accelerated conversion to sinus rhythm after operation, a much larger trial would be necessary to determine whether early conversion influences outcome</i>
Delle Karth 2001 <sup>31</sup>	<ul style="list-style-type: none"> <li>The number of patients achieving successful rate reduction (<math>\geq 30\%</math>) within 4 hours was not significantly different between the groups: diltiazem group (group 1), <math>n = 14</math> (70%); amiodarone bolus group (group 2), <math>n = 11</math> (55%); amiodarone bolus + 24 hours group (group 3), <math>n = 15</math> (75%) (<math>\chi^2 = 1.95</math>; <math>p = 0.38</math>)</li> <li>The conversion to sinus rhythm within 4 hours was not significantly different between the groups: group 1, <math>n = 6</math> (30%); group 2,</li> </ul>	<ul style="list-style-type: none"> <li>Bradycardia developed in one patient in the diltiazem group. Bradycardia was not observed in the amiodarone groups</li> <li>Hypotension, which resulted in a premature discontinuation of the study medication, occurred more often in the diltiazem group (diltiazem, <math>n = 6/20</math>, 30%; amiodarone bolus, <math>n = 0/20</math>; amiodarone bolus + 24 hours, <math>n = 1/20</math>, 5%) (<math>p = 0.01</math>)</li> </ul>	NR

TABLE 4 Results of RCTs (continued)

Study	Results	Adverse effects	Recommendations for/barriers to future research
	<p><math>n = 8</math> (40%); group 3, <math>n = 9</math> (45%) (<math>p = 0.61</math>). When the amiodarone groups were pooled, the occurrence of sinus rhythm was still not significantly different when compared with the diltiazem group: <math>n = 17/40</math> (42.5%) vs. <math>n = 6/20</math> (30%), accordingly (<math>\chi^2 = 0.88</math>; <math>p = 0.34</math>)</p> <ul style="list-style-type: none"> <li>• A significant heart rate reduction at 24 hours was reported in all groups when compared with the initial heart rate at time 0 (study entry) (<math>p = 0.0001</math> for all). The authors reported a trend towards a poorer rate control beyond 11 hours for the amiodarone bolus group</li> <li>• Diltiazem showed slight but significantly better rate reduction when compared with the amiodarone groups: <math>F_{\text{group 1 vs. 3}} = 32.6</math>, <math>p = 0.0001</math>; <math>F_{\text{over time}} = 179</math>, <math>p = 0.0001</math>; <math>F_{\text{group 1 vs. 2}} = 48.7</math>, <math>p = 0.0001</math>; <math>F_{\text{over time}} = 117</math>, <math>p = 0.001</math></li> <li>• The authors reported no significant difference between the amiodarone groups: <math>F_{\text{group 2 vs. 3}} = 3.02</math>, <math>p = 0.08</math>; <math>F_{\text{over time}} = 102.68</math>, <math>p = 0.0001</math></li> </ul>		
NR, not reported.			

then followed by a continuous infusion at a rate of 45 mg/hour over 24 hours. Reported conversion rates within 4 hours were similar in both groups: 30% converted back to sinus rhythm in the diltiazem group, 40% in the amiodarone bolus group and 45% in the amiodarone bolus in combination with 24-hour infusion group. The authors reported a small number of adverse events (see Table 4).

### Prospective comparative studies

We identified two prospective comparative studies, of which one<sup>32</sup> investigated the effects of pharmacological treatments for NOAF and the other<sup>27</sup> looked at prophylactic treatment to prevent NOAF in patients with septic shock. Details are presented in Tables 5 and 6.

### Pharmacological treatments

Gerlach *et al.*<sup>32</sup> conducted a small study ( $n = 61$ ) that compared the effects of diltiazem with those of amiodarone in a surgical ICU population in the USA.<sup>32</sup> Ninety per cent of the included study participants were diagnosed with NOAF. Both study treatments were administered in accordance with the protocol developed by the participating surgical ICU medical team. The primary outcomes were conversion to normal sinus rhythm at 24 hours, time to conversion and adverse treatment effects. The lengths of ICU

TABLE 5 Methods and characteristics of prospective comparative studies (non-RCTs) of NOAF treatments

Study details	Population characteristics			Intervention	Comparator
First author and year: Gerlach 2008 <sup>32</sup>	Primary diagnosis			Intervention treatment given to patients during the first year of the study. Diltiazem: 0.25 mg/kg i.v. bolus, followed by continuous infusion of 5–15 mg/hour titrated to a heart rate of < 120 b.p.m. Decisions to continue, discontinue or change to oral therapy after 48 hours were at the discretion of the managing physicians	Comparator treatment given to patients during the second year of the study. Amiodarone: 150 mg i.v., over at least 10 minutes, followed by continuous infusion of 1 mg per minute for 6 hours then decreased to 0.5 mg per minute. The decision to continue, discontinue or change to oral therapy after 48 hours was at the discretion of the managing physicians
Setting: surgical ICU	Primary diagnosis	Diltiazem (n)	Amiodarone (n)		
Country: USA	Trauma	5	9		
Sample size: n = 61	Gastrointestinal	15	11		
	Vascular	4	5		
NOAF patients: n = 55 (90%) (diltiazem, n = 28; amiodarone, n = 27)	Other surgery	7	5	Line of NOAF treatment: not specifically reported; however, no other treatments reported	Line of NOAF treatment: not specifically reported; however, no other treatments reported
	Mean age: diltiazem, 68.5 ± 14.6 years; amiodarone, 66.1 ± 16 years				
Male: diltiazem, n = 18 (58%); amiodarone, n = 21 (70%)					
Severity of illness: NR					
Patients on vasopressors at the time of onset: n = 11 (18%) (diltiazem, n = 8, 26%; amiodarone, n = 3, 10%)					
Patients with CVD: n = 11 (18%) (diltiazem, n = 5, 16%; amiodarone, n = 6, 20%)					
Patients with acute renal failure: NR					
Patients with acute respiratory failure: NR					
Mechanical ventilation at NOAF onset: NR					
Serum potassium: NR					
Definition of NOAF: NR					

Study details	Population characteristics			Intervention	Comparator	
First author and year: Launey 2019 <sup>27</sup>	Primary diagnosis: septic shock			A hydrocortisone bolus of 100 mg followed by an infusion of 200 mg/day for 7 days followed by a short wean if the patient remained on vasopressors	No prophylactic treatment	
Setting: five academic ICUs	<b>Infection site</b>	<b>Hydrocortisone, n (%)</b>	<b>No hydrocortisone, n (%)</b>	Line of NOAF treatment: not applicable as prophylactic treatment studied		
Country: France	Intra-abdominal	72 (59)	72 (52)			
Sample size: n = 261 (hydrocortisone, n = 123; no hydrocortisone, n = 138)	Thoracic	24 (20)	32 (23)			
	Urinary	17 (14)	14 (10)			
	Other	10 (8)	20 (14)			
NOAF patients: NA	Mean age: hydrocortisone, 65 ± 13 years; no hydrocortisone, 63 ± 15 years					
	Male: hydrocortisone, 61%; no hydrocortisone, 58%					
	Severity of illness: mean SOFA score (baseline) – hydrocortisone, 10 ± 4; no hydrocortisone, 8 ± 3					
	Mean SAPS II (baseline): hydrocortisone, 56 ± 20; no hydrocortisone, 50 ± 20					
	Mean SOFA score reported (during the first 24 hours of septic shock): hydrocortisone, 13 ± 0; no hydrocortisone, 10 ± 0					
Patients on vasopressors						
	<b>Vasopressors</b>	<b>Hydrocortisone, n (%)</b>	<b>No hydrocortisone, n (%)</b>			
	Noradrenaline	122 (99)	135 (98)			
	Dobutamine	29 (24)	6 (4)			
	Adrenaline	15 (12)	10 (7)			

continued

TABLE 5 Methods and characteristics of prospective comparative studies (non-RCTs) of NOAF treatments (continued)

Study details	Population characteristics		Intervention	Comparator
Patients with CVD				
	CVD	Hydrocortisone, n (%)	No hydrocortisone, n (%)	
	Coronary disease	11 (9)	12 (9)	
	Valvular disease	5 (4)	7 (5)	
Patients with acute renal failure: NR				
Patients with acute respiratory failure: NR				
Mechanical ventilation at NOAF onset: NR				
Serum potassium: NR				
Definition of NOAF: AF was defined as 30 seconds or more of an irregular ventricular rhythm with absent P waves				
b.p.m., beats per minute; CVD, cardiovascular disease; NA, not applicable; NR, not reported; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.				

TABLE 6 Results of prospective comparative studies (non-RCTs) of NOAF treatments

Study	Methods to address confounding	Results	Adverse effects	Recommendations for/barriers to future research
Gerlach 2008 <sup>32</sup>	NR	<ul style="list-style-type: none"> <li>No differences between treatments</li> <li>24-hour conversion rate: diltiazem, 87.1%; amiodarone, 86.7% (<math>p = 0.96</math>)</li> <li>Mean time to conversion: diltiazem, 6.9 hours; amiodarone, 5 hours (<math>p = 0.35</math>)</li> <li>Both groups had similar lengths of ICU stay (mean days <math>\pm</math> SD) (diltiazem, <math>13.5 \pm 11.9</math> days; amiodarone group, <math>11.6 \pm 10.9</math> days; <math>p = 0.54</math>) and hospital length of stay (diltiazem, <math>22.5 \pm 18.9</math> days; amiodarone, <math>24.2 \pm 24.2</math> days; <math>p = 0.76</math>)</li> </ul>	<ul style="list-style-type: none"> <li>Transient hypotension: diltiazem, <math>n = 1</math>; amiodarone, <math>n = 2</math>. In the diltiazem patient, hypotension resolved after decreasing the infusion rate. One amiodarone recipient was treated with fluids; in the other, blood pressure recovered spontaneously</li> </ul>	<i>More studies including randomized controlled trials are needed to compare the use of diltiazem versus amiodarone for conversion of post-operative AF</i>
Launey 2019 <sup>27</sup>	The authors used inverse probability of treatment weighting using a multivariable logistic regression model to estimate the probability of treatment. Covariates included multiple measures of sepsis severity including admission severity scores and maximum doses of vasoactive medication	<ul style="list-style-type: none"> <li>In the weighted sample, the proportions of patients who developed AF were 28.8% and 16.8% in the no-hydrocortisone and hydrocortisone groups, respectively. The risk difference was <math>-11.9\%</math> (95% CI <math>-23.4\%</math> to <math>-0.5\%</math>; <math>p = 0.040</math>) and the RR was 0.58 (95% CI 0.35 to 0.98; <math>p = 0.041</math>)</li> </ul>	NR	<i>It would be interesting to study high-risk patients who develop AF and the short- and long-term outcomes in patients treated or not with hydrocortisone</i>

CI, confidence interval; NR, not reported; RR, relative risk; SD, standard deviation.

and hospital stays were also reported. The authors found no statistically significant differences between the study groups in the conversion rate at 24 hours and in the time to conversion. Similar lengths of ICU and hospital stays were also reported. One patient in the diltiazem group and two patients in the amiodarone group developed transient hypotension. This study was small and, therefore, probably underpowered to detect any treatment differences. No power calculations were reported and methods to account for confounding factors were not reported as being used in the analysis.

### Prophylactic treatments

A study<sup>27</sup> set in five French academic ICUs assessed the effect of hydrocortisone to prevent NOAF in 261 patients diagnosed with septic shock. Hydrocortisone was administered at the discretion of the attending physician, although a study treatment schedule was recommended. Patients who received hydrocortisone were more severely ill than those who did not. The unadjusted ICU and 28-day mortalities in the hydrocortisone group were higher than in the no-hydrocortisone group [37% vs. 24% ( $p = 0.018$ ) and 38% vs. 26% ( $p = 0.036$ ), respectively]. No relative risks (RRs) for ICU and 28-day mortality were reported in the study. However, in the propensity score-weighted analysis, patients who

received hydrocortisone were less likely to develop NOAF than those who did not. The risk difference between the groups was 11.9% and the RR of developing NOAF was 0.58 [95% confidence interval (CI) 0.35 to 0.98], which indicates a benefit of hydrocortisone.

### Retrospective comparative studies

Nine retrospective comparative studies<sup>28,29,33–38,48</sup> were identified, with sample sizes ranging between 33 and 7522 patients. Seven studies<sup>28,29,33–36,48</sup> had a sample size of > 100 patients. Six studies took place in the USA,<sup>28,29,36–38,48</sup> two in Asia<sup>33,34</sup> and one in Europe.<sup>35</sup> All studies were published after 2010. Five studies<sup>33,34,36,37,48</sup> were available only as conference abstracts; therefore, limited data were available. None of the studies reported treatment adverse events. Details of these studies can be found in Tables 7 and 8.

### Pharmacological treatments

Seven studies<sup>28,33–38</sup> investigated the effects of pharmacological treatments. Four studies included patients with sepsis<sup>28,33</sup> or septic shock<sup>35,37</sup> as their primary diagnosis. One study<sup>38</sup> was conducted in a surgical population and two studies<sup>34,36</sup> did not clearly specify the type of ICU and study population. A study by Walkey *et al.*<sup>28</sup> was not limited to an ICU population. A large proportion of studies did not report on the dose<sup>28,33,36–38</sup> or the mode of administration<sup>33,36–38</sup> of any treatment given. One study<sup>33</sup> investigated the treatment effects of rate and rhythm control strategies, but the conference abstract did not report which specific interventions were studied. Outcomes reported included cardioversion to sinus rhythm,<sup>33–36,38</sup> mortality<sup>28,33,35,37</sup> and lengths of ICU and hospital stays.<sup>37</sup>

Most of the larger studies<sup>28,34–36</sup> (sample size > 100 patients) compared amiodarone with beta-blockers (e.g. landiolol and metoprolol). A large study<sup>28</sup> from the USA reported that patients treated with amiodarone were more likely than patients treated with beta-blockers to be critically ill with septic shock. The RR of hospital mortality for patients who received beta-blockers compared with patients who received amiodarone was 0.67 (95% CI 0.59 to 0.77) after adjustment for confounding, which indicates a better outcome for patients with beta-blockers. However, the patient characteristics between these groups were different and the matching of groups in the NOAF cohort was not reported. Balik *et al.*<sup>35</sup> reported higher ICU mortality in patients receiving amiodarone (40%) than in patients receiving metoprolol (21%); however, this was reported as being not statistically significant. Three studies<sup>34–36</sup> compared conversion rates between amiodarone and beta-blockers, and found that rates of conversion to sinus rhythm were slightly, but not significantly, higher in patients receiving beta-blockers. However, Balik *et al.*<sup>35</sup> did not adjust for confounding factors such as sickness score. Matsumoto *et al.*<sup>34</sup> and Mieure *et al.*<sup>36</sup> did not report the methods used for the analysis.

Walkey *et al.*<sup>28</sup> compared outcomes in patients who received digoxin and those who received beta-blockers. Following propensity score matching ( $n = 1932$ ), the RR of hospital mortality for patients who received beta-blockers compared with patients who received digoxin was 0.75 (95% CI 0.64 to 0.88), which indicates a better outcome for patients treated with beta-blockers.<sup>28</sup> However, only around 60% of patients in the propensity score-matched cohorts were ICU patients, and the study was restricted to patients with sepsis; therefore, this study's results should not be considered applicable to a broad ICU population. Moreover, the study was judged as being at a serious risk of bias owing to confounding (see *Risk-of-bias assessments*).

Four studies<sup>28,36–38</sup> investigated the effects of calcium channel blockers (e.g. diltiazem). Walkey *et al.*<sup>28</sup> found no statistically significant difference in mortality between patients who received beta-blockers and patients who received calcium channel blockers (RR 0.99, 95% CI 0.86 to 1.15). Similarly, a conference abstract by Jaffer *et al.*<sup>37</sup> reported no statistically significant difference in death at discharge between patients administered beta-blockers and patients administered calcium channel blockers. Two studies<sup>36,38</sup> compared conversion rates between patients who were administered calcium channel blockers and patients who were administered either amiodarone<sup>36</sup> or beta-blockers. No meaningful conclusions from the results of these two studies could have been made owing to the small sample sizes.

TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments

Study details	Population characteristics	Intervention	Comparator												
First author and year: Balik 2017 <sup>35</sup>	Primary diagnosis: septic shock	Propafenone: the median total dose of propafenone was 2.5 g (IQR 1.0–4.0 g). The length of therapy was 5.0 days (IQR 2.0–8.5 days)	Amiodarone: median total dose of amiodarone was 3.0 g (IQR 1.8–4.6 g), given by infusion over 4 days (2–6 days)												
Setting: 15-bed general ICU	Primary sources of septic shock: respiratory (57.3%), abdominal (25.2%), urosepsis (7.3%), wound/surgical (5.2%), catheter related (4.2%), maxillofacial (0.4%), neuroinfection (0.4%)														
Country: Czechia	Mean age: amiodarone, 67.8 ± 11.4 years; propafenone, 66.8 ± 11.3 years; metoprolol, 60.9 ± 8.3 years	Line of NOAF treatment: first and second line	Line of NOAF treatment: first and second line												
Sample size: n = 234 (amiodarone, n = 177; propafenone, n = 42; metoprolol, n = 15)	Male: n = 139 (59.4%)		Metoprolol: the median i.v. metoprolol dose was 84 mg/day (48–120 mg/day)												
NOAF patients: n = 163 (69.7%)	Severity of illness at the start of the anti-arrhythmic therapy:		The median length of therapy was 5 days (2–9 days)												
	APACHE II – amiodarone, 25 ± 11.4; propafenone, 23.2 ± 11.1; metoprolol, 19.4 ± 11.9		Line of NOAF treatment: first line												
	SOFA – amiodarone, 11.1 ± 4; propafenone, 10.2 ± 4; metoprolol, 7.0 ± 4.2														
	Patients on vasopressors:														
	<table><tr><th>Vasopressor</th><th>Amiodarone, n (%)</th><th>Propafenone, n (%)</th><th>Metoprolol, n (%)</th></tr><tr><td>Dobutamine</td><td>24 (16.9)</td><td>6 (7.7)</td><td>–</td></tr><tr><td>Vasopressin</td><td>10 (7)</td><td>2 (2.6)</td><td>–</td></tr></table>	Vasopressor	Amiodarone, n (%)	Propafenone, n (%)	Metoprolol, n (%)	Dobutamine	24 (16.9)	6 (7.7)	–	Vasopressin	10 (7)	2 (2.6)	–		
Vasopressor	Amiodarone, n (%)	Propafenone, n (%)	Metoprolol, n (%)												
Dobutamine	24 (16.9)	6 (7.7)	–												
Vasopressin	10 (7)	2 (2.6)	–												
	Patients with CVD: n = 117 (50%) (amiodarone, n = 79, 56%; propafenone, n = 34, 43.6%; metoprolol, n = 4, 28.6%)														
	Patients with acute renal failure: n = 64 (27.4%)														
	Patients with acute respiratory failure: NR														
	Mechanical ventilation at NOAF onset: n = 232 (99.1%) (although does not specify whether or not this was at the onset)														
	Serum potassium level (mmol/l): amiodarone, 4.4 ± 0.6; propafenone, 4.4 ± 0.6; metoprolol, 4.3 ± 0.5														
	Definition of NOAF: NR														
continued															

TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments (continued)

Study details	Population characteristics	Intervention	Comparator
First author and year: Cho 2017 <sup>33</sup> (conference abstract)	Primary diagnosis: sepsis	Rhythm control (43.5% patients): amiodarone used in 95.4% of rhythm control cohort	Rate control (56.7% patients)
Setting: medical ICU	Mean age: 68.2 years		Line of NOAF treatment: not specified
Country: Republic of Korea	Male: 68.9%	Line of NOAF treatment: not specified	
Sample size: $n = 448$	Severity of illness: median CHA <sub>2</sub> DS <sub>2</sub> -VASc score, 3; median APACHE II score, 24		
NOAF patients: 100%	Patients on vasopressors: 59.9% (at the time of NOAF onset)		
	Patients with CVD: NR		
	Patients with acute renal failure: NR		
	Patients with acute respiratory failure: NR		
	Mechanical ventilation at NOAF onset: 84.5%		
	Serum potassium level: NR		
	Definition of NOAF: NR		
First author and year: Jaffer 2016 <sup>37</sup> (conference abstract)	Primary diagnosis: septic shock	Amiodarone (administered to 49% of patients)	Calcium channel blockers (administered to 15% of patients) and beta-blockers (administered to 12% of patients)
Setting: ICU	Mean age: NR	Line of NOAF treatment: not specified	
Country: USA	Male: 56%		Line of NOAF treatment: not specified
Sample size: $n = 65$	Severity of illness: NR		
NOAF patients: 100%	Patients on vasopressors: NR		
	Patients with CVD: NR		
	Patients with acute renal failure: NR		
	Patients with acute respiratory failure: NR		
	Mechanical ventilation at NOAF onset: NR		

Study details	Population characteristics	Intervention	Comparator
First author and year: Kane 2014 <sup>48</sup> (conference abstract)	Serum potassium level: NR	Hydrocortisone (median duration 4.2 days, IQR 1.1–8.1 days)	No treatment  Line of NOAF treatment: not applicable
	Definition of NOAF: NR		
	Primary diagnosis: septic shock		
	Mean age: NR		
	Male: NR		
	Severity of illness: mean APACHE IV score reported, 97 ± 32.5		
	Patients on vasopressors: NR		
	Patients with CVD: NR		
	Patients with acute renal failure: NR		
	Patients with acute respiratory failure: NR		
Setting: ICU	Male: NR	Line of NOAF treatment: not applicable as prophylactic treatment studied	
	Country: USA		
	Sample size: <i>n</i> = 109 (hydrocortisone, <i>n</i> = 39)		
	NOAF patients: not applicable as prophylactic treatment studied		
	Patients with acute renal failure: NR		
	Patients with acute respiratory failure: NR		
	Mechanical ventilation at NOAF onset: NR		
	Serum potassium level: NR		
	Definition of NOAF: NR		
	First author and year: Matsumoto 2015 <sup>34</sup> (conference abstract)		
Mean age: NR			
Male: NR			
Severity of illness: NR			
Patients on vasopressors: NR			
Patients with CVD: NR			
Patients with acute renal failure: NR			
Patients with acute respiratory failure: NR			
NOAF patients: 100%			

continued

**TABLE 7** Methods and characteristics of retrospective comparative studies of NOAF treatments (*continued*)

Study details	Population characteristics	Intervention	Comparator
	Mechanical ventilation at NOAF onset: NR		
	Serum potassium level: NR		
	Definition of NOAF: NR		
First author and year: Brown 2018 <sup>38</sup>	Primary diagnosis: oesophagectomy, <i>n</i> = 8; intra-abdominal surgery, <i>n</i> = 9; other surgery, <i>n</i> = 9, trauma <i>n</i> = 7	Beta-blockers	Amiodarone and calcium channel blockers
Setting: surgical ICU	Sepsis at the time of onset: <i>n</i> = 16 (48.5%)	Line of NOAF treatment: first line	Line of NOAF treatment: first, second and third
Country: USA	Mean age: median age (IQR) 71 (64–80) years		
Sample size: <i>n</i> = 33	Male: <i>n</i> = 19 (58%)		Sixteen patients (48%) received a second medication owing to failure to restore sinus rhythm, with amiodarone being the most common ( <i>n</i> = 13, 81%)
Initial treatment: beta-blockers, <i>n</i> = 22; amiodarone, <i>n</i> = 6; calcium channel blockers, <i>n</i> = 2; no treatment, <i>n</i> = 3	Severity of illness: NR for baseline or onset characteristics		
	Patients on vasopressors (within 24 hours of NOAF onset): <i>n</i> = 12 (36%)		
	Patients with CVD: coronary artery disease, 20%; stroke, 12%; peripheral vascular disease, 9%		
NOAF patients: 100%	Patients with acute renal failure: NR		
NOAF with rapid ventricular rate	Patients with acute respiratory failure: NR		
	Mechanical ventilation at NOAF onset (only reported for within 24 hours of onset): <i>n</i> = 5 (15%)		
	Serum potassium level: patients with serum potassium of < 4 mmol/l on first laboratory after AF onset, <i>n</i> = 15 (45%)		
	Definition of NOAF: AF occurring in any patient with no documented history of AF		

Study details	Population characteristics					Intervention	Comparator
First author and year: Mieure 2011 <sup>36</sup> (conference abstract)	Primary diagnosis: NR					Amiodarone	Diltiazem
	Mean age: NR					Line of NOAF treatment: not specified	Line of NOAF treatment: not specified
Setting: ICU	Male: NR						Metoprolol
Country: USA	Severity of illness: NR						Line of NOAF treatment: Not specified
Sample size: $n = 126$ (amiodarone, $n = 61$ ; diltiazem, $n = 41$ ; metoprolol, $n = 24$ )	Patients on vasopressors: NR						
	Patients with CVD: NR						
	Patients with acute renal failure: NR						
NOAF patients: 100%	Patients with acute respiratory failure: NR						
	Mechanical ventilation at NOAF onset: NR						
	Serum potassium level: NR						
	Definition of NOAF: 'onset 120 beats per minute'						
First author and year: Walkey 2016 <sup>28</sup>	Primary diagnosis: sepsis					Intravenous beta-blocker (metoprolol, esmolol, atenolol, labetalol, propranolol)	Intravenous calcium channel blocker (diltiazem, verapamil)
Setting: 20% of hospitals in the USA	<b>Infection site</b>	<b>Beta-blocker, <math>n</math> (%)</b>	<b>Calcium channel blocker, <math>n</math> (%)</b>	<b>Digoxin, <math>n</math> (%)</b>	<b>Amiodarone, <math>n</math> (%)</b>	Line of NOAF treatment: not specified	Intravenous digoxin (cardiac glycosides, digoxin, digitalis)
Country: USA	Respiratory	3583 (31.7)	5882 (41.4)	3118 (39.3)	2369 (37.8)		Intravenous amiodarone
	Gastrointestinal	2107 (18.7)	1692 (11.9)	1030 (13.0)	896 (14.3)		
	Urinary tract	4173 (37.0)	5439 (38.3)	3008 (37.9)	1980 (31.6)		
	Skin or soft tissue	982 (8.7)	1217 (8.6)	696 (8.8)	507 (8.1)		Line of NOAF treatment: not specified
	Primary bacteraemia or fungaemia	140 (1.2)	150 (1.1)	82 (1.0)	76 (1.2)		
Sample size: $n = 39,693$ (calcium channel blockers, $n = 14,202$ ; beta-blockers, $n = 11,290$ ; digoxin, $n = 7937$ ; amiodarone, $n = 6264$ )	Mean age: beta-blockers, $75.7 \pm 11.3$ years; calcium channel blockers, $75.6 \pm 11.4$ years; digoxin, $77.1 \pm 10.7$ years; amiodarone, $73.1 \pm 11.7$ years						
NOAF patients: $n = 3174$							

continued

TABLE 7 Methods and characteristics of retrospective comparative studies of NOAF treatments (continued)

Study details	Population characteristics	Intervention	Comparator
Note: outcomes reported separately for NOAF patients	Male: beta-blockers, 50.4%; calcium channel blockers, 47.4%; digoxin, 48.5%; amiodarone, 55.1%		
	Severity of illness: NR		
	Patients on vasopressors on first hospital day: beta-blockers, 29.1%; calcium channel blockers, 26.5%; digoxin, 44.1%; amiodarone, 64.0%		
	Patients with CVD: NR		
	Patients with acute renal failure: NR		
	Patients with acute respiratory failure: NR		
	Mechanical ventilation at NOAF onset: NR		
	Serum potassium level: NR		
	Definition of NOAF: AF that was not documented on hospital admission		
First author and year: Walkey 2016 <sup>29</sup>	Primary diagnosis: sepsis		
	Mean age: anticoagulation, 73.2 ± 11.7 years; no anticoagulation, 75.8 ± 11.7 years		
Setting: non-federal US hospitals	Male: anticoagulation, n = 6941 (51%); no anticoagulation, n = 12,035 (42.2%)		
Country: USA	Severity of illness mean (SD) CHA <sub>2</sub> DS <sub>2</sub> -VASc score reported: anticoagulation, 3.4 (1.5); no anticoagulation, 3.6 (1.5)		
Sample size: n = 38,582 (pre-existing AF, n = 31,060)	Patients on vasopressors: anticoagulation, n = 5084 (37.4%); no anticoagulation, n = 10,002 (40.1%)		

Study details	Population characteristics			Intervention	Comparator
NOAF patients: <i>n</i> = 7522 ( <i>n</i> = 5585 analysed with propensity score approach)	Patients with CVD			Intravenous or subcutaneous administration of therapeutic-dose anticoagulant (including i.v. heparin, SC enoxaparin, SC dalteparin, SC fondaparinux)	No anticoagulation
Note: outcomes reported separately for NOAF patients	Cardiovascular disease	Anticoagulation, (N = 13,611) (35.3%), <i>n</i> (%)	No anticoagulation, (N = 24,971) (64.7%), <i>n</i> (%)		Line of NOAF treatment: not applicable
	Heart failure	5712 (42.0)	9792 (39.2)		
	Coronary heart disease or myocardial infarction	4532 (33.3)	7970 (31.9)		
	Valvular heart disease	2010 (14.8)	3348 (13.4)		
	Patients with acute renal failure: anticoagulation, <i>n</i> = 7612 (55.9%); no anticoagulation, <i>n</i> = 15,814 (63.3%)			Patients who received oral anticoagulants as their initial anticoagulant were excluded in the primary analysis	
	Patients with acute respiratory failure: anticoagulation, <i>n</i> = 5308 (39.0%); no anticoagulation, <i>n</i> = 9442 (37.8%)				
	Mechanical ventilation at NOAF onset: NR				
	Serum potassium level: NR				
	Definition of NOAF: ‘incident AF that was not present on admission’			Line of NOAF treatment: not applicable as NOAF treatment not studied	
APACHE, Acute Physiology and Chronic Health Evaluation; CHA <sub>2</sub> DS <sub>2</sub> -VASc, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischaemic attack, vascular disease; CVD, cardiovascular disease; IQR, interquartile range; NR, not reported; SC, subcutaneous; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.					

TABLE 8 Methods and characteristics of retrospective comparative studies of NOAF treatments (further information)

Study	Methods to address confounding	Results	Recommendations for/barriers to the future research
Balik 2017 <sup>35</sup>	Linear regression analysis involving univariate and multivariate testing	<ul style="list-style-type: none"> <li>Amiodarone: restoration to sinus rhythm was observed in 74% of patients in the amiodarone group. Four patients were switched to the amiodarone group from the propafenone group owing to failure to restore sinus rhythm, and one patient from the metoprolol group did so because of haemodynamic instability. Cardioversion was achieved in 114 patients. However, 23.7% of those required additional electric cardioversion. Forty patients (26%) who failed to restore sinus rhythm were switched to the propafenone group during the first 24 hours</li> <li>Propafenone: sinus rhythm was achieved in 88.9% of patients. Forty patients were moved from the amiodarone group to the propafenone group. Four patients were switched from propafenone to amiodarone. Overall cardioversion success rate of 86.1% at 24 hours was reported. Of those, 35.5% needed additional electric cardioversion to achieve sinus rhythm</li> <li>Metoprolol: sinus rhythm was restored in 92.3% of patients without any additional electric cardioversion. One patient was moved to amiodarone infusion</li> <li>The authors reported statistically not significant but higher ICU mortality of amiodarone (40.4%, OR 1.79) than propafenone (30.4%) and metoprolol (21.4%). The 28-day mortality was reported as higher in the amiodarone group (49.6%) than in the propafenone group (39.5%) and metoprolol group (21.4%). In the univariate 1-year survival analysis, long-term survival of the propafenone group was similar to the long-term survival of the metoprolol group. Long-term survival in both the propafenone and the metoprolol group was significantly higher than in the amiodarone group (HR 1.76, 95% CI 1.06 to 2.3; <math>p = 0.02</math>). The authors confirmed the result by multivariate survival analysis. This was corrected for age, dosage of noradrenaline, SOFA score and rate of CRRT (HR 1.58, 95% CI 1.04 to 2.4; <math>p = 0.03</math>). In the univariate analysis, which</li> </ul>	NR

TABLE 8 Methods and characteristics of retrospective comparative studies of NOAF treatments (further information) (continued)

Study	Methods to address confounding	Results	Recommendations for/barriers to the future research
		excluded chronic AF patients, a 1-year mortality benefit in favour of restoration of sinus rhythm in septic shock (HR 0.48; $p = 0.002$ ) was shown. After adjustment for age, dosage of noradrenaline, SOFA score and presence of CRRT, the result was not statistically significant. (HR 0.67; $p = 0.113$ )	
Cho 2017 <sup>33</sup> (abstract)	Propensity matching	<ul style="list-style-type: none"> <li>The authors reported that patients managed by rhythm control strategy showed higher sinus conversion rate than those with rate control strategy (39.8% vs. 19.8%; <math>p &lt; 0.001</math>). However, mortality rate (54.9% vs. 49.3%; <math>p = 0.529</math>) or thromboembolic events (5.5% vs. 7.6%; <math>p = 0.635</math>) did not differ between the two groups</li> </ul>	NR
Jaffer 2016 <sup>37</sup> (abstract)	None	<ul style="list-style-type: none"> <li>The authors reported no significant difference between the groups in the analysis of the primary outcome of mortality or for the secondary outcomes of lengths of ICU and hospital stay. The MELD score (liver function) at the end of the ICU stay for the amiodarone group (<math>20.85 \pm 8.70</math>) was significantly higher (<math>p = 0.03</math>) when adjusted for age and gender than the control (15.40), beta-blocker (12.88) and calcium channel blocker (17.10) groups</li> </ul>	<i>Further investigation into the management of arrhythmias in septic shock is needed to further elucidate the potential benefits and harms of various pharmaceutical agents</i>
Kane 2014 <sup>48</sup> (abstract)	Multivariate regression	<ul style="list-style-type: none"> <li>The authors reported the overall incidence of AF as 34.9%. It was concluded that NOAF was significantly less common in patients who received hydrocortisone than those who did not (20.5% vs. 42.9%; <math>p = 0.022</math>). The authors reported that multivariate regression showed that the receipt of hydrocortisone was significantly associated with a reduction in NOAF (<math>p = 0.006</math>). No differences in mortality, AF requiring intervention or length of stay were reported</li> </ul>	<i>Given the incidence rate of AF in septic shock, a preventative study using [hydrocortisone] may be appropriate. Furthermore, future studies using [hydrocortisone] in this patient population should include AF as a secondary endpoint</i>
continued			

**TABLE 8** Methods and characteristics of retrospective comparative studies of NOAF treatments (further information) (continued)

Study	Methods to address confounding	Results	Recommendations for/barriers to the future research
Matsumoto 2015 <sup>34</sup> (abstract)	NR	<ul style="list-style-type: none"> <li>The authors reported that single-drug pharmacological cardioversion was attempted with amiodarone in 26 cases (50% cardioversion rate). Single-drug pharmacological cardioversion with landiolol was attempted in 42 cases (67% cardioversion rate). The mean time to sinus conversion was 124 minutes (95% CI 66 to 182 minutes) in the amiodarone group and 72 minutes (95% CI 52 to 91 minutes) in the landiolol group. No evidence of difference was found for sinus conversion rates between the amiodarone and landiolol groups. The authors reported that patients receiving landiolol had statistically significant faster sinus rhythm recovery than those who received amiodarone (<math>p &lt; 0.001</math>)</li> </ul>	NR
Brown 2018 <sup>38</sup>	Markov chain analysis to account for patients who have achieved the outcome (sinus rhythm restoration). This analysis recognises that the outcome can be achieved by different medication. No other methods to address confounding were reported	<ul style="list-style-type: none"> <li>The authors reported that amiodarone was the most successful at achieving the rate and rhythm control in both cases, as an initial treatment and as a second-line treatment: six patients (27%) who received beta-blockers as a first-line therapy converted to sinus rhythm vs. five patients (83%) who received amiodarone as a first-line treatment vs. one patient (50%) who received calcium channel blocker as a first-line treatment; 11 patients (85%) who received amiodarone as a second treatment converted to sinus rhythm vs. one patient (33%) who received calcium channel blockers as a second-line treatment converted to sinus rhythm. Markov chains analysis showed that administering amiodarone as a first-, second- or third-line medication was more likely to result in rate and rhythm control than if beta-blockers were administered (<math>p = 0.001</math>)</li> <li>The greatest success rate (92%) to convert to sinus rhythm was when beta-blockers were used first, followed by amiodarone. This may suggest an additive effect of the two medications</li> </ul>	<i>Future studies are needed to further explore this and determine many unknowns including optimal dosing and route, need for anticoagulation, and duration of treatment</i>

TABLE 8 Methods and characteristics of retrospective comparative studies of NOAF treatments (further information) (continued)

Study	Methods to address confounding	Results	Recommendations for/barriers to the future research
Mieure 2011 <sup>36</sup> (abstract)	NR	<ul style="list-style-type: none"> <li>The ventricular rate control to &lt; 100 b.p.m. within 24 hours from initiation of treatment was achieved in 85.2% (52/61) of amiodarone patients, 85.0% (35/41) of diltiazem patients and 87.5% (21/24) of metoprolol patients (<math>p = 1.00</math>). The authors reported that the mean relative heart rate reduction (<math>\pm</math> SD) was <math>40.5 \pm 13\%</math>, <math>38 \pm 16\%</math> and <math>41.9 \pm 12\%</math> in the amiodarone, diltiazem and metoprolol groups, respectively (<math>p = 0.52</math>). Conversion to and maintenance of sinus rhythm throughout the study period occurred in 21.3% of amiodarone patients, 7.3% of diltiazem patients and 37.5% of metoprolol patients (<math>p = 0.013</math>)</li> </ul>	<i>A large randomized controlled trial designed to determine the optimal therapeutic strategy for a heterogeneous cohort of patients with new onset AF with RVR [rapid ventricular rate] is needed</i>
Walkey 2016 <sup>28</sup>	Propensity score matching approach using over 30 covariates covering specific patient demographics, hospital characteristics, prevalent comorbidities, type of acute organ failure and type of infection	<ul style="list-style-type: none"> <li>Beta-blockers vs. calcium channel blockers: no differences in hospital mortality between the groups, RR 0.99 (95% CI 0.86 to 1.15)</li> <li>Beta-blockers vs. digoxin: RR of hospital mortality for patients who received beta-blockers compared with patients who received digoxin was 0.75 (95% CI 0.64 to 0.88), indicating a better outcome for patients treated with beta-blockers</li> <li>Beta-blockers vs. amiodarone: RR of hospital mortality for patients who received beta-blockers compared with patients who received amiodarone was 0.67 (95% CI 0.59 to 0.77), indicating a better outcome for patients treated with beta-blockers</li> </ul>	<i>Our outcome findings should be considered hypothesis generating and supportive of the need for future clinical trials to investigate optimal treatment of AF during sepsis</i>
Walkey 2016 <sup>29</sup>	A propensity score approach was used to adjust for variables representing hospital characteristics, patient demographics, comorbidities, use of intensive care, measures of acute organ dysfunction, source of infection and year of hospitalisation	The authors reported RR of in-hospital ischaemic stroke associated with anticoagulation as 0.85 (95% CI 0.57 to 1.27) for patients with newly diagnosed AF. The RR of bleeding associated with parenteral anticoagulation was reported as 0.97 (95% CI 0.83 to 1.14) for patients with newly diagnosed AF	<i>Whereas current evidence suggests that benefits may not outweigh risks of parenteral anticoagulation for AF during sepsis, further study is warranted to determine optimal timing for restarting treatment with oral anticoagulants among patients with pre-existing AF and long-term anticoagulation strategies after hospitalisation for patients with newly diagnosed AF during sepsis</i>

b.p.m., beats per minute; CRRT, continuous renal replacement therapy; HR, hazard ratio; MELD, Model for End-stage Liver Disease; NR, not reported; OR, odds ratio; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.

In addition, the Mieure *et al.*<sup>36</sup> study was available only as a conference abstract in which the study methods and population characteristics were not reported.

### **Prophylactic treatments**

A small ( $n = 109$  patients) study<sup>48</sup> assessed the association of hydrocortisone with NOAF in patients who were diagnosed with septic shock. The authors concluded that administering hydrocortisone was associated with a reduction in the incidence of NOAF (20.5% in patients who received hydrocortisone vs. 42.9% in those who did not;  $p = 0.022$ ).<sup>48</sup> No evidence of a difference in mortality and length of stay between the study groups was reported. This study was published as a conference abstract; therefore, limited data were available on the study population and analysis.

### **Anticoagulants**

One large study<sup>29</sup> ( $n = 7522$ ) included a subgroup of patients who developed NOAF during sepsis in hospital, of whom just over 60% of whom were treated in an ICU. Rates of in-hospital stroke were low ( $n = 104$ , 1.9%). Given that the length of hospital stay was not reported, the duration of exposure was unclear. Following propensity score matching ( $n = 5585$  analysed) there was no evidence of a difference in rates of in-hospital ischaemic stroke events between patients who did and those who did not receive parenteral anticoagulation (RR 0.85, 95% CI 0.57 to 1.27). Given the low event rate, the study may have had inadequate power to determine whether or not a statistically significant difference exists. There was no statistically significant difference in the risk of bleeding associated with parenteral anticoagulation between the groups (RR 0.97, 95% CI 0.83 to 1.14).

### **Prospective single-group studies**

Six prospective single-group studies<sup>39,40,45–47,49</sup> were included in the review. The sample sizes of the included studies<sup>39,45–47,49</sup> ranged from 16 to 37 patients; one study<sup>40</sup> did not report the sample size. Four studies were undertaken in Europe,<sup>39,46,47,49</sup> one in Asia<sup>45</sup> and one in North America.<sup>40</sup> Five articles<sup>39,40,46,47,49</sup> were published between 2002 and 2008, and one article<sup>45</sup> was published in 2016. One publication<sup>40</sup> was available only as a conference abstract.

One study<sup>45</sup> was conducted in a mixed ICU and one study<sup>40</sup> was conducted in a general ICU. Two studies<sup>47,49</sup> were conducted in specialty ICUs, such as surgical or medical ICUs. The type of ICU was not clearly specified in two studies.<sup>39,46</sup> Four studies<sup>39,45–47</sup> investigated the treatment effects of pharmacological treatments and one study<sup>49</sup> looked at electrical treatments. One study<sup>40</sup> reported both the treatment effects of pharmacological treatments and the preventative effects of anticoagulation for stroke prophylaxis. Details of the prospective single-group studies can be found in *Appendix 3, Tables 15 and 16*.

### **Pharmacological treatments**

Pharmacological treatments such as amiodarone,<sup>40</sup> ibutilide,<sup>46,47</sup> beta-blockers<sup>45</sup> and MgSO<sub>4</sub>–amiodarone step-up scheme<sup>39</sup> were investigated. Four studies<sup>39,40,46,47</sup> reported conversion to sinus rhythm as the primary outcome and one study<sup>45</sup> looked at mortality as an outcome.

Slavik *et al.*<sup>40</sup> investigated the treatment effects of amiodarone; however, results were not clearly reported in this conference abstract.

A study<sup>45</sup> ( $n = 16$ ) set in Japan investigated the effects of switching therapy from landiolol to the Bisoprolol patch (Bisono® tape, Toa Eiyo Corp, Tokyo, Japan) in a mixed ICU population. This study reported that survival was achieved in 81% of the patients in whom switching therapy was introduced. Another very small study<sup>39</sup> ( $n = 29$ ) investigated the effects of a new treatment protocol consisting of the infusion of magnesium sulphate (MgSO<sub>4</sub>) as a first-line therapy and amiodarone as a second-line therapy in the case of no conversion. The study population was mixed and comprised medical and surgical ICU patients who were diagnosed with NOAF. Study treatments were administered as per institutional protocol based on MgSO<sub>4</sub>–amiodarone step-up scheme, for which infusion of amiodarone was started if conversion to sinus rhythm or reduction in the ventricular rate of  $< 110$  beats per

minute (b.p.m.) within 1 hour after the start of  $\text{MgSO}_4$  infusion was not achieved. The authors reported that amiodarone was required in 13  $\text{MgSO}_4$  non-responders, of whom 11 converted to normal sinus rhythm within 24 hours. No adverse events were reported.

Two very small studies<sup>46,47</sup> investigated the treatment effects of ibutilide. Both studies administered i.v. ibutilide, with a maximum dose of 2 mg. Hennesdorf *et al.*<sup>46</sup> ( $n = 26$ ) reported slightly lower conversion rate to sinus rhythm than Delle Karth *et al.*<sup>47</sup> ( $n = 17$ ) (71% vs. 82%, respectively).

### Electrical treatments

A small study<sup>49</sup> ( $n = 37$ ) assessed the effect of direct current cardioversion (DCC) in a surgical ICU population. The treatment for patients with regular supraventricular tachyarrhythmia consisted of a maximum of four consecutive cardioversions with an energy delivery of 50 J, 100 J, 200 J and 300 J. For patients with irregular supraventricular tachycardia, cardioversion was performed with an energy delivery of 100 J, 200 J and 360 J. Thirty-five per cent of patients ( $n = 13$ ) primarily responded to DCC with restoration of sinus rhythm for  $\geq 5$  minutes, of whom 62% ( $n = 8$ ) remained in sinus rhythm at 1 hour. At 24 and 48 hours, 16% and 13.5% of patients remained in sinus rhythm, respectively.

### Anticoagulants

Slavik *et al.*<sup>40</sup> studied i.v. heparin as a prophylactic treatment for stroke; this was used in 36% of NOAF episodes. The authors did not report which anticoagulant was used in the other 64% of NOAF cases. It was reported that stroke prophylaxis was achieved in 91% of NOAF episodes. The authors concluded that the appropriateness of therapy for stroke prophylaxis was 'optimal'. This was decided using prespecified study definitions. Five per cent of the study population experienced major bleeding as a side effect of i.v. heparin.<sup>40</sup> It must be noted that only an abstract was available for this study; therefore, limited data were obtained. Moreover, the definition of 'appropriateness of therapy assessed as optimal, appropriate and inappropriate' was not provided.

### Retrospective single-group studies

Six retrospective single-group<sup>8,41–44,50</sup> studies were identified, with sample sizes ranging from 30 to 240 patients. Four studies<sup>8,41–43</sup> had a sample size of  $> 100$  patients. Two studies were set in each of North America<sup>8,44</sup> and Asia,<sup>41,50</sup> one in Europe<sup>43</sup> and one in Australia.<sup>42</sup> One article<sup>43</sup> was published in 2004 and five articles<sup>8,41,42,44,50</sup> were published between 2010 and 2019.

Four studies<sup>8,42,43,50</sup> were conducted in mixed ICUs, one study in a surgical ICU<sup>44</sup> and one study in a medical ICU.<sup>41</sup> Three studies investigated the treatment effects of pharmacological treatments,<sup>8,42,43</sup> one study investigated electrical treatments<sup>50</sup> and two studies looked at both pharmacological and electrical treatments.<sup>41,44</sup> The details of the retrospective single-group studies can be found in *Appendix 3, Tables 17 and 18*.

### Pharmacological treatments

The following pharmacological treatments were investigated in the included studies: amiodarone,<sup>8,41–44</sup> beta-blockers (e.g. metoprolol, esmolol and sotalol),<sup>8,41,44</sup> calcium channel blockers (e.g. diltiazem)<sup>41,44</sup> and digoxin.<sup>41,44</sup> Two studies<sup>41,44</sup> did not report on the dose and mode of administration of the treatments studied.

Four larger studies<sup>8,41–43</sup> ( $n > 100$  patients) investigated the treatment effects of amiodarone. Conversion rates to normal sinus rhythm ranged from 65% to 87%.<sup>8,41,43</sup> Studies reported different time points for conversion rates; for example, at some point while receiving amiodarone<sup>8</sup> and during the first 48 hours of amiodarone therapy.<sup>43</sup> Maintenance of normal sinus rhythm in patients who had converted back while receiving amiodarone ranged from 49% to 59% at the time of ICU discharge.<sup>8,42</sup> The studies reported different time points at which maintenance of sinus rhythm was achieved, such as until discharge from the ICU.<sup>42</sup> It should be noted that, where reported, the dose and administration of amiodarone were heterogeneous between the studies.<sup>8,42,43</sup> One study<sup>43</sup> reported on treatment adverse effects associated with amiodarone, finding increases in serum concentrations of creatinine and bilirubin.

A study<sup>41</sup> undertaken in a population with sepsis reported that 76% of patients who were given beta-blockers ( $n = 88$ ), 71% of those who were administered calcium channel blockers ( $n = 66$ ) and 55% of those who were given digoxin glycosides ( $n = 27$ ) converted back to sinus rhythm within 7 days after the onset of NOAF. Although some authors also studied the treatment effects of beta-blockers, calcium channel blockers and digoxin, the sample sizes were too small to make any meaningful conclusions<sup>8,44</sup> or the results were not clearly reported.<sup>44</sup>

### Electrical treatments

Kyo *et al.*<sup>50</sup> investigated the effect of electrical cardioversion in a mixed ICU population ( $n = 85$ ). A median of one shock per electrical cardioversion session was reported and the delivered electrical cardioversion energies in the first and second shocks were  $\leq 100$  J in 91% and 83% of all electrical cardioversion patients, respectively. The authors reported successful electrical cardioversion, defined as conversion to sinus rhythm for at least 5 minutes after an electrical cardioversion session, in 48% of patients, and 13% of these patients maintained sinus rhythm until ICU discharge.

Liu *et al.*<sup>41</sup> administered electrical cardioversion to eight patients and reported that 50% of these patients converted back to normal sinus rhythm. No more details on the intervention and outcome were available.

### Reviews and guidelines

Twelve review articles<sup>53–64</sup> were included in the current review. Of these, two were systematic reviews,<sup>53,56</sup> six were narrative review articles<sup>54,57–59,62,64</sup> and four were review articles<sup>55,60,61,63</sup> that proposed a treatment algorithm based on available evidence. Most of the included reviews<sup>53–55,57–61,63,64</sup> ( $n = 10$ ) were published after 2012. No guidelines were identified in this scoping review.

### Systematic reviews

Yoshida *et al.*<sup>53</sup> conducted a systematic review of the epidemiology, prevention and treatment of NOAF in critically ill patients. One database was searched and eligibility criteria were specified for study inclusion in the systematic review. The authors assessed the methodological quality of the included studies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.<sup>65</sup> No studies on NOAF prevention were included in the systematic review and five studies<sup>8,30,39,66,67</sup> investigating treatments for NOAF were eligible. Of the five studies identified by Yoshida *et al.*,<sup>53</sup> three<sup>8,30,39</sup> were eligible for this scoping review and two<sup>66,67</sup> were excluded on outcome. The five included studies, of which one was a RCT,<sup>30</sup> evaluated the clinical effectiveness of NOAF treatments, such as amiodarone, beta-blockers, calcium channel blockers, digoxin, magnesium sulphate and DCC. However, no conclusive findings on the treatment strategies were reported. The authors concluded that the current evidence for the management of NOAF in a general ICU population is very limited and further research is urgently required.

In 2008, Kanji *et al.*<sup>56</sup> published a systematic review of RCTs to assess the treatments of NOAF in non-cardiac ICU patients. Three databases were systematically searched, the study eligibility criteria were clearly specified and a quality assessment of each included RCT was conducted using a basic rating instrument (the Jadad scale<sup>68</sup>). Four RCTs<sup>30,51,52,69</sup> that assessed the efficiency of procainamide (a sodium-channel blocker), flecainide (a sodium-channel blocker), esmolol, amiodarone, verapamil, diltiazem and magnesium were included in the Kanji *et al.*<sup>56</sup> review. Only one RCT<sup>30</sup> identified by Kanji *et al.*<sup>56</sup> was included in this scoping review. Two RCTs<sup>51,52</sup> had a study population consisting of  $< 70\%$  of NOAF patients (and so were not eligible for this scoping review). The other study<sup>69</sup> included in the Kanji *et al.*<sup>56</sup> review investigated patients with AF; however, it was not clear whether or not these patients had NOAF (therefore, this study was excluded on population in this scoping review). The authors were not able to make evidence-based recommendations for pharmacological rhythm conversion strategies for a general ICU NOAF population owing to considerable methodological heterogeneity of the included RCTs. The authors emphasised the need for well-designed and adequately powered RCTs to evaluate treatment strategies for critically ill patients with NOAF. Moreover, they

recommended that future research should address treatments of choice and goals of care using a standardised outcome measure of success.

### Other types of review

The evidence on pharmacological<sup>54,55,57–63</sup> and electrical<sup>55,59,62,63</sup> treatment strategies for NOAF was discussed in the other review articles. Four articles<sup>54,57,59,63</sup> discussed the management of NOAF in sepsis patients and six articles<sup>57,60–64</sup> reviewed the literature on anticoagulation strategies for critically ill patients with NOAF. Four articles<sup>55,60,61,63</sup> proposed an algorithm for the management of NOAF in an ICU setting based on the available evidence.

### Pharmacological treatments

It is widely reported that the management of arrhythmias in critical care settings is a major problem<sup>59,62</sup> and that research on optimal therapeutic strategies for critically ill patients with NOAF is urgently needed.<sup>54,55,57–59,61–63</sup> Some articles<sup>55,58,61</sup> argued that beta-blockers may be a reasonable first-choice treatment given the current evidence of decreased mortality<sup>55</sup> and improved heart rate control.<sup>55,58</sup> By contrast, some authors discussed amiodarone as being a potentially effective treatment<sup>54,57,59,60,62</sup> based on current evidence and its widespread use; however, it was also recognised that amiodarone has potentially significant side effects.<sup>54,60,62</sup> Other pharmacological treatments, such as propafenone,<sup>54,62</sup> calcium channel blockers,<sup>55,62,63</sup> digoxin<sup>54,55,62</sup> and ibutilide,<sup>62</sup> were discussed, but no conclusive findings were made. Four articles<sup>55,60,61,63</sup> proposed a treatment algorithm, but the algorithms should be interpreted cautiously because they were developed based on limited evidence that was not identified and critiqued systematically.

### Electrical treatments

Reviews suggested that DCC might often be unsuccessful<sup>55</sup> and might also be associated with a high relapse rate.<sup>55,62</sup> More evidence in critically ill populations is required to support this<sup>62</sup> and the current findings should be used to guide research in therapy and mechanisms.

### Anticoagulants

A review article<sup>62</sup> concluded that there was no clear evidence of whether or not stroke risk reduction outweighs the increased risk of bleeding when using therapeutic anticoagulation in critically ill patients with NOAF. Labbe *et al.*<sup>64</sup> reported a high frequency of major bleeding events and recommended that anticoagulation therapy should be administered only in patients with the highest risk of arterial thromboembolic events. This assertion of high bleeding rates referenced one study that did not compare bleeding events between patients who received anticoagulation and patients who did not, and one study that found no significant difference in bleeding events between these two patient groups. A patient-centred single-case decision approach of whether or not to use anticoagulant therapy was also suggested in another review.<sup>57</sup> Sibley and Muscedere<sup>61</sup> recommended that anticoagulation therapy should be initiated if AF persists for > 48 hours and in patients with a high risk of arterial thromboembolic events.<sup>61</sup> Only one review article<sup>61</sup> discussed which drug would be appropriate to use for anticoagulation in ICU patients. Unfractionated heparin was reported to be the drug of choice for critically ill patients owing to its short half-life and reversibility with protamine; however, it must be noted that the authors of the review<sup>61</sup> did not provide any references for this statement.

### Surveys and opinion pieces

#### Surveys

Only one survey<sup>16</sup> was identified in the current review. The UK-wide survey on the practice of the management of NOAF in critically ill patients was conducted in 2016 and was sent to all members of the Intensive Care Society (London, UK). A total of 3152 questionnaires were sent and 397 responses were received. The survey included questions on demographic variables of participants and their critical care unit, and a set of questions that aimed to determine the management strategies for NOAF and anticoagulation practice. In total, 72% of respondents were consultants, 46% worked in a district

general hospital and 81% worked in a mixed ICU. The authors reported that 81% of respondents used amiodarone for the treatment of NOAF. Only 12% of respondents reported using beta-blockers. It was reported that 64% of respondents would not use anticoagulant therapy in critically ill patients with NOAF, whereas 31% of respondents would start anticoagulation therapy within 72 hours. The survey revealed that low-molecular-weight or high-molecular-weight heparin was considered appropriate for anticoagulant therapy.

### Opinion pieces

Four opinion pieces<sup>70–73</sup> were identified in the current review. Two<sup>72,73</sup> were published in 2008 and are responses to a systematic review of RCTs investigating the treatments for NOAF in a critically ill, non-cardiac ICU population.<sup>56</sup> Both authors<sup>72,73</sup> agree with the conclusion of Kanji *et al.*:<sup>56</sup> that the evidence is lacking and that the answers still need to be provided. Walton<sup>72</sup> believes that the best agent for use in NOAF is amiodarone because it combines rapid rate control effects and a low risk of precipitating ventricular tachyarrhythmias.<sup>72</sup> However, Trohman<sup>73</sup> favours the use of beta-blockers as the initial pharmacotherapy. Both authors<sup>72,73</sup> emphasised that treatments must be carefully studied to design an evidence-based approach to guide treatment strategies in NOAF patients in an ICU.

Walkey *et al.*<sup>70</sup> recommend beta-blockers as a reasonable first choice of initial AF therapy, given the limited and indirect evidence. The authors also commented on managing the risks of stroke, and concluded that evidence is currently lacking on risks of bleeding and estimates of stroke risk reduction associated with use of anticoagulation in critically ill patients. Therefore, the authors did not recommend using anticoagulation in NOAF patients with elevated bleeding risk because it is not currently known whether or not the benefits outweigh the risks.<sup>70</sup>

Vieillard-Baron and Boyd<sup>71</sup> suggest a non-anti-arrhythmic-based approach to reduce NOAF by optimising electrolytes and fluid status, limiting sympathetic activation and controlling the central venous catheter position before considering any anti-arrhythmic drugs. It must be noted that this treatment strategy was developed by the authors, and was based on the pathophysiology of AF and its risk factors present in patients with sepsis. No high-quality evidence is available to support this treatment approach.

### Definitions used for new-onset atrial fibrillation

Studies varied in how they reported and defined NOAF. Four studies<sup>38,43,47,49</sup> required NOAF to have a heart rate of > 100 b.p.m. and two studies<sup>31,36</sup> required NOAF to have a heart rate of > 120 b.p.m. Nineteen studies<sup>8,27–30,32–35,37,39–42,44–46,48,50</sup> did not provide a heart rate threshold for NOAF. Studies also reported different time periods for which NOAF must be sustained, ranging from 30 seconds to 24 hours.<sup>27,30,31,41,43,47,49</sup> Eighteen studies<sup>8,28,29,32–40,42,44–46,48,50</sup> did not define the time period for which NOAF must be sustained. Six studies<sup>8,28,29,38,39,50</sup> clarified in which instances AF would be considered as new onset; for example, when a patient had no prior history of AF,<sup>38</sup> when a patient had no previous history of atrial tachyarrhythmias and anti-arrhythmic drug use,<sup>39</sup> when AF occurred during an ICU stay,<sup>39,50</sup> and when AF was absent on admission.<sup>28,29</sup> Ten studies<sup>32–35,37,40,44–46,48</sup> did not provide any definition for NOAF.

### Recommendations for and barriers to future research

Most researchers concluded that further prospective research accounting for confounding factors is required to determine the success and clinical implications of prophylactic and rhythm and rate control strategies in critically ill patients with NOAF.<sup>8,27,28,30,32,36,37,39,41,44,45,48,53–58,61,62,70</sup> Moreover, it has been emphasised that the optimal regimens and the best dosing strategies for treatments are yet to be established.<sup>38,42,49</sup> Eight primary studies<sup>31,33–35,40,43,46,47</sup> and four review articles<sup>59,60,63,64</sup> did not provide any recommendations for future research.

Kanji *et al.*<sup>56</sup> recognised that there are very few prospective studies conducted to evaluate the treatment strategies for NOAF in the critically ill population, given the prevalence of NOAF in this population and the

associated morbidity and mortality. Kanji *et al.*<sup>56</sup> argue that the lack of prospective trials is because of the nature of this population. NOAF is considered an emergency, and enrolling these patients into prospective trials is logistically difficult because rapid treatment is often needed. Moreover, the lack of standardised outcome measures, such as the definition of successful cardioversion, was identified as a major limitation. Kanji *et al.*<sup>56</sup> also suggested that grouping AF together with other types of supraventricular tachycardias might be inappropriate because the physiology and their treatment response might be different.

Two primary studies<sup>29,40</sup> and three review articles<sup>61,62,64</sup> that discussed anticoagulation strategies in critically ill patients with NOAF did not provide any recommendations for the future research in this population.

### Expert panel review

We convened an expert panel (see *Appendix 8*) to review the findings of the scoping review to inform definitions, treatments and confounders to be used in the ICU database analysis (see *Chapter 4*). The scoping review highlighted that definitions of NOAF in patients in an ICU and definitions of treatment success varied. In the absence of any consensus definition of NOAF, we adopted the agreed definition of AF in patients outside an ICU: any AF lasting  $\geq 30$  seconds. We defined time to cardioversion as the time to first reversion of sinus rhythm, and the time to rate control was defined as the time to a heart rate of  $< 110$  b.p.m. Two studies<sup>27,41</sup> defined AF as lasting for longer than 30 seconds. No studies provided a definition for time to cardioversion. Where studies defined a heart rate threshold for AF, it was either  $> 100$  b.p.m.<sup>38,43,47,49</sup> or  $> 120$  b.p.m.<sup>31,36</sup> A list of the interventions used in the studies identified in the scoping review was created and reviewed, but was not altered by the expert panel. We then screened our databases for presence of data pertaining to identified interventions. A list of identified and available interventions is shown in *Appendix 8, Treatments to be included in the analysis* and identified but unavailable interventions in *Appendix 8, Treatments of interest, but not possible with our data*. A list of confounding variables was created from those identified in studies in our scoping review. This list was then supplemented through two rounds of individual review by expert panel members, resulting in a final list of confounders that was ratified by the panel. We then screened our databases for the presence of data pertaining to identified confounders. The final list is shown in *Appendix 8, Confounding/matching variables*.



# Chapter 3 Database analysis part 1: RISK-II database

## Database analysis part 1: methods

### Data sources

We analysed patient records from the RISK-II database, which includes anonymised, linked, routinely collected data from (1) the Case Mix Programme (CMP) national clinical audit of adult intensive care,<sup>74</sup> (2) Hospital Episode Statistics (HES) for England and (3) the Office for National Statistics (ONS) mortality database.

Case Mix Programme data are collected for the purpose of service evaluation and quality improvement in critical care.<sup>75</sup> The CMP includes records for each admission to a participating adult high-dependency unit or ICU in England, Wales and Northern Ireland. Not all ICUs participated during the period for which data were extracted; coverage of adult general ICUs increased over the study period, reaching 100% in the final year of extracted data. Some, but not all, specialist ICUs participated (cardiothoracic ICUs were excluded from the analysis; see *Inclusion and exclusion criteria*). The CMP was used to identify the study sample, provide dates for the start and end of hospital admission and critical care, and to identify patient demographics.

The HES database is collected for the purpose of reimbursing NHS trusts for the provision of hospital services. The RISK-II database includes records from the admitted patient care section of HES, which contains one record for each 'episode of care' under one consultant during a hospital admission. One hospital admission may contain multiple episodes of care, one of which would generally correspond to the period in critical care, but there are differences between trusts in the way that these data are recorded; therefore, HES and CMP records do not align consistently. Each HES record includes up to 20 *International Classification of Diseases and Related Health Problems*, Tenth Revision (ICD-10), diagnosis codes and up to 24 *Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures* (OPCS-4) codes that were used to identify NOAF, comorbidities and diagnosis-specific rates of subsequent hospitalisation (see *Identification of new-onset atrial fibrillation*).

The ONS mortality database contains information about all of the deaths registered in the UK, and was used to derive indicators of mortality.

The anonymised RISK-II database is maintained by the Intensive Care National Audit and Research Centre (ICNARC) (London, UK) and was linked by NHS Digital (Leeds, UK) using a standard deterministic algorithm involving the NHS number (a unique patient identifier), date of birth, postcode and sex. The RISK-II database includes CMP records from 1 April 2009 to 31 March 2016, HES records from 1 April 2004 to 31 March 2016 and ONS records from 1 April 2009 to 31 October 2018.

### Inclusion and exclusion criteria

We included the records of patients admitted to an ICU between 1 April 2009 and 31 March 2016 (5 financial years). Contiguous ICU admissions, representing transfers between ICUs and readmissions to an ICU within 1 calendar day, were combined into single records. We excluded admissions to cardiothoracic units, admissions lasting < 4 hours and patients aged < 16 years at the time of ICU admission.

### Identification of new-onset atrial fibrillation

The codes used for identifying health conditions are summarised in *Table 9*. We defined patients as having NOAF during an ICU admission by identifying a CMP record that overlapped with a linked HES

TABLE 9 The ICD-10 diagnosis codes and OPCS-4 procedure codes

Condition	ICD-10 or OPCS-4 code
Atrial fibrillation	
Diagnosis	I48
Atrial ablation/maze procedure <sup>a</sup>	K572, K575, K578, K622 and K623
Pacemaker insertion <sup>a</sup>	K601-19, K731-9, K741-3, K748-9, U311 and U318-9
Direct current cardioversion <sup>a</sup>	K578, X501, X502 and K624
Comorbidities	
Diabetes mellitus	E10-14
Hypertension	I10-15
Prior thromboembolism	I63-4, I74
Valvular heart disease	I08-9, I33-8, Q22-3 and Q2484
Dilated cardiomyopathy	I42
Pulmonary hypertension	I270-2
Heart failure	I50
Subsequent hospitalisation with	
Atrial fibrillation	I48
Stroke	I63
Heart failure	I50

<sup>a</sup> Used only to differentiate NOAF from prior AF.

record that was the first HES record containing an ICD-10 code for AF for that patient anywhere in the database. Adopting a cautious approach to defining NOAF, we excluded patients with a linked HES record relating to the same hospital admission and contained an OPCS-4 procedure code for atrial ablation, pacemaker insertion or DCC during the same hospital admission from this group, because AF may have developed prior to ICU admission.

There are many possible ways that CMP records and HES records can overlap: the HES record may commence on the same day or on an earlier/later date than the CMP record, and similarly may finish on the same day or on an earlier/later date. Many of these scenarios result in uncertainty about whether the AF developed prior to ICU admission, in an ICU or after discharge from an ICU. We, therefore, implemented the following rules for classifying NOAF (*Table 10*):

- If the HES record commenced on the same day as the CMP record, then it was considered NOAF only if there was also a prior HES record from the same hospital admission (i.e. if the patient was admitted straight to an ICU from an emergency room and, therefore, had no prior HES record from that hospital admission then we assumed that the AF developed prior to ICU admission).
- If the HES record commenced on an earlier date than the CMP record, then the AF was assumed to have developed prior to ICU admission and not to represent NOAF.
- If the HES record commenced after the CMP record commenced and finished before the CMP record finished, then the admission was considered to represent NOAF.

If the HES record continued beyond the CMP record, then it was considered NOAF only if the discrepancy was only 1 day (to allow for minor discrepancies in data entry between the systems), otherwise it was assumed that the AF developed after discharge from the ICU. As a sensitivity analysis,

TABLE 10 Classification of AF in the RISK-II database

Overlap between HES and CMP records			
HES record start date	HES record end date	Admitted to hospital on same day as the ICU?	Classification of AF
Before CMP record start	Any	No (by definition)	Pre-existing AF
Same as CMP record start	Any	Yes	Pre-existing AF
Same as CMP record start	Same as or before CMP record end	No	NOAF
Same as CMP record start	After CMP record end (up to 1 day)	No	NOAF
Same as CMP record start	After CMP record end (> 1 day)	No	Subsequent AF <sup>a</sup>
After CMP record start and same as or before CMP record end	Same as or before CMP record end	Either	NOAF
After CMP record start and same as or before CMP record end	After CMP record end (up to 1 day)	Either	NOAF
After CMP record start and same as or before CMP record end	After CMP record end (> 1 day)	Either	Subsequent AF <sup>a</sup>
After CMP record end	After CMP record end (by definition)	Either	Subsequent AF

<sup>a</sup> Classified as NOAF in the sensitivity analysis.

we allowed for any amount of discrepancy in end date provided that other rules were met. This resulted in two possible definitions of NOAF: one for use in the primary analysis and an alternative approach described above for use in the sensitivity analysis. Both, however, reflect a cautious approach to identification of NOAF and exclude many scenarios for which we cannot distinguish NOAF from prior or subsequent AF. This has implications for the interpretation of results that will be highlighted below.

### Identification of comorbidities and outcomes

Comorbidities were identified from any previously linked HES record that contained an ICD-10 diagnosis code for diabetes mellitus, hypertension, thromboembolism, valvular heart disease, dilating cardiomyopathy, pulmonary hypertension or heart failure (see Table 9). The date and cause of death were obtained from the linked ONS records. Subsequent hospital admissions were identified by linked HES records and classified as involving AF, stroke or heart failure.

### Selection of matched comparators

Observational research using routine data has a fixed 'observation window' within which the data are collected (and within the RISK-II database, this window varies across the contributing data sets, as described in Data sources). Patients admitted to an ICU at different points in time are, therefore, followed up for different amounts of time. It is also common for the quality of routine data to vary over time and between contributors to a data set (e.g. between hospitals). To ensure that follow-up and data quality are comparable between patients with NOAF and any comparison group, we selected a cohort of comparators matched on hospital and month/year of admission to ICU.

Comparator patients were selected from all available admissions that were classified as neither NOAF nor prior AF (but including admissions for patients who subsequently developed AF). To ensure that patients with multiple admissions were not over-represented among comparators, one admission was selected at random from each patient's set of candidate comparator admissions for consideration in the

matching process. Matching was then performed with the largest ratio that could be supported while ensuring that at least 99% of patients with NOAF were included in comparisons.

### Statistical analysis

Patient characteristics and comorbidities are reported as median with interquartile range (IQR) or as counts and percentages. To account for varying duration of follow-up of patients admitted at different points in time, outcomes were estimated using time-to-event methods with censoring of patients at the end of the relevant data set's observation window (31 October 2020 for mortality or 30 March 2020 for hospitalisation). Mortality was estimated using the Kaplan–Meier cumulative incidence function from the date of ICU admission and, separately, from the date of hospital discharge among hospital survivors. The cumulative incidences of subsequent hospitalisation with AF, stroke and heart failure were estimated using non-parametric methods to account for the competing risk of death.<sup>76,77</sup> Mortality was assessed at hospital discharge, and at 90 days, 1 year, 3 years and 5 years after hospital discharge, among hospital survivors. The cumulative incidences of hospitalisation with AF, stroke and heart failure were assessed at 1, 3 and 5 years after hospital discharge, among hospital survivors.

We estimated the associations between NOAF and outcomes before and after adjustment for patient characteristics and comorbidities using multivariable regression models adjusting for age, sex and comorbidities. Odds ratios (ORs) for hospital mortality were estimated using logistic regression. Hazard ratios (HRs) for mortality after hospital discharge were estimated using Cox proportional hazard regression. For subsequent hospitalisation with AF, stroke and heart failure, we estimated unadjusted and adjusted cause-specific hazard ratios (CHRs),<sup>78,79</sup> censoring patients at death or the limit of follow-up. The proportional hazard assumption was tested by visual inspection of Schoenfeld residual plots. All covariates were modelled using dummy variables except for age, which was modelled continuously using a restricted cubic spline. Knot positions for the restricted cubic spline were selected in accordance with the recommendations of Harrell.<sup>80</sup>

Finally, results for the primary analysis were compared with a sensitivity analysis that employed an alternative operational definition for NOAF, as detailed in *Identification of new-onset atrial fibrillation*.

## Database analysis part 1: results

### Data linkage and matching

The selection of records is summarised in *Figure 2*. Between 1 April 2009 and 31 March 2016, there were 965,576 admissions to 248 ICUs participating in the CMP, with links available to HES and ONS. After combining multiple records representing transfers and readmissions, a total of 919,801 distinct ICU admissions were extracted. Of these, 841,005 ICU admissions met the inclusion criteria. Of 8203 records identified as NOAF or possible NOAF, 8145 were matched to 48,870 comparators. A total of 4615 (56.7%) patients with NOAF and 27,690 matched comparators were included in the primary analysis.

### How common is new-onset atrial fibrillation in critical care?

Of the 841,005 critical care admissions examined, 4615 (0.6%) admissions had a linked HES record indicating likely NOAF. A further 3548 (0.4%) admissions had a linked HES record indicating possible NOAF but where the HES record continued for > 1 day beyond the CMP record (the latter were included in the sensitivity analysis). Although the prevalence of NOAF using either definition appeared stable over time, the prevalence of prior AF ( $n = 165,150$ , 19.6%) increased over the first 5 years of the observation window (*Figure 3*). A reduction in prior AF in the final year of the data partly reflects the unavailability of procedure codes for identifying atrial ablation and pacemaker insertion in that year (a structural limitation of the database, which did not appear to affect the identification of NOAF).




FIGURE 2 Record selection and matching.




FIGURE 3 Prevalence of AF in the RISK-II database.

***What are the typical characteristics of patients with new-onset atrial fibrillation in critical care and how do these compare with other patients in critical care?***

Patient characteristics and comorbidities are summarised in *Table 11*. Patients with NOAF tended to be older and have higher levels of comorbidity, especially hypertension, heart failure and valvular heart disease, than comparator patients without NOAF.

***What are the outcomes for patients with new-onset atrial fibrillation in critical care and how do these compare with those for other patients in critical care?***

The outcomes are summarised in *Table 12* and are illustrated in *Figures 4* and *5*. Patients with NOAF were more likely to die, both during their hospital admission and after discharge, than comparator patients without NOAF. They were also more likely to be subsequently admitted to hospital with AF, stroke or heart failure.

***How much of the difference in outcomes is explained by differences in patient characteristics and comorbidities?***

Adjusted outcomes are summarised in *Table 13*, with model coefficients provided in *Appendix 5, Tables 20* and *21*. The excess risk of hospital mortality reduced by about half when controlling for differences in patient characteristics and comorbidities (OR 3.22, 95% CI 3.02 to 3.44, before adjustment, reducing to OR 2.32, 95% CI 2.16 to 2.48, after adjustment).

**TABLE 11** Patient characteristics and comorbidities

Characteristic	NOAF patients (N = 4615)	Comparator patients (N = 27,690)
Demographics		
Age (years), mean (SD)	71.5 (11.3)	59.1 (17.8)
Sex (male), n (%)	2646 (57.3)	15,008 (54.2)
Ethnicity, n (%)		
White	4332 (93.9)	25,157 (90.9)
Mixed	7 (0.2)	113 (0.4)
Asian	86 (1.9)	854 (3.1)
Black	48 (1.0)	564 (2.0)
Other	35 (0.8)	294 (1.1)
Not stated	107 (2.3)	708 (2.6)
Comorbidities, n (%)		
Hypertension	3050 (66.1)	13,056 (47.2)
Heart failure	1146 (24.8)	2791 (10.1)
Diabetes mellitus	1085 (23.5)	5691 (20.6)
Valvular heart disease	578 (12.5)	1720 (6.2)
Prior thromboembolism	418 (9.1)	1715 (6.2)
Pulmonary hypertension	121 (2.6)	322 (1.2)
Dilated cardiomyopathy	30 (0.7)	141 (0.5)
SD, standard deviation.		

TABLE 12 Outcomes for patients with NOAF in critical care

Outcome	Cumulative incidence of event (95% CI) (%)	
	NOAF patients (N = 4615)	Comparator patients (N = 27,690)
Mortality		
During hospital admission, n (%)	2000 (43.9)	5367 (19.5)
Time after hospital discharge		
90 days	8.4 (7.4 to 9.5)	4.1 (3.9 to 4.4)
1 year	17.4 (15.9 to 18.8)	10.6 (10.6 to 11.4)
3 years	31.8 (30.0 to 33.7)	22.2 (21.7 to 22.8)
5 years	44.0 (42.0 to 46.2)	30.0 (29.3 to 30.6)
Subsequent hospital admission for		
Atrial fibrillation		
1 year <sup>a</sup>	25.9 (24.1 to 27.7)	2.3 (2.1 to 2.6)
3 years <sup>a</sup>	36.8 (34.6 to 38.9)	4.9 (4.6 to 5.3)
5 years <sup>a</sup>	42.7 (40.2 to 45.2)	7.0 (6.6 to 7.5)
Stroke		
1 year <sup>a</sup>	1.5 (1.1 to 2.1)	0.6 (0.5 to 0.7)
3 years <sup>a</sup>	2.7 (2.0 to 3.5)	1.3 (1.2 to 1.6)
5 years <sup>a</sup>	4.2 (3.2 to 5.6)	1.9 (1.7 to 2.2)
Heart failure		
1 year <sup>a</sup>	10.6 (9.4 to 11.9)	4.1 (3.8 to 4.4)
3 years <sup>a</sup>	16.5 (14.9 to 18.2)	7.2 (6.8 to 7.6)
5 years <sup>a</sup>	20.1 (18.8 to 23.0)	9.3 (8.9 to 9.8)

<sup>a</sup> Estimates of risk of hospital admission use a non-parametric method to account for the competing risk of death.






FIGURE 4 Cumulative incidence of mortality from ICU admission, estimated using the Kaplan-Meier method.



**FIGURE 5** Cumulative incidence of mortality and hospitalisation after hospital discharge. (a) Mortality after discharge; (b) hospitalisation with AF; (c) hospitalisation with stroke; (d) hospitalisation with heart failure. Cumulative incidence of mortality estimated using the Kaplan–Meier approach. The cumulative incidences of hospital admission with AF, stroke and heart failure estimated using non-parametric methods to account for competing risk of death. (*continued*)



**FIGURE 5** Cumulative incidence of mortality and hospitalisation after hospital discharge. (a) Mortality after discharge; (b) hospitalisation with AF; (c) hospitalisation with stroke; (d) hospitalisation with heart failure. Cumulative incidence of mortality estimated using the Kaplan–Meier approach. The cumulative incidences of hospital admission with AF, stroke and heart failure estimated using non-parametric methods to account for competing risk of death.

**TABLE 13** Regression models: main results

Outcome	NOAF group (N = 4615)		Comparator group (N = 27,690)		Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Mortality during hospital admission	2000		5367		3.22 (3.02 to 3.44)	2.32 (2.16 to 2.48)
Outcome	Number of events	Number of person-years at risk	Number of events	Number of person-years at risk	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
Death 1–90 days after hospital discharge	213	609	907	5400	2.11 (1.83 to 2.44)	1.46 (1.26 to 1.70)
Death 91 days to 1 year after hospital discharge	227	2250	1512	20,688	1.38 (1.20 to 1.59)	0.99 (0.86 to 1.15)
Death > 1 year after hospital discharge	736	9548	4675	96,268	1.66 (1.53 to 1.79)	1.04 (0.96 to 1.12)
Outcome	Number of events	Number of person-years at risk	Number of events	Number of person-years at risk	Unadjusted CHR (95% CI)	Adjusted CHR (95% CI)
Subsequent hospital admission for atrial fibrillation	855	4231	1017	53,458	9.77 (8.91 to 10.70)	5.86 (5.33 to 6.44)
Subsequent hospital admission for stroke	68	5574	283	54,509	2.31 (1.77 to 3.02)	1.47 (1.12 to 1.93)
Subsequent hospital admission for heart failure	395	5087	1462	52,907	2.68 (2.39 to 2.99)	1.28 (1.14 to 1.44)

Odds ratios estimated using logistic regression ± adjustment for age (using a restricted cubic spline with knots at positions 25, 54, 68 and 84 years), sex, diabetes mellitus, hypertension, prior thromboembolism, valvular heart disease, pulmonary hypertension and heart failure. HRs estimated using Cox proportional hazards regression ± adjustment for the same factors. CHRs were estimated using Cox proportional hazards regression with censoring at death ± adjustment for the same factors.

For outcomes post discharge from hospital, an examination of the Schoenfeld residuals indicated that the proportion hazards assumption was unlikely to be met for mortality or subsequent hospitalisation with AF, but was met for subsequent hospitalisation with stroke and with heart failure. In response to this, for mortality we partitioned follow-up into three time periods: 1–90 days, 90 days to 1 year and > 1 year. We then fitted separate Cox regression models for each time period (see *Table 12*). Results suggested that a similar proportion of the excess risk of death in the first 90 days after hospital discharge was explained by differences in patient characteristics and comorbidities as for death in hospital. After 90 days, adjustment for these factors explained all of the excess risk of death associated with NOAF (CHR  $\approx$  1.00, after adjustment).

The analysis of subsequent hospitalisations was complicated by the need to account for both the proportion hazards assumption and the competing risk of death. Because subsequent hospitalisation with AF exhibited the largest between-group difference, we elected to ignore the possible violation of the proportional hazards assumption and present analysis of the entire follow-up period, in keeping with the hospitalisation with stroke and heart failure. The results for hospitalisation with AF should, therefore, be interpreted as an average over the follow-up period that should not be assumed to be constant. Adjustment for patient characteristics and comorbidities indicated that about half of the excess risk of subsequent hospitalisation with each of AF, stroke and heart failure was explained by these factors.

### ***Sensitivity analysis***

For the sensitivity analysis, patients who had less-certain evidence indicating possible NOAF and their corresponding comparators were included in the analysis ( $n = 8145$  patients with NOAF or possible NOAF and  $n = 48,870$  comparators). Patient characteristics and comorbidities were similar between the primary and the sensitivity analysis (see *Appendix 5, Table 22*). However, hospital mortality fell from 43.9% among patients with NOAF in the primary analysis to 34.5% among patients using the expanded definition of NOAF in the sensitivity analysis (mortality among comparators was equivalent between the analyses) (see *Appendix 5, Table 23*). The results from regression models (see *Appendix 5, Table 24*) were consistent with the primary analysis in terms of the proportion explained by patient characteristics and comorbidities. There remained a small but statistically significant impact of NOAF on mortality > 1 year after hospital discharge; however, the CI overlapped with the equivalent interval from the primary analysis. Sensitivity analysis outcomes are illustrated in *Appendix 5, Figures 11 and 12*.

## Chapter 4 Database analysis part 2: intensive care unit databases

Parts of this chapter are adapted with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

The analysis of the RISK-II database shows that patients who develop NOAF during an ICU admission are at a significantly increased risk of mortality and hospital readmission with AF, heart failure and stroke. This highlights the importance of optimal management of this common problem.

Our scoping review has shown that the existing evidence for the best management of NOAF acquired in an ICU is limited. Common concerns included small sample sizes and inadequate adjustment for differences between treatment groups.

We, therefore, aimed to compare the clinical effectiveness of different NOAF treatments by analysing two large ICU databases after performing comprehensive adjustments for measured confounding.

### Database analysis part 2: methods

#### Study design

We carried out a retrospective observational study of two large ICU databases from the UK (PICRAM<sup>82</sup>) and the USA [Medical Information Mart for Intensive Care III (MIMIC-III) v1.4<sup>83</sup>].

The PICRAM database comprises data relating to > 12,000 patients who were treated in three general ICUs in the UK from 2008 to 2015. MIMIC-III comprises data relating to > 40,000 patients who were admitted to critical care units at a tertiary care hospital in the USA between 2001 and 2012.

All analyses were performed on each database individually given the potential for differences in case mix and interventions. Combined analyses were performed for each outcome to confirm findings. We adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<sup>84</sup>

#### Study population

We included all adult (aged  $\geq 16$  years) patients. For patients who were admitted more than once to an ICU, we used their first admission. We excluded patients:

- cared for by a coronary care or cardiac surgery team
- with missing hospital outcome data
- with an ICU length of stay of < 24 hours<sup>85</sup>
- with significant arrhythmia in the first 3 hours of arrival to an ICU
- with pre-existing arrhythmias.

We defined patients as having a pre-existing arrhythmia if an arrhythmia or a medication prescribed with an indication of heart rhythm management were identified in the patient's medical history.

### **Exposure and outcomes**

For all ICUs that were included in the databases, routine practice was to display three lead electrocardiograms continuously, with heart rhythm recorded by the bedside nurse at regular intervals. We defined NOAF as the documentation of AF or atrial flutter lasting for  $\geq 30$  seconds.<sup>30</sup> A documented heart rhythm was assumed to persist until the next identifiable rhythm was recorded.

The availability of data relating to the interventions of interest was assessed in the MIMIC-III and PICRAM databases. The MIMIC-III database allowed four interventions to be compared: i.v. amiodarone, i.v. beta-blockers, i.v. calcium channel blockers and electrical cardioversion. The PICRAM database allowed three interventions to be compared: i.v. amiodarone, i.v. beta-blockers and i.v. digoxin. We analysed each intervention in an intention-to-treat fashion, in which treatment groups were determined by first treatment after NOAF onset.<sup>86</sup>

### **Primary outcomes**

The primary end points of this study were ICU mortality, hospital mortality, rate control and rhythm control, which were analysed as time-to-event outcomes. We censored rate and rhythm control at 24 hours and censored mortality at 30 days. In the absence of a consensus definition of treatment success for ICU-acquired NOAF, we defined time to cardioversion with our expert panel as the time to first reversion of sinus rhythm<sup>42</sup> and we defined time to rate control as the time to a heart rate of  $< 110$  b.p.m. in the subset of patients with a heart rate of  $\geq 110$  b.p.m.<sup>87</sup>

### **Secondary outcomes**

We analysed the association of NOAF with hospital mortality. We calculated the CHR to estimate the aetiological association between NOAF and hospital outcomes, considering hospital discharge as a competing risk to mortality. We adjusted for the Oxford Acute Severity of Illness Score (OASIS),<sup>88</sup> which was limited to the first 3 hours of ICU admission to avoid confounding post-NOAF onset. The use of early scores has been shown to remain predictive of outcome.<sup>89</sup>

We explored the haemodynamic changes (heart rate, blood pressure and vasoactive medication dose) that are associated with NOAF. We calculated the proportion of patients receiving vasoactive medications in our cohort before and after NOAF onset. We calculated the vasoactive-inotropic score<sup>90</sup> to quantify the change in composite dose of vasoactive medications for patients already receiving vasoactive medications prior to AF onset.

Focusing on the period 6 hours pre and post NOAF, we used smooth additive quantile regression models<sup>91</sup> to fit the 75%, 50% and 25% quantiles of the distribution of each haemodynamic variable. We excluded the haemodynamic data recorded after each patient's first treatment for NOAF to establish a natural history. All models included a binary covariate to indicate the onset of NOAF and allowed for changes in smoothing spline post-AF onset.

We used multilevel linear models to test whether or not there were significant changes in heart rate, blood pressure and vasoactive medication dose associated with NOAF. Each model included fixed linear segmented regression terms, with a random effect per patient to account for repeated measurements.

### **Adjustment for confounding**

We carried out a propensity score-weighted time-to-event analysis to adjust for measured confounding in the selection of patients between treatment groups. All statistical analyses were performed using R Core v4.0.2. We generated propensity score weights that were optimised to balance the covariate distributions of the treatment groups<sup>92</sup> using the WeightIt package.<sup>93</sup> The confounding variables included admission variables, laboratory variables and physiological variables adjacent to NOAF onset. The list of confounding variables was generated based on the studies identified in our scoping review. This list was then reviewed and supplemented by members of the study oversight panel. The admission

variables included age; sex; the OASIS<sup>88</sup> within the first 3 hours of ICU admission; use of preadmission beta-blocker, antipsychotic or thyroid medication; severe congestive cardiac failure; chronic obstructive pulmonary disease (COPD); liver disease; and thyroid disease. The laboratory variables at NOAF onset included the most recent (to NOAF onset) plasma sodium, potassium, magnesium, creatinine and urea concentrations; white cell count; platelet count; haemoglobin concentration; and prothrombin time. The physiological/intervention variables at NOAF onset included systolic and mean blood pressure, heart rate, body temperature, presence and dose of vasoactive agent, presence of bronchodilator therapy, mechanical ventilation, renal replacement therapy and presence of central venous access.

We assessed the balance of covariates across weighted groups by tabulating group means pre and post weighting. We calculated standardised mean differences (SMDs)<sup>94</sup> and the maximum SMD of all pairwise treatment group comparisons for each covariate.

We carried out a weighted Cox survival analysis to determine the average treatment effect of NOAF treatments on our outcomes of interest. Missing laboratory values were handled by using multiple imputation. We generated 20 imputed data sets. To account for the uncertainty in the generated propensity scores and to allow for the estimation of 95% CIs around effect estimates, we performed resampling with replacement (bootstrapping) with recalculation of propensity score weights and effect estimates with each bootstrap sample. We obtained 1000 bootstrap samples from each imputed data set.<sup>95</sup> The effect estimates and CIs from each imputed data set were combined using Rubin's rules.<sup>96</sup>

### **Critical Care Health Informatics Collaborative database analysis**

We also analysed the Critical Care Health Informatics Collaborative (CCHIC) database.<sup>97</sup> This database was created with retrospectively collected detailed data from the ICU clinical information systems from four general ICUs in London and Cambridge, in the UK, from 2014 to 2018.

Of our drugs of interest, the CCHIC database contains beta-blocker data only. We, therefore, decided to use this database to analyse only the epidemiology and characteristics of NOAF to compare with our main analyses.


We used the eligibility criteria stated in *Study population*. However, we were unable to exclude patients with documented pre-existing arrhythmias because these data were not available in the CCHIC database. Pre-existing arrhythmia was, therefore, determined only by the presence of arrhythmia during the first 3 hours of ICU admission. Full methods are outlined in *Appendix 7*.

## **Database analysis part 2: results**

### **Study population**


The MIMIC-III database contains data from 22,684 adult index ICU admissions. Of these patients, 220 had an ICU length of stay of < 24 hours. We identified 3905 of the remaining 22,464 patients as having pre-existing AF or AF documented within the first 3 hours of their ICU admission. Of the 18,559 patients who fulfilled our inclusion criteria, 1065 (5.7%) developed NOAF during their ICU stay. Of these patients, 742 went on to receive one of the interventions of interest. Only two patients received digoxin as their initial treatment and were, therefore, excluded, leaving 740 patients for the comparative analysis. This process is displayed in *Figure 6*.

The PICRAM database contains data from 12,270 adult index ICU admissions. Of these patients, 3004 had an ICU length of stay of < 24 hours. We identified 899 of the remaining 9266 patients as having pre-existing AF or AF documented within the first 3 hours of ICU admission. Of the 8367 patients who fulfilled our inclusion criteria, 952 (11.4%) developed NOAF during their ICU stay. Of these patients, 471 went on to receive one of the interventions of interest. Five patients had missing outcome data and were, therefore, excluded from the analysis. Of those 466 patients with outcome data, only six patients



**FIGURE 6** Study CONSORT flow diagrams. (a) MIMIC-III database; (b) PICRAM database. Reproduced with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure. (continued)

received DCC or calcium channel blockers and were, therefore, excluded, leaving 460 patients for the comparative analysis. This process is displayed in Figure 6. In both databases, patients who developed NOAF were older, with a similar age difference as was identified in the RISK-II database analysis. Patients who developed NOAF also had longer ICU and hospital length of stay, and higher ICU and hospital mortality (see Appendix 6, Tables 25 and 26), than those who did not develop NOAF. The characteristics of included patients are displayed in Table 14.



**FIGURE 6** Study CONSORT flow diagrams. (a) MIMIC-III database; (b) PICRAM database. Reproduced with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

TABLE 14 Characteristics of included patients

Characteristic	MIMIC-III database (N = 740)	PICRAM database (N = 460)	Overall (N = 1200)
Age (years), median (IQR)	74 (64–82)	70 (63–77)	72 (64–80)
Sex, n (%)			
Female	372 (50)	186 (40)	558 (46)
Male	368 (50)	274 (60)	642 (54)
COPD, n (%)	53 (7.2)	63 (14)	116 (9.7)
Dialysis-dependent renal failure, n (%)	1 (0.1)	7 (1.5)	8 (0.7)
NYHA class III/IV heart failure, n (%)	0 (0)	2 (0.4)	2 (0.2)
Chronic liver disease, n (%)	11 (1.5)	20 (4.3)	31 (2.6)
Thyroid disorder, n (%)	33 (4.5)	28 (6.1)	61 (5.1)
Beta-blocker therapy prior to admission, n (%)	281 (42)	63 (14)	344 (30)
Antipsychotic therapy prior to admission, n (%)	27 (4.0)	7 (1.5)	34 (3.0)
Highest OASIS at 3 hours, median (IQR)	36 (31–41)	34 (26–39)	35 (29–40)
Mechanical ventilation at time of NOAF, n (%)	343 (46)	243 (53)	586 (49)
Renal replacement therapy during or < 12 hours prior to NOAF, n (%)	47 (6.4)	65 (14)	112 (9.3)
i.v. vasoactive medication at time of NOAF, n (%)	101 (14)	124 (27)	225 (19)
Therapeutic anticoagulation at time of NOAF, n (%)	36 (4.9)	48 (10)	84 (7.0)
Central venous catheter at time of NOAF, n (%)	429 (58)	326 (71)	755 (63)
Bronchodilator therapy on day of, or day preceding, NOAF, n (%)	258 (35)	75 (16)	333 (28)
Plasma concentration, median (IQR)			
Sodium (mmol/l)	139.0 (136.0–143.0)	137.0 (134.0–141.0)	139.0 (136.0–142.0)
Potassium (mmol/l)	4.00 (3.70–4.40)	4.20 (3.90–4.50)	4.00 (3.80–4.40)
Magnesium (mmol/l)	0.82 (0.78–0.95)	0.96 (0.84–1.12)	0.86 (0.78–1.00)
Urea (mmol/l)	9 (6–16)	14 (9–20)	11 (7–18)
Creatinine (μmol/l)	97 (62–159)	125 (78–214)	104 (69–186)
White cell count ( $\times 10^9/l$ ), median (IQR)	12 (8–16)	11 (8–16)	12 (8–16)
Haemoglobin concentration (g/l), median (IQR)	102 (92–115)	98 (88–113)	101 (90–114)
Platelet count ( $\times 10^9/l$ ), median (IQR)	190 (123–283)	166 (109–234)	181 (117–265)
Prothrombin time (seconds), median (IQR)	2.65 (2.57–2.80)	2.78 (2.71–2.94)	2.71 (2.61–2.89)
Systolic blood pressure prior to AF onset (mmHg), median (IQR)	123 (106–141)	116 (101–133)	120 (104–138)
Mean blood pressure prior to AF onset (mmHg), median (IQR)	80 (69–91)	77 (68–88)	78 (69–90)
Heart rate prior to AF onset (b.p.m.), median (IQR)	96 (84–112)	115 (96–140)	102 (87–124)

TABLE 14 Characteristics of included patients (continued)

Characteristic	MIMIC-III database (N = 740)	PICRAM database (N = 460)	Overall (N = 1200)
Treatment group (by first treatment), n (%)			
Amiodarone	94 (13)	344 (75)	438 (36)
Beta-blocker	473 (64)	47 (10)	520 (43)
Calcium channel blocker	144 (19)	0 (0)	144 (12)
Digoxin	0 (0)	69 (15)	69 (5.8)
Electrical cardioversion	29 (3.9)	0 (0)	29 (2.4)

NYHA, New York Heart Association.

Reproduced with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.

The CCHIC database included data that were related to 33,451 adult first admissions to an ICU. Of these patients, 7889 had an ICU length of stay of < 24 hours. We identified 2713 patients being paced or with another significant arrhythmia during the first 3 hours of ICU admission. Of the remaining 22,849 patients, 1003 had missing hospital mortality data. Of the remaining 21,846 eligible patients, 2618 (12%) developed NOAF (see Appendix 7, Figure 23). The characteristics of patients with and without NOAF are shown in Appendix 7, Table 34.

### Characteristics of new-onset atrial fibrillation in treated patients

The time from ICU admission to the onset of NOAF in treated patients was similar between the MIMIC-III and the PICRAM databases [median 40.5 hours (IQR 21–79 hours) vs. 40.3 hours (IQR 41–75 hours), respectively]. Patients with data reported in the MIMIC-III database had, on average, shorter total durations of AF [median 11.6 hours (IQR 4–37 hours) vs. 18.1 hours (IQR 6–44 hours), respectively]. The timing of onset and AF duration data are displayed in Figures 7 and 8, respectively.




FIGURE 7 Time from ICU admission to AF onset in treated patients. (a) MIMIC-III database; (b) PICRAM database. Data from 93 patients with time to AF onset > 168 hours (7 days) not shown.




FIGURE 8 Total duration of AF per treated patient. (a) MIMIC-III database; (b) PICRAM database. Data from 89 patients with AF duration > 120 hours (5 days) not shown.

### Association of new-onset atrial fibrillation with hospital mortality

In the unadjusted analysis, NOAF was associated with an almost identical increased risk of hospital mortality in the MIMIC-III and PICRAM databases [CHR 1.89 (95% CI 1.69 to 2.13) and CHR 1.89 (95% CI 1.68 to 2.13) respectively]. After adjustment for illness severity at ICU admission, this association remained evident [CHR 1.47 (95% CI 1.31 to 1.65) and CHR 1.73 (95% CI 1.54 to 1.96) respectively].

### New-onset atrial fibrillation treatments

Of the patients who were identified in the MIMIC-III database, 94 received amiodarone, 473 received beta-blockers, 144 received calcium channel blockers and 29 received electrical cardioversion as their initial NOAF treatment. In the PICRAM database, 344 patients received amiodarone, 47 received beta-blockers and 69 received digoxin as their initial NOAF treatment. The characteristics of patients by treatment group are displayed in *Appendix 6, Tables 27 and 28*, for the MIMIC-III and PICRAM databases, respectively.

### Adjustment for confounding

After propensity score weighting, covariates were well matched across all treatment groups in each database. Across 30 variables, only the mean urea concentration in the MIMIC-III database had the maximum pairwise SMD of > 0.2. Unweighted and weighted means for each treatment group can be found in *Appendix 6, Tables 29 and 30*.

### Rate control

#### The MIMIC-III database

The time at which 50% of patients had achieved rate control was 60 minutes, 60 minutes, 80 minutes and 10 minutes in the amiodarone, beta-blocker, calcium channel blocker and electrical cardioversion groups, respectively. The cumulative incidence curves of rate control for each treatment group are shown in *Appendix 6, Figure 13*.

In the unadjusted analysis, no differences were observed between any intervention and amiodarone in the time to achieving rate control (see *Appendix 6, Table 31*).

After propensity score weighting, beta-blockers, calcium channel blockers and cardioversion were not associated with any significant difference in rate of achieving rate control when compared with amiodarone (HR 1.09, 95% CI 0.78 to 1.51; HR 0.81, 95% CI 0.55 to 1.19; and HR 1.59, 95% CI 0.44 to 5.75; respectively) (*Figure 9*; see *Appendix 6, Table 31*).

After initial rate control, reversion to a heart rate of  $\geq 110$  b.p.m. was common. Of those patients achieving rate control, 65%, 62%, 80% and 68% of patients in the amiodarone, beta-blocker, calcium channel blocker and electrical cardioversion groups, respectively, had at least one episode of a heart rate of  $\geq 110$  b.p.m. within the 24 hours after initial rate control (see *Appendix 6, Figure 14*).

### The PICRAM database

The time at which 50% of patients had achieved rate control was 96 minutes, 115 minutes and 241 minutes in the amiodarone, beta-blocker and digoxin groups, respectively. The unadjusted cumulative incidence curves of rate control for each treatment group are displayed in *Appendix 6, Figure 15*.

In the unadjusted analysis, there was no evidence of a difference in achieving rate control between beta-blocker therapy and amiodarone (HR 0.85, 95% CI 0.57 to 1.27); however, digoxin appeared inferior to amiodarone in achieving rate control (HR 0.64, 95% CI 0.45 to 0.92).

After propensity score weighting, beta-blocker therapy was not associated with any significant difference in the rate of achieving rate control [adjusted hazard ratio (aHR) 0.82, 95% CI 0.48 to 1.42] compared with amiodarone. The reduced rate of achieving rate control with digoxin therapy remained evident (aHR 0.56, 95% CI 0.34 to 0.92) (see *Figure 9* and *Appendix 6, Table 32*).

After initial rate control, reversion to a heart rate of  $> 110$  b.p.m. was common. Of those achieving rate control, 66%, 59% and 76% of patients in the amiodarone, beta-blocker and digoxin groups, respectively, had at least one episode of a heart rate of  $\geq 110$  b.p.m. within the 24 hours after initial rate control. These findings are displayed in *Appendix 6, Figure 16*. These differences were not significant in the unadjusted or adjusted analysis.

### Combined database analysis


In the unadjusted combined analysis, beta-blocker therapy was associated with a higher rate of achieving rate control (HR 1.26, 95% CI 1.10 to 1.43) and digoxin was associated with a lower rate of achieving rate control (HR 0.69, 95% CI 0.52 to 0.91) than amiodarone. After adjustment, we found no evidence of a difference between beta-blocker therapy and amiodarone in the rate of achieving rate control (aHR 1.14, 95% CI 0.91 to 1.44). Consistent with the PICRAM database analysis, we found that digoxin therapy was associated with a lower rate of achieving rate control than amiodarone (aHR 0.52, 95% CI 0.32 to 0.86) (see *Appendix 6, Table 33*).

In the unadjusted combined analysis, calcium channel blockers were associated with an increased rate of reversion to a heart rate of  $\geq 110$  b.p.m. in those patients who initially achieved rate control (HR 1.62, 95% CI 1.28 to 2.06). This finding bordered on significance after adjustment (HR 1.54, 95% CI 1.00 to 2.37).

### Rhythm control

#### The MIMIC-III database

The time at which 50% of patients had achieved rhythm control was 159 minutes, 144 minutes, 285 minutes and 40 minutes in the amiodarone, beta-blocker, calcium channel blocker and electrical cardioversion groups, respectively (see *Appendix 6, Figure 17*).



**FIGURE 9** Unadjusted and adjusted HRs for rate and rhythm control. (a) MIMIC-III unadjusted; (b) PICRAM unadjusted; (c) MIMIC-III adjusted; (d) PICRAM adjusted. Adapted with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

In the unadjusted analysis, there was no evidence of a difference in achieving rhythm control between beta-blockers or cardioversion and amiodarone. Calcium channel blocker therapy was associated with a reduced rate of achieving rhythm control (HR 0.65, 95% CI 0.50 to 0.84).

After propensity score weighting, there remained no evidence of a difference in achieving rhythm control between beta-blockers (HR 0.91, 95% CI 0.61 to 1.35) or cardioversion (HR 2.00, 95% CI 0.86 to 4.65) and amiodarone. Calcium channel blockers remained associated with a lower rate of achieving rhythm control (HR 0.59, 95% CI 0.37 to 0.92) than amiodarone (see *Figure 9* and *Appendix 6, Table 31*).

After initial rhythm control, reversion to AF was common. Of those patients achieving rhythm control, 36%, 39%, 47% and 46% of patients in the amiodarone, beta-blocker, calcium channel blocker and electrical cardioversion groups, respectively, had at least one episode of AF within the 24 hours after initial cardioversion (see *Appendix 6, Figure 18*). The differences in reversion rates were not significant in the unadjusted or adjusted analysis (see *Appendix 6, Table 31*).

### The PICRAM database

The time at which 50% of patients had achieved rhythm control was 80 minutes, 37 minutes and 255 minutes in the amiodarone, beta-blocker and digoxin groups, respectively. Cumulative incidence curves of rhythm control for each treatment group are shown in *Appendix 6, Figure 19*.

In the unadjusted analysis, there was no evidence of a difference in achieving rhythm control between beta-blocker therapy and amiodarone (HR 0.95, 95% CI 0.64 to 1.40); however, digoxin appeared to be inferior to amiodarone (HR 0.57, 95% CI 0.41 to 0.81).

After propensity score weighting, beta-blocker therapy was not associated with any significant difference in the rate of achieving rhythm control (HR 0.99, 95% CI 0.57 to 1.72). Digoxin was no longer significantly associated with a lower rate of achieving rhythm control (HR 0.67, 95% CI 0.41 to 1.09) (see *Figure 9* and *Appendix 6, Table 32*).

After initial rhythm control, reversion to AF was common. Of those patients achieving rhythm control, 54%, 51% and 70% of patients in the amiodarone, beta-blocker and digoxin groups, respectively, had at least one episode of AF within the 24 hours after initial cardioversion (see *Appendix 6, Figure 20*). Differences in reversion rates were not significant in the unadjusted or adjusted analysis (see *Appendix 6, Table 32*).

### Combined analysis

Consistent with the individual database analyses, the unadjusted combined analysis suggested that calcium channel blockers (HR 0.58, 95% CI 0.47 to 0.71) and digoxin (HR 0.58, 95% CI 0.41 to 0.83) were associated with a reduced rate of achieving rhythm control compared with amiodarone. Furthermore, beta-blocker therapy was also associated with a lower rate of achieving rhythm control than amiodarone (HR 0.81, 95% CI 0.71 to 0.93).

After adjustment, we found no evidence of differences between beta-blockers (aHR 0.86, 95% CI 0.67 to 1.11), digoxin (aHR 0.64, 95% CI 0.35 to 1.17) or electrical cardioversion (aHR 1.58, 95% CI 0.71 to 3.51) and amiodarone in the rate of achieving rhythm control. We found that calcium channel blocker therapy was associated with a lower rate of achieving rhythm control than amiodarone (aHR 0.56, 95% CI 0.39 to 0.79), which was consistent with our MIMIC-III database analysis (see *Appendix 6, Table 33*).

Consistent with the individual database analyses, there was no evidence of a difference in the rates of reversion to AF between treatments in the unadjusted or the adjusted analyses.

## Hospital survival

### The MIMIC-III database

In the unadjusted analysis, beta-blocker therapy was associated with a reduced hospital mortality rate (HR 0.64, 95% CI 0.44 to 0.93). Unadjusted survival curves for each treatment group in the MIMIC-III database are displayed in *Appendix 6, Figure 21*.

After propensity score weighting, we found no evidence of a difference between beta-blockers (aHR 1.03, 95% CI 0.53 to 2.03), calcium channel blockers (aHR 1.30, 95% CI 0.61 to 2.76) or electrical cardioversion (HR 0.96, 95% CI 0.31 to 3.01) and amiodarone in hospital mortality (see *Appendix 6, Table 31*).

### The PICRAM database

We found no differences in hospital survival in the unadjusted analyses. Unadjusted survival curves for each treatment group in the PICRAM database are displayed in *Appendix 6, Figure 22*.

After propensity score weighting, there remained no differences between beta-blockers (aHR 0.75, 95% CI 0.30 to 1.84) or digoxin (aHR 1.37, 95% CI 0.75 to 2.50) and amiodarone in hospital mortality (see *Appendix 6, Table 32*).

### Combined analysis

Consistent with our MIMIC-III database analysis, the combined unadjusted analysis suggested that beta-blockers were associated with a reduced hospital mortality rate (HR 0.78, 0.62 to 0.99).

Cardioversion appeared to be associated with a significantly increased hospital mortality rate (HR 1.92, 95% CI 1.16 to 3.17). After propensity score weighting, we found no significant difference between beta-blockers (aHR 0.97, 95% CI 0.56 to 1.68), calcium channel blockers (aHR 1.21, 95% CI 0.62 to 2.39), digoxin (aHR 1.77, 95% CI 0.77 to 4.06) or cardioversion (aHR 0.87, 95% CI 0.25 to 3.00) and amiodarone in hospital mortality (see *Appendix 6, Table 33*).

## Haemodynamic changes associated with atrial fibrillation onset


Multilevel linear modelling revealed that NOAF was associated with a significant heart rate increase of 22 b.p.m. ( $p < 0.001$ ) and 19 b.p.m. ( $p < 0.001$ ) in the MIMIC-III and PICRAM databases, respectively. The average heart rate after AF onset was 122 b.p.m. and 127 b.p.m., respectively.

New-onset atrial fibrillation was associated with a significant reduction in systolic blood pressure in the MIMIC-III and the PICRAM databases of 7 mmHg and 4 mmHg, respectively ( $p < 0.001$ ). This was despite significant increases in the doses of vasoactive medication after NOAF onset in those receiving vasoactive medications prior to NOAF onset [vasoactive-inotropic score increase of 2.5 ( $p < 0.001$ ) and 1.8 ( $p = 0.001$ ), respectively]. New hypotension (systolic blood pressure of  $< 90$  mmHg or mean blood pressure of  $< 65$  mmHg) occurred after NOAF in 28% and 21% of patients with a systolic blood pressure of  $\geq 90$  mmHg or a mean blood pressure of  $\geq 65$  mmHg prior to AF onset, respectively. There was a non-significant increase in the proportion of patients receiving vasoactive medications after NOAF onset in the MIMIC-III database (17.6% to 20.2%;  $p = 0.29$ ). This proportion was unchanged after NOAF onset in the PICRAM database (29%).


The change in heart rate, blood pressure and vasoactive medication use over time, before and after AF onset, is displayed in *Figure 10*.

## Summary

This study demonstrated that NOAF during an ICU stay is common and is associated with significant increases in heart rate, reductions in blood pressure and increases in vasoactive medication requirements. NOAF was associated with an increased rate of hospital mortality despite adjusting for variables in a validated mortality prediction model.



**FIGURE 10** Haemodynamic changes associated with AF onset. (a) Heart rate, MIMIC-III database; (b) heart rate PICRAM database; (c) systolic blood pressure, MIMIC-III database; (d) systolic blood pressure, PICRAM database; (e) vasoactive-inotropic score, MIMIC-III database; (f) vasoactive-inotropic score, PICRAM database; (g) proportion of patients on vasoactive medications, MIMIC-III database; (h) proportion of patients on vasoactive medications, PICRAM database. Vasoactive-inotropic score shown for those patients receiving vasoactive medications prior to AF onset. VIS = dopamine dose ( $\mu\text{g/kg/minute}$ ) + dobutamine dose ( $\mu\text{g/kg/minute}$ ) +  $100 \times$  adrenaline dose ( $\mu\text{g/kg/minute}$ ) +  $10 \times$  milrinone dose ( $\mu\text{g/kg/minute}$ ) +  $10,000 \pm$  vasopressin dose (units/kg/minute) +  $100 \times$  noradrenaline dose ( $\mu\text{g/kg/minute}$ ). Reproduced with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure. (continued)



**FIGURE 10** Haemodynamic changes associated with AF onset. (a) Heart rate, MIMIC-III database; (b) heart rate PICRAM database; (c) systolic blood pressure, MIMIC-III database; (d) systolic blood pressure, PICRAM database; (e) vasoactive-inotropic score, MIMIC-III database; (f) vasoactive-inotropic score, PICRAM database; (g) proportion of patients on vasoactive medications, MIMIC-III database; (h) proportion of patients on vasoactive medications, PICRAM database. Vasoactive-inotropic score shown for those patients receiving vasoactive medications prior to AF onset. VIS = dopamine dose ( $\mu\text{g/kg/minute}$ ) + dobutamine dose ( $\mu\text{g/kg/minute}$ ) +  $100 \times$  adrenaline dose ( $\mu\text{g/kg/minute}$ ) +  $10 \times$  milrinone dose ( $\mu\text{g/kg/minute}$ ) +  $10,000 \pm$  vasopressin dose (units/kg/minute) +  $100 \times$  noradrenaline dose ( $\mu\text{g/kg/minute}$ ). Reproduced with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

Beta-blocker therapy was not associated with any difference in achieving rate or rhythm control, or with any difference in hospital survival when compared with amiodarone. The hospital mortality benefit with beta-blocker therapy that was identified in the unadjusted analysis of the MIMIC-III database was no longer apparent after adjustment. This suggests that differences in survival were only because of differences in patient characteristics between treatment groups.

Digoxin therapy was associated with a lower rate of achieving rate control than amiodarone. Calcium channel blocker therapy was associated with a lower rate of achieving rhythm control than amiodarone.



## Chapter 5 Expert panel

To highlight our findings, identify uncertainties and formulate research recommendations we convened an expert panel. We followed the National Institute for Health and Care Excellence Research Recommendations Process and Methods Guide.<sup>98</sup> Panel members are listed in *Appendix 7, Table 35*.



# Chapter 6 Discussion

## Statement of principal findings

The evidence base available for NOAF management in critically ill patients identified by our scoping review was very limited. Many studies lacked a comparator group and many of those that had a comparator group did not control for confounding factors. Only two randomised trials were identified, both of which were small and inconclusive. We identified significant heterogeneity in the definitions of both NOAF and successful treatment, making a synthesis of results difficult.

The limited evidence from our scoping review suggested that beta-blockers might be more effective than amiodarone for the conversion to sinus rhythm and mortality outcomes; however, residual bias in previous studies may explain these assertions. Whether or not and when to use anticoagulation is unknown. No conclusive findings were reported owing to the low quality of the reviewed evidence. Only one clinician survey was found, with a very low response rate.<sup>16</sup>

Our analysis of the RISK-II database demonstrated that patients who developed NOAF in an ICU were older and had higher levels of comorbidity than those who did not. Even after controlling for these differences, patients with NOAF still had substantially higher mortality in hospital and during the first 90 days after discharge. Patients who developed NOAF in an ICU also had higher rates of subsequent hospitalisation with AF, stroke and heart failure than those who did not.

Our analysis of the detailed within-ICU MIMIC-III and PICRAM databases showed that NOAF is a common problem that occurs in 6–11% of eligible ICU patients, depending on the data source. In an ICU, NOAF is associated with a significant increase in heart rate and a significant decrease in blood pressure, despite an increase in vasoactive medication doses. Supporting our RISK-II findings, we identified a significantly increased hospital mortality rate associated with NOAF, even after adjusting for other factors that are predictive of mortality.

These findings highlight the importance of identifying optimal treatment strategies for NOAF in patients in an ICU. We found that the treatment of NOAF with digoxin or calcium channel blockers as first-line therapy is associated with poorer rate control and rhythm control, respectively. Prior to adjustment for confounding variables, we found that beta-blocker therapy was associated with improved hospital survival. We also demonstrated that patients who received beta-blockers were less unwell at admission and more stable after AF onset than those who received amiodarone. After comprehensive adjustment of these factors, there were no identifiable differences in any outcome between beta-blocker therapy and amiodarone.

## Scoping review

The evidence base available for NOAF management in critically ill patients was very limited. A key problem with the studies identified in this scoping review was that many ( $n = 12$ ) were single-group studies (i.e. lacking a comparator group). Of the 25 primary studies included in the review, only two were RCTs<sup>30,31</sup> and only three of the non-randomised comparative studies<sup>27–29</sup> attempted to control for confounding factors, which may have affected outcomes. For all of these studies, which used more robust approaches, there were still serious concerns about how bias (arising from their designs and/or analyses) might affect their results. Although the two RCTs<sup>30,31</sup> did not find statistically significant differences in conversion rates between the treatments studied, each contained < 60 patients. Many studies<sup>27–30</sup> concluded that more research is needed.

Heterogeneity in the treatment dose (e.g. total doses ranging from < 1 g to 8 g for amiodarone<sup>8,31,32,34,35,42,43</sup>) and administration (e.g. bolus or continuous infusion), and varying time points to assess conversion to sinus rhythm (e.g. within 2 hours,<sup>30</sup> 4 hours,<sup>31</sup> 12 hours<sup>30</sup> and 24 hours<sup>8,32,35,36</sup>) were observed across studies. Comparing studies was, therefore, challenging. There is a need to establish optimal treatment dosing and administration regimens, as well as validated definitions of treatment success. Six studies<sup>33,34,36,37,40,48</sup> (14%) were available only as conference abstracts. Only limited data could be extracted for these studies, making their results more difficult to interpret.

Studies varied in how they reported and defined NOAF. Different heart rate thresholds for NOAF were used.<sup>31,36,38,43,47,49</sup> Studies also reported different time periods for which NOAF must be sustained<sup>27,30,41,43,47,49</sup> and for which instances AF would be considered NOAF.<sup>8,28,29,38,39,50</sup> Ten studies<sup>32–35,37,40,44–46,48</sup> did not provide any definition for NOAF.

The evidence from this review<sup>34–36</sup> suggests that beta-blockers might be more effective than amiodarone for the conversion back to normal sinus rhythm, with better outcomes for mortality reported in those who received beta-blockers than in those who received amiodarone.<sup>28,35</sup> A recent UK-wide survey<sup>16</sup> found that amiodarone is the most commonly used pharmacological treatment for NOAF in UK ICUs, which suggests that these studies are not changing current practice. Calcium channel blockers appeared to be less effective than beta-blockers and amiodarone for conversion to sinus rhythm.<sup>30,31,36</sup> Two studies<sup>27,48</sup> reported that hydrocortisone might be effective as a prophylactic treatment. However, a larger comparative study<sup>27</sup> reported slightly higher (but not statistically significant) mortality associated with the use of hydrocortisone. All of the studies reporting effects of hydrocortisone had significant methodological limitations.

The evidence base for NOAF treatment strategies was reported as very limited in two systematic reviews, which agrees with our findings.<sup>53,56</sup> Both systematic reviews were not able to report any conclusive findings, citing the low quality of the reviewed evidence<sup>53</sup> and methodological differences between the included studies.<sup>56</sup> In agreement with our findings, the review by Kanji *et al.*<sup>56</sup> concluded that a standardised outcome measure of success is needed as varying time points used to assess conversion to sinus rhythm limits recommendations on treatment efficacy.<sup>56</sup> Both systematic reviews emphasised the urgent need for further research studies.<sup>53,56</sup>

The current literature<sup>29,62</sup> suggests that it is unclear if the benefits of administering anticoagulants in critically ill patients with NOAF for stroke prevention outweigh the increased risk of bleeding. Two review articles<sup>61,64</sup> proposed a patient-centred approach to administer anticoagulants only in patients with high risk of arterial thromboembolic events. Outside the ICU, withholding anticoagulation for a short time in the perioperative period in patients with AF undergoing elective surgery was not associated with an increased risk of arterial thromboembolism and decreased the risk of major bleeding.<sup>99</sup> It is, however, not known how these findings translate to critically ill patients in ICUs.

The risk assessment scores for subsequent thromboembolism following the development of NOAF have generally not been developed or validated in the ICU population. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>100</sup> has, however, once been shown to be predictive of thromboembolic event risk in the ICU setting, although with poor sensitivity and predictive value.<sup>101</sup> Bleeding risk scores to guide anticoagulation decisions in NOAF have been developed using population-based cohorts of patients with AF in the community. Common risk factors used in these scores include older age, renal dysfunction, hypertension and a history of bleeding. Comparative studies of these tools report varying results depending on the patient population.<sup>102–105</sup> Patients who develop NOAF during sepsis are at a higher risk of in-hospital and post-discharge stroke and death than those who do not, despite adjusting for confounders.<sup>14,106</sup> Those with NOAF are at a higher risk of thromboembolic complications than patients with pre-existing AF.<sup>106</sup> However, the individual risk of stroke and thromboembolic events in patients who develop NOAF during an ICU admission remains poorly understood.

Although community-based bleeding risk scores are chiefly composed of chronic comorbidities, the bleeding risk in patients in an ICU is likely to be more related to acute factors, such as illness severity, systemic inflammation, type and location of surgery, nutritional status, invasive devices, and acute coagulopathy and thrombocytopenia.<sup>70,107–109</sup> Bleeding risk in critically ill patients with NOAF is higher than patients in the community, with one study demonstrating that 9% of patients who received systemic anticoagulation had significant bleeding warranting cessation of anticoagulation and at least one blood transfusion.<sup>8</sup>

A recent UK-wide survey suggested that around one-third of clinicians initiate anticoagulation in patients with NOAF during an ICU admission.<sup>16</sup> Once in stable AF in the community, anticoagulation can be recommended for almost all patients with AF. However, the balance of risks in patients either in an ICU or in whom AF was demonstrated only during the ICU admission is likely to be more complex and dynamic. Modified risk scores that incorporate such complexities are, therefore, required for critically ill patients with NOAF.

### *The RISK-II database analysis*

This analysis of the RISK-II database provides clear evidence of a patient group developing NOAF in critical care with substantially worse short- and long-term outcomes than patients without any record of AF during or prior to ICU admission. We adopted a restrictive approach to ensure that patients' CMP and HES records provided sufficient confidence in discriminating NOAF in the ICU from prior and subsequent AF. In our sensitivity analysis, we adopted a slightly broader, yet still conservative, definition of NOAF. The outcomes, although somewhat less severe, remained consistent with the primary analysis. Outcomes were substantially worse for patients with AF than for patients with no AF, even after controlling for patient characteristics and past medical history. Patients developing NOAF during an ICU admission were less likely to survive and more likely to be readmitted with AF, stroke or heart failure than those who did not develop NOAF. Comparison with other data sources suggests that our methodology identified a subset of all patients who develop NOAF in critical care. Given the inconsistent nature with which diagnoses are recorded in HES,<sup>110</sup> the group identified as developing NOAF in this analysis might best be interpreted as representing patients for whom their AF was of sufficient clinical importance to be documented in their clinical notes (which are then used to code diagnoses in HES records).

The evidence provided by multivariable regression indicates that the impact of NOAF on mortality is not constant over time, but rather focused on the period in and immediately after discharge from hospital. Patients who developed NOAF in an ICU had increased mortality up to the limit of follow-up. However, from 90 days after hospital discharge, the increased mortality appeared to be entirely explained by their older age, sex and comorbidities. During hospital admission and the first 90 days after discharge, roughly half of the increased mortality appeared attributable to either NOAF or unobserved clinical factors that are associated with it. These findings emphasise the importance of developing strategies for both the treatment and the anticoagulation management of NOAF in the period of critical illness and its immediate aftermath, for which current evidence is lacking.

We did not break down multivariable models for subsequent hospitalisation into similar time periods, given the complexity of interpreting proportional hazards regressions with both non-proportional hazards (effects that vary over time) and competing risks. However, given that hospitalisation is closely related to mortality, it may be reasonable to assume that a similar pattern of varying effects over time would be observed.

### *The MIMIC-III and PICRAM database analysis*

To the best of our knowledge, this is the first study to quantify the haemodynamic changes associated with NOAF onset in ICU patients accounting for patients' pre-AF parameters at scale. We found that NOAF during an ICU admission is associated with a significant increase in heart rate and a significant decrease in blood pressure, despite an increase in vasoactive medication doses. Organised atrial

activity contributes to ventricular filling, cardiac output and the closure of the atrioventricular valves.<sup>6</sup> New-onset atrial fibrillation precludes these mechanisms and the effects of the loss of atrial contraction on ventricular filling may be compounded by the diastolic dysfunction commonly seen during critical illness.<sup>111</sup> These mechanisms may explain why NOAF is temporally associated with a reduction in cardiac index in non-ICU patients with chronic heart failure.<sup>7</sup> Our findings are consistent with one previous study that found that haemodynamic instability developed in 37% of post-surgical ICU patients after NOAF.<sup>8</sup>

Atrial contractile dysfunction occurs after brief episodes of AF<sup>112</sup> and can last for several weeks after achieving rhythm control.<sup>113</sup> Any AF may, therefore, have considerable impact in any critically ill patient with minimal physiological reserve. Indeed, episodes of NOAF lasting for  $\geq 30$  minutes in the ICU are independently associated with increased hospital mortality.<sup>11</sup> We found that NOAF is associated with hospital mortality after adjustment for confounding variables, regardless of whether NOAF is diagnosed based on continuous monitoring (ICU databases analysis) or from hospital diagnosis codes (RISK-II database analysis). In both cases, some, but not all, of this association is explained by confounding variables. The associated mortality risk was higher in our RISK-II analysis than in our in-ICU analysis. This may be explained by the differing definitions, with NOAF in the RISK-II data probably representing AF significant enough to result in a HES code versus any AF in the in-ICU data.

Together, our findings highlight the importance of optimal treatment and follow-up of patients who develop NOAF during an ICU stay. We found that the use of digoxin is associated with lower rates of achieving heart rate control than the use of amiodarone. Digoxin may be selected to reduce heart rates without inducing hypotension; however, digoxin may be less effective during states of increased sympathetic drive,<sup>114</sup> including critical illness. One small study of patients in the ICU with AF with rapid ventricular response (not exclusive to NOAF) demonstrated that digoxin was less effective at rate control in patients receiving catecholaminergic medication.<sup>115</sup>

We found that the use of calcium channel blockers was associated with lower rates of achieving rhythm control than amiodarone. These findings are supported by a small, randomised study of paroxysmal AF outside the ICU,<sup>116</sup> which reported a cardioversion proportion of 0% in patients who received verapamil compared with 77% in patients who received amiodarone. Our findings contrast with one RCT identified in our scoping review, which compared amiodarone with calcium channel blockers<sup>31</sup> and found no difference in achieving rhythm control. However, this study included only 20 patients per treatment group, making it difficult to draw any conclusions. We did not identify any significant difference in hospital survival between any of the treatments when compared with amiodarone.

In the MIMIC-III database, the unadjusted analysis demonstrated an apparent mortality benefit in the beta-blocker treatment group. However, patients in the beta-blocker group were younger and less unwell at presentation than those in the amiodarone group. After developing NOAF, patients in the beta-blocker group had higher blood pressures, were less likely to be on vasoactive medications and had lower inflammatory markers. After our comprehensive adjustment, the difference in mortality was no longer evident. Our adjusted results conflict with one large study,<sup>28</sup> which suggested a survival benefit with beta-blockers over amiodarone therapy in patients with sepsis. However, this study was unable to adjust for features around NOAF onset. Our study demonstrates that important differences exist between treatment groups after the onset of AF, which may influence treatment choice. Failure to adjust for these factors is likely to result in residual confounding.

## Strengths and limitations

The scoping review was performed using systematic, transparent and robust methods. The bibliographic database searches were comprehensive, which allowed maximal identification of relevant studies while also minimising the possibility of publication or language biases affecting the review. We carried out the

screening and data extraction processes in duplicate to reduce the risk of reviewer errors or biases affecting the review. The main limitation of the scoping review was the methodological shortcomings of the studies identified.

Our RISK-II database analysis allowed us to include > 4000 patients who developed NOAF and 27,000 matched comparators from ICUs across England, with long-term follow-up using routinely collected data. However, the analysis is limited by the sensitivity of diagnostic records. Along with the limitations in defining patients with NOAF, some outcomes also need careful interpretation. For example, 'hospitalisation with stroke' may miss both extremes of severity, in which mild strokes and transient ischaemic events may not result in hospital admission and catastrophic strokes may result in death without admission.

Our analysis of two within-ICU databases has several strengths. First, we carried out comprehensive adjustment that included variables around the onset of AF. We show significant differences in these peri-AF variables that have not been adjusted for in previous studies. Second, our analysis of granular health-care data allowed a detailed analysis of the haemodynamic changes associated with NOAF. Third, our analysis of routinely collected data over many years provided a sample size large enough to demonstrate differential efficacy in NOAF treatments. This analysis also has limitations. The study was retrospective in nature and the development of NOAF was not independently verified. Documentation of AF in the MIMIC-III database has, however, been shown to be accurate for determining AF onset to within 1 hour after independent review of a sample of electrocardiographic waveforms.<sup>89</sup> Documentation of comorbidities in the MIMIC-III database relied on hospital billing codes, which may not have identified all cases. Furthermore, although good balance of numerous confounding covariates was achieved prior to assessing treatment efficacy, we are unable to exclude bias introduced by residual unmeasured confounding. Unmeasured variables, such as echocardiographic parameters, may have contributed to the association between NOAF in ICU and outcome, and would not be represented in the propensity weights. Finally, we acknowledge the difference in case mixes between UK and USA data. Overall, patients in the MIMIC-III database were younger and had lower mortality than those in the PICRAM database, which may explain part of the difference in NOAF incidence. Identifying patients who developed NOAF reduced these differences by identifying sufficiently unwell patients in both databases. Owing to the underlying differences, we primarily analysed each database in isolation, using the combined analysis to support these primary findings.

## Uncertainties

Either amiodarone or beta-blockers are commonly used in critically ill patients to control AF, but there is little evidence to support whether or not one is superior. Purported beneficial effects of beta-blocker therapy may be because of residual confounding in some studies.

In patients who develop NOAF while in an ICU, it is not clear in whom anticoagulation following hospital discharge might be beneficial.

The incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following the development of NOAF while in an ICU is unknown. However, readmission with heart failure and thromboembolism is increased over the 5 years following an episode of NOAF while in an ICU, particularly in the first year.

It remains unclear to what extent NOAF in patients in an ICU is causally related to worse outcomes. Evidence for causality may be supported by future randomised prevention trials, in which a reduction in AF burden is associated with better outcomes, or through the application of robust causal inference methods in observational studies.



# Chapter 7 Conclusions

## Implications for service provision

There are insufficient data available to make firm recommendations for service provision in the management of NOAF identified during an ICU admission.

## Suggested research priorities

Research priorities were suggested by the expert panel following data review (following the National Institute for Health and Care Excellence Research Recommendations Process and Methods Guide;<sup>98</sup> see *Appendix 8*). NOAF during an ICU stay is associated with substantially increased mortality, after correction for associated risk factors. Both amiodarone and beta-blockers are commonly used, but have significant side effects. Whether or not one is superior to the other has not been demonstrated. A RCT of amiodarone compared with beta-blockers for the management of NOAF in critically ill patients should be undertaken (see *Appendix 8, Table 36*).

The evidence for or against anticoagulation for patients who develop NOAF in an ICU is very scarce. The risk of thromboembolism is increased in those who develop NOAF compared with those who do not develop NOAF, even when corrected for known risk factors. However, current risk stratification tools have not been validated in the 'NOAF during ICU population' and do not take into account whether or not ICU treatments may affect future outcome. Whether or not there are subgroups of patients who develop NOAF while in an ICU who may benefit from long-term anticoagulation is unknown. Studies should be undertaken to create risk stratification tools or to investigate whether or not current tools are applicable to the 'NOAF during ICU population' to identify patients sufficiently at risk of future thromboembolism to merit consideration of anticoagulation (see *Appendix 8, Table 37*).

Readmissions with heart failure and thromboembolism increase over the 5 years following an episode of NOAF while in an ICU, particularly in the first year. Whether these events are driven by persistent left ventricular dysfunction and/or AF is unknown. A prospective cohort study to demonstrate the incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following development of NOAF should be undertaken (see *Appendix 8, Table 38*).



# Acknowledgements

The authors wish to thank Mrs Valerie Keston-Hole, Mr Rob Lawrence, and Dr Ian and Mrs Cathy Taylor (public and patient representatives), and the members of the expert panel: Dr Andy Walden and Professor Ben O'Brien.

## Contributions of authors

**Jonathan Bedford** (<https://orcid.org/0000-0001-9455-022X>) (Doctoral Research Fellow) extracted data for the scoping review, extracted data from the PICRAM database, performed the statistical analysis on data from the MIMIC-III and PICRAM databases, and co-wrote the report.

**Laura Drikite** (<https://orcid.org/0000-0002-5194-4189>) (Research Assistant) extracted data for the scoping review, drafted the scoping review and reviewed the data.

**Mark Corbett** (<https://orcid.org/0000-0002-5937-1493>) (Research Fellow, Systematic Reviews) contributed to the protocol, devised and supervised the scoping review, critically appraised the review evidence, and contributed to the writing of the report.

**James Doidge** (<https://orcid.org/0000-0002-3674-3100>) (Senior Statistician, Epidemiology) contributed to the conception and supervision of the analysis, and to manuscript preparation.

**Paloma Ferrando-Vivas** (<https://orcid.org/0000-0002-2163-645X>) (Statistician, Risk Modelling) contributed to the analysis and interpretation of the data, and contributed to the writing of the report.

**Alistair Johnson** (<https://orcid.org/0000-0002-8735-3014>) (Scientist) extracted data from the MIMIC-III database and harmonised data from the MIMIC-III and PICRAM databases.

**Kim Rajappan** (<https://orcid.org/0000-0001-8996-2983>) (Consultant Cardiologist, Cardiac Electrophysiology Specialist) provided expert reviews and advice on atrial fibrillation/arrhythmias.

**Paul Mouncey** (<https://orcid.org/0000-0002-8510-8517>) (Project Management at ICNARC) contributed to the study conception, study management and database analyses.

**David Harrison** (<https://orcid.org/0000-0002-9002-9098>) (Lead Statistician) contributed to study conception and contributed to the acquisition, analysis and interpretation of data.

**Duncan Young** (<https://orcid.org/0000-0002-6838-4835>) (retired Professor of Intensive Care Medicine) was involved in the study design, data extraction specifications and interpretation of the results. He was the chief investigator for the PICRAM study, which provided one of the databases for the CAFE study.

**Kathryn Rowan** (<https://orcid.org/0000-0001-8217-5602>) (Project Lead at ICNARC) contributed to study conception, design and data analysis.

**Peter Watkinson** (<https://orcid.org/0000-0003-1023-3927>) (Principal Investigator) contributed to study conception, design and data analysis, and co-wrote the manuscript.

## Publications

Drikite L, Bedford JP, O'Bryan L, Petrinic T, Rajappan K, Doidge J, *et al.* Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. *Crit Care* 2021;**25**:257.

Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, *et al.* Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. *J Crit Care* 2022;**67**:14–56.

## Data-sharing statement

All data requests should be submitted to the corresponding author for consideration. Access to available anonymised data or study materials may be granted following review.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

# References

1. Bedford J, Harford M, Petrinic T, Young JD, Watkinson PJ. Risk factors for new-onset atrial fibrillation on the general adult ICU: protocol for a systematic review. *BMJ Open* 2018;**8**:e024640. <https://doi.org/10.1136/bmjopen-2018-024640>
2. Artucio H, Pereira M. Cardiac arrhythmias in critically ill patients: epidemiologic study. *Crit Care Med* 1990;**18**:1383–8. <https://doi.org/10.1097/00003246-199012000-00015>
3. Walkey AJ, Greiner MA, Heckbert SR, Jensen PN, Piccini JP, Sinner MF, et al. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. *Am Heart J* 2013;**165**:949–55.e3. <https://doi.org/10.1016/j.ahj.2013.03.020>
4. Knotzer H, Mayr A, Ulmer H, Lederer W, Schobersberger W, Mutz N, Hasibeder W. Tachyarrhythmias in a surgical intensive care unit: a case-controlled epidemiologic study. *Intensive Care Med* 2000;**26**:908–14. <https://doi.org/10.1007/s001340051280>
5. Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. *Crit Care* 2014;**18**:688. <https://doi.org/10.1186/s13054-014-0688-5>
6. Samet P, Bernstein W, Levine S. Significance of the atrial contribution to ventricular filling. *Am J Cardiol* 1965;**15**:195–202. [https://doi.org/10.1016/0002-9149\(65\)90454-6](https://doi.org/10.1016/0002-9149(65)90454-6)
7. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. *J Am Coll Cardiol* 1998;**32**:197–204. [https://doi.org/10.1016/S0735-1097\(98\)00221-6](https://doi.org/10.1016/S0735-1097(98)00221-6)
8. Kanji S, Williamson DR, Yaghchi BM, Albert M, McIntyre L, Canadian Critical Care Trials Group. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. *J Crit Care* 2012;**27**:326.e1–8. <https://doi.org/10.1016/j.jcrc.2011.10.011>
9. Clayton B, Ball S, Read J, Waddy S. Risk of thromboembolism in patients developing critical illness-associated atrial fibrillation. *Clin Med* 2018;**18**:282–7. <https://doi.org/10.7861/clinmedicine.18-4-282>
10. Wetterslev M, Haase N, Hassager C, Belley-Cote EP, McIntyre WF, An Y, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review. *Intensive Care Med* 2019;**45**:928–38. <https://doi.org/10.1007/s00134-019-05633-x>
11. Bedford JP, Gerry S, Hatch RA, Rechner I, Young JD, Watkinson PJ. Hospital outcomes associated with new-onset atrial fibrillation during ICU admission: a multicentre competing risks analysis. *J Crit Care* 2020;**60**:72–8. <https://doi.org/10.1016/j.jcrc.2020.07.009>
12. Fernando SM, Mathew R, Hibbert B, Rochweg B, Munshi L, Walkey AJ, et al. New-onset atrial fibrillation and associated outcomes and resource use among critically ill adults – a multicenter retrospective cohort study. *Crit Care* 2020;**24**:15. <https://doi.org/10.1186/s13054-020-2730-0>
13. Arrigo M, Feliot E, Gayat E, Mebazaa A. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: a report from the FROG-ICU study. *Int J Cardiol* 2018;**270**:203. <https://doi.org/10.1016/j.ijcard.2018.07.080>
14. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. *Chest* 2014;**146**:1187–95. <https://doi.org/10.1378/chest.14-0003>

15. National Institute for Health and Care Excellence (NICE). *Atrial Fibrillation: Management*. Clinical Guideline [CG180]. London: NICE; 2014. URL: [www.nice.org.uk/guidance/cg180](http://www.nice.org.uk/guidance/cg180) (accessed 1 October 2020).
16. Chean CS, McAuley D, Gordon A, Welters ID. Current practice in the management of new-onset atrial fibrillation in critically ill patients: a UK-wide survey. *PeerJ* 2017;**5**:e3716. <https://doi.org/10.7717/peerj.3716>
17. Drikite L, Bedford JP, O'Bryan L, Petrinic T, Rajappan K, Doidge J, *et al*. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. *Crit Care* 2021;**25**:257. <https://doi.org/10.1186/s13054-021-03684-5>
18. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;**8**:19–32. <https://doi.org/10.1080/1364557032000119616>
19. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci* 2010;**5**:69. <https://doi.org/10.1186/1748-5908-5-69>
20. Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team's experience with Arksey and O'Malley's framework. *BMC Med Res Methodol* 2013;**13**:48. <https://doi.org/10.1186/1471-2288-13-48>
21. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, *et al*. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;**169**:467–73. <https://doi.org/10.7326/M18-0850>
22. Watkinson P, Johnson A, Rajappan K, Corbett M, Mouncey P, Harrison DA, *et al*. *Critical care Atrial Fibrillation Evaluation (CAFE): Protocol*. 2019. URL: <https://fundingawards.nihr.ac.uk/award/17/71/04> (accessed 1 October 2019).
23. Bedford JP, Harford M, Petrinic T, Young JD, Watkinson PJ. Risk factors for new-onset atrial fibrillation on the general adult ICU: a systematic review. *J Crit Care* 2019;**53**:169–75. <https://doi.org/10.1016/j.jcrc.2019.06.015>
24. Yokota T, Uchino S, Yoshida T, Fujii T, Takinami M. Predictors for sustained new-onset atrial fibrillation in critically ill patients: a retrospective observational study. *J Anesth* 2018;**32**:681–7. <https://doi.org/10.1007/s00540-018-2537-1>
25. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, *et al*. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;**366**:l4898. <https://doi.org/10.1136/bmj.l4898>
26. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, *et al*. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;**355**:i4919. <https://doi.org/10.1136/bmj.i4919>
27. Launey Y, Lasocki S, Asehnoune K, Gaudriot B, Chassier C, Cinotti R, *et al*. Impact of low-dose hydrocortisone on the incidence of atrial fibrillation in patients with septic shock: a propensity score-inverse probability of treatment weighting cohort study. *J Intensive Care Med* 2019;**34**:238–44. <https://doi.org/10.1177/0885066617696847>
28. Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study. *Chest* 2016;**149**:74–83. <https://doi.org/10.1378/chest.15-0959>
29. Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. *JAMA Cardiol* 2016;**1**:682–90. <https://doi.org/10.1001/jamacardio.2016.2181>

30. Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, *et al.* Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. *Anesthesiology* 1998;**89**:1052–9. <https://doi.org/10.1097/0000542-199811000-00004>
31. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, *et al.* Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. *Crit Care Med* 2001;**29**:1149–53. <https://doi.org/10.1097/00003246-200106000-00011>
32. Gerlach A, Kane-Gill S, F Dasta J, Steinberg S, C Martin L, Cook C. Diltiazem versus amiodarone for new-onset atrial arrhythmias in non-cardiac post surgical patients: a cohort study. *Crit Care Shock* 2008;**11**(3).
33. Cho MS, Nam G-B, Kim YN, Hwang J, Kim M, Lee JH, *et al.* Abstract 20382: comparison of outcomes after rhythm or rate control strategy for the new-onset atrial fibrillation in critically ill sepsis patients managed in the medical intensive care unit. *Circulation* 2017;**136**:A20382-A.
34. Matsumoto Y, Shibata SC, Maeda A, Imada T, Okitsu K, Fujino Y. *Comparison of the Short Acting Beta1 Blocker Landiolol with Amiodarone for Pharmacological Cardioversion for Atrial Fibrillation in Intensive Care Unit Patients*. Proceedings of the 2015 Annual Meeting of the International Anesthesia Research Society, 21–24 March 2015, Honolulu, HI, USA. <https://doi.org/10.1213/01.ane.0000470325.07465.0f>
35. Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock-comparison to amiodarone and metoprolol. *J Crit Care* 2017;**41**:16–23. <https://doi.org/10.1016/j.jcrc.2017.04.027>
36. Mieure KD, Moranville MP, Park JJ, Lat I, Jennings HR, Lazar S, *et al.* *A Comparison of Intravenous Rate Control Agents for New Onset Atrial Fibrillation with Rapid Ventricular Rate*. Proceedings of the 32nd Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm, 4–7 May 2011, San Francisco, CA, USA.
37. Jaffer F, Anand S, Ajay-obe A, Parbtani R, Doraiswamy V, Malo J. Use of amiodarone in management of atrial tachyarrhythmia in septic shock. *Chest* 2016;**150**:361A. <https://doi.org/10.1016/j.chest.2016.08.374>
38. Brown M, Nassoiy S, Chaney W, Plackett TP, Blackwell RH, Luchette F, *et al.* Impact and treatment success of new-onset atrial fibrillation with rapid ventricular rate development in the surgical intensive care unit. *J Surg Res* 2018;**229**:66–75. <https://doi.org/10.1016/j.jss.2018.03.009>
39. Sleeswijk ME, Tulleken JE, Van Noord T, Meertens JH, Ligtenberg JJ, Zijlstra JG. Efficacy of magnesium-amiodarone step-up scheme in critically ill patients with new-onset atrial fibrillation: a prospective observational study. *J Intensive Care Med* 2008;**23**:61–6. <https://doi.org/10.1177/0885066607310181>
40. Slavik RS, de Lemos J, Gorman SK, Buchkowsky S. Patterns of practice for the acute management of new-onset atrial fibrillation in critically-ill intensive care unit patients. *Crit Care Med* 2003;**31**:A137-A.
41. Liu WC, Lin WY, Lin CS, Huang HB, Lin TC, Cheng SM, *et al.* Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation. *Crit Care* 2016;**20**:373. <https://doi.org/10.1186/s13054-016-1548-2>
42. Mitrić G, Udy A, Bandeshe H, Clement P, Boots R. Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. *Crit Care* 2016;**20**:90. <https://doi.org/10.1186/s13054-016-1252-2>

43. Mayr AJ, Dünser MW, Ritsch N, Pajk W, Friesenecker B, Knotzer H, *et al.* High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study. *Wien Klin Wochenschr* 2004;**116**:310–17. <https://doi.org/10.1007/BF03040901>
44. Burris JM, Subramanian A, Sansgiry S, Palacio CH, Bakaeen FG, Awad SS. Perioperative atrial arrhythmias in noncardiothoracic patients: a review of risk factors and treatment strategies in the veteran population. *Am J Surg* 2010;**200**:601–5. <https://doi.org/10.1016/j.amjsurg.2010.07.019>
45. Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. *J Anesth* 2016;**30**:891–4. <https://doi.org/10.1007/s00540-016-2199-9>
46. Hennersdorf MG, Perings SM, Zühlke C, Heidland UE, Perings C, Heintzen MP, Strauer BE. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. *Intensive Care Med* 2002;**28**:925–9. <https://doi.org/10.1007/s00134-002-1317-3>
47. Delle Karth G, Schillinger M, Geppert A, Haumer M, Gwechenberger M, Meyer B, *et al.* Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population. *Wien Klin Wochenschr* 2005;**117**:92–7. <https://doi.org/10.1007/s00508-004-0297-4>
48. Kane S, Hanes S. Impact of hydrocortisone on atrial fibrillation in septic shock. *Crit Care Med* 2014;**42**:A1588. <https://doi.org/10.1097/01.ccm.0000458443.11317.7a>
49. Mayr A, Ritsch N, Knotzer H, Dünser M, Schobersberger W, Ulmer H, *et al.* Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. *Crit Care Med* 2003;**31**:401–5. <https://doi.org/10.1097/01.CCM.0000048627.39686.79>
50. Kyo M, Hosokawa K, Ohshimo S, Kida Y, Tanabe Y, Ota K, Shime N. High serum potassium level is associated with successful electrical cardioversion for new-onset atrial fibrillation in the intensive care unit: a retrospective observational study. *Anaesth Intensive Care* 2019;**47**:52–9. <https://doi.org/10.1177/0310057X18811815>
51. Chapman MJ, Moran JL, O’Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. *Intensive Care Med* 1993;**19**:48–52. <https://doi.org/10.1007/BF01709278>
52. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. *Crit Care Med* 1995;**23**:1816–24. <https://doi.org/10.1097/00003246-199511000-00005>
53. Yoshida T, Fujii T, Uchino S, Takinami M. Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review. *J Intensive Care* 2015;**3**:19. <https://doi.org/10.1186/s40560-015-0085-4>
54. Balik M, Matousek V, Maly M, Brozek T. Management of arrhythmia in sepsis and septic shock. *Anaesthesiol Intensive Ther* 2017;**49**:419–29. <https://doi.org/10.5603/AIT.a2017.0061>
55. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. *Chest* 2018;**154**:1424–34. <https://doi.org/10.1016/j.chest.2018.03.040>
56. Kanji S, Stewart R, Fergusson DA, McIntyre L, Turgeon AF, Hébert PC. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. *Crit Care Med* 2008;**36**:1620–4. <https://doi.org/10.1097/CCM.0b013e3181709e43>

57. Keller M, Meierhenrich R. [New onset atrial fibrillation in patients with sepsis.] *Anaesthesist* 2017;**66**:786–94. <https://doi.org/10.1007/s00101-017-0334-0>
58. Rehberg S, Joannidis M, Whitehouse T, Morelli A. Landiolol for managing atrial fibrillation in intensive care. *Eur Heart J supplements* 2018;**20**:A15–18. <https://doi.org/10.1093/eurheartj/sux039>
59. Schwartz A, Brotfain E, Koyfman L, Klein M. Cardiac arrhythmias in a septic ICU population: a review. *J Crit Care Med* 2015;**1**:140–6. <https://doi.org/10.1515/jccm-2015-0027>
60. Shapiro WA, Schulze K. An algorithm for the practical management of the new onset of atrial fibrillation in patients admitted to the ICU. *ICU Director* 2012;**3**:179–84. <https://doi.org/10.1177/1944451612449649>
61. Sibley S, Muscedere J. New-onset atrial fibrillation in critically ill patients. *Can Respir J* 2015;**22**:179–82. <https://doi.org/10.1155/2015/394961>
62. Sleeswijk ME, Van Noord T, Tulleken JE, Ligtenberg JJ, Girbes AR, Zijlstra JG. Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients – a clinical framework. *Crit Care* 2007;**11**:233. <https://doi.org/10.1186/cc6136>
63. Tran B. *Atrial Fibrillation in Sepsis: Should We Worry?* Relias Media; 2018. URL: [www.reliasmedia.com/articles/142049-atrial-fibrillation-in-sepsis-should-we-worry](http://www.reliasmedia.com/articles/142049-atrial-fibrillation-in-sepsis-should-we-worry) (accessed 1 October 2019).
64. Labbe V, Ederhy S, Fartoukh M, Cohen A. Should we administrate anticoagulants to critically ill patients with new onset supraventricular arrhythmias? *Arch Cardiovasc Dis* 2015;**108**:217–9. <https://doi.org/10.1016/j.acvd.2015.01.001>
65. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;**336**:924. <https://doi.org/10.1136/bmj.39489.470347.AD>
66. Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bögelein D, *et al.* Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. *Crit Care* 2010;**14**:R108. <https://doi.org/10.1186/cc9057>
67. Seguin P, Laviolle B, Maurice A, Leclercq C, Mallédant Y. Atrial fibrillation in trauma patients requiring intensive care. *Intensive Care Med* 2006;**32**:398–404. <https://doi.org/10.1007/s00134-005-0032-2>
68. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;**17**:1–12. [https://doi.org/10.1016/0197-2456\(95\)00134-4](https://doi.org/10.1016/0197-2456(95)00134-4)
69. Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. *Intensive Care Med* 1994;**20**:42–4. <https://doi.org/10.1007/BF02425054>
70. Walkey AJ, Hogarth DK, Lip GYH. Optimizing atrial fibrillation management: from ICU and beyond. *Chest* 2015;**148**:859–64. <https://doi.org/10.1378/chest.15-0358>
71. Vieillard-Baron A, Boyd J. Non-antiarrhythmic interventions in new onset and paroxysmal sepsis-related atrial fibrillation. *Intensive Care Med* 2018;**44**:94–7. <https://doi.org/10.1007/s00134-017-4986-7>
72. Walton J. The need for adequate rate control points to amiodarone as the drug of choice for treating critically ill patients with acute onset atrial fibrillation. *Crit Care Med* 2008;**36**:3132–3. <https://doi.org/10.1097/CCM.0b013e31818be8ad>
73. Trohman RG. Atrial fibrillation in the critically ill: common sense for a common problem. *Crit Care Med* 2008;**36**:1681–2. <https://doi.org/10.1097/CCM.0b013e31817014d2>

74. Intensive Care National Audit and Research Centre. *About the CMP*. URL: [www.icnarc.org/Our-Audit/Audits/Cmp/About](http://www.icnarc.org/Our-Audit/Audits/Cmp/About) (accessed 1 October 2020).
75. Harrison DA, Brady AR, Rowan K. Case mix, outcome and length of stay for admissions to adult, general critical care units in England, Wales and Northern Ireland: the Intensive Care National Audit. Research Centre Case Mix Programme Database. *Crit Care* 2004;**8**:R99–111. <https://doi.org/10.1186/cc2834>
76. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. *Stata J* 2004;**4**:103–12. <https://doi.org/10.1177/1536867x0400400201>
77. Marubini E, Valsecchi MG. *Analysing Survival Data from Clinical Trials and Observational Studies*. Hoboken, NJ: John Wiley & Sons; 2004.
78. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. *Am J Epidemiol* 2009;**170**:244–56. <https://doi.org/10.1093/aje/kwp107>
79. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. *Biometrics* 1978;**34**:541–54. <https://doi.org/10.2307/2530374>
80. Harrell J, Jr. *Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis*. New York, NY: Springer; 2001. <https://doi.org/10.1007/978-1-4757-3462-1>
81. Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, et al. Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. *J Crit Care* 2022;**67**:14–56. <https://doi.org/10.1016/j.jcrc.2021.11.005>
82. Johnson AE, Burgess J, Pimentel MA, Clifton DA, Young JD, Watkinson PJ, Tarassenko L. Physiological trajectory of patients pre and post ICU discharge. *Annu Int Conf IEEE Eng Med Biol Soc* 2014;**2014**:3160–3. <https://doi.org/10.1109/EMBC.2014.6944293>
83. Johnson AE, Pollard TJ, Shen L, Lehman LW, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. *Sci Data* 2016;**3**:160035. <https://doi.org/10.1038/sdata.2016.35>
84. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;**370**:1453–7. [https://doi.org/10.1016/S0140-6736\(07\)61602-X](https://doi.org/10.1016/S0140-6736(07)61602-X)
85. Palmer E, Post B, Klapaukh R, Marra G, MacCallum NS, Brealey D, et al. The association between supraphysiologic arterial oxygen levels and mortality in critically ill patients. a multicenter observational cohort study. *Am J Respir Crit Care Med* 2019;**200**:1373–80. <https://doi.org/10.1164/rccm.201904-0849OC>
86. Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol* 2016;**183**:758–64. <https://doi.org/10.1093/aje/kwv254>
87. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010;**362**:1363–73. <https://doi.org/10.1056/NEJMoa1001337>
88. Johnson AE, Kramer AA, Clifford GD. A new severity of illness scale using a subset of acute physiology and chronic health evaluation data elements shows comparable predictive accuracy. *Crit Care Med* 2013;**41**:1711–18. <https://doi.org/10.1097/CCM.0b013e31828a24fe>
89. Ho KM, Dobb GJ, Knuiman M, Finn J, Lee KY, Webb SA. A comparison of admission and worst 24-hour Acute Physiology and Chronic Health Evaluation II scores in predicting hospital mortality: a retrospective cohort study. *Crit Care* 2006;**10**:R4. <https://doi.org/10.1186/cc3913>

90. Koponen T, Karttunen J, Musialowicz T, Pietiläinen L, Uusaro A, Lahtinen P. Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. *Br J Anaesth* 2019;**122**:428–36. <https://doi.org/10.1016/j.bja.2018.12.019>
91. Fasiolo M, Wood SN, Zaffran M, Nedellec R, Goude Y. Fast calibrated additive quantile regression. *J Am Stat Assoc* 2020;**116**:1402–12. <https://doi.org/10.1080/01621459.2020.1725521>
92. Huling JD, Mak S. Energy balancing of covariate distributions. *arXiv* 2020;2004.13962.
93. Greifer N. *WeightIt: Weighting for Covariate Balance in Observational Studies*. 2020. URL: <https://ngreifer.github.io/WeightIt/> (accessed 1 October 2010).
94. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res* 2011;**46**:399–424. <https://doi.org/10.1080/00273171.2011.568786>
95. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. *Stat Sci* 1986;**1**:54–75. <https://doi.org/10.1214/ss/1177013815>
96. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. New York, NY: Wiley; 1987. <https://doi.org/10.1002/9780470316696>
97. Harris S, Shi S, Brealey D, MacCallum NS, Denaxas S, Perez-Suarez D, et al. Critical Care Health Informatics Collaborative (CCHIC): data, tools and methods for reproducible research: a multi-centre UK intensive care database. *Int J Med Inform* 2018;**112**:82–9. <https://doi.org/10.1016/j.ijmedinf.2018.01.006>
98. National Institute for Health and Care Excellence (NICE). *Research Recommendations Process and Methods Guide*. London: NICE; 2015.
99. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med* 2015;**373**:823–33. <https://doi.org/10.1056/NEJMoa1501035>
100. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. *Chest* 2010;**137**:263–72. <https://doi.org/10.1378/chest.09-1584>
101. Champion S, Lefort Y, Gaüzère BA, Drouet D, Bouchet BJ, Bossard G, et al. CHADS2 and CHA2DS2-VASc scores can predict thromboembolic events after supraventricular arrhythmia in the critically ill patients. *J Crit Care* 2014;**29**:854–8. <https://doi.org/10.1016/j.jcrc.2014.05.010>
102. Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS, Noseworthy PA. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin k antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. *Am J Cardiol* 2017;**120**:1549–56. <https://doi.org/10.1016/j.amjcard.2017.07.051>
103. Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Romiti GF, Marin F, Lip GYH. Predicting bleeding events in anticoagulated patients with atrial fibrillation: a comparison between the HAS-BLED and GARFIELD-AF bleeding scores. *J Am Heart Assoc* 2018;**7**:e009766. <https://doi.org/10.1161/JAHA.118.009766>
104. Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. *BMJ Open* 2017;**7**:e017157. <https://doi.org/10.1136/bmjopen-2017-017157>

105. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. *J Am Coll Cardiol* 2012;**60**:861–7. <https://doi.org/10.1016/j.jacc.2012.06.019>
106. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. *JAMA* 2011;**306**:2248–54. <https://doi.org/10.1001/jama.2011.1615>
107. Russell L, Holst LB, Kjeldsen L, Stensballe J, Perner A. Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies. *Ann Intensive Care* 2017;**7**:119. <https://doi.org/10.1186/s13613-017-0341-y>
108. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, *et al.* Bleeding during critical illness: a prospective cohort study using a new measurement tool. *Clin Invest Med* 2007;**30**:E93–102. <https://doi.org/10.25011/cim.v30i2.985>
109. Granholm A, Zeng L, Dionne JC, Perner A, Marker S, Krag M, *et al.* Predictors of gastrointestinal bleeding in adult ICU patients: a systematic review and meta-analysis. *Intensive Care Med* 2019;**45**:1347–59. <https://doi.org/10.1007/s00134-019-05751-6>
110. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC). *Int J Epidemiol* 2017;**46**:1093–1093i. <https://doi.org/10.1093/ije/dyx015>
111. Landesberg G, Gilon D, Meroz Y, Georgieva M, Levin PD, Goodman S, *et al.* Diastolic dysfunction and mortality in severe sepsis and septic shock. *Eur Heart J* 2012;**33**:895–903. <https://doi.org/10.1093/eurheartj/ehr351>
112. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, *et al.* Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. *J Am Coll Cardiol* 1994;**23**:1535–40. [https://doi.org/10.1016/0735-1097\(94\)90652-1](https://doi.org/10.1016/0735-1097(94)90652-1)
113. Louie EK, Liu D, Reynertson SI, Loeb HS, McKiernan TL, Scanlon PJ, Hariman RJ. ‘Stunning’ of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: demonstration by transesophageal Doppler techniques in a canine model. *J Am Coll Cardiol* 1998;**32**:2081–6. [https://doi.org/10.1016/S0735-1097\(98\)00508-7](https://doi.org/10.1016/S0735-1097(98)00508-7)
114. Ang EL, Chan WL, Cleland JG, Moore D, Krikler SJ, Alexander ND, Oakley CM. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. *Br Heart J* 1990;**64**:256–60. <https://doi.org/10.1136/hrt.64.4.256>
115. Gritsenko D, Paris D, Aitken SL, Lee YI, Altshuler J. Amiodarone versus digoxin for rate control in critically ill patients with rapid atrial fibrillation or flutter. *J Emerg Crit Care Med* 2018;**2**. <https://doi.org/10.21037/jeccm.2018.06.07>
116. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. *Am J Cardiol* 1990;**65**:679–80. [https://doi.org/10.1016/0002-9149\(90\)91053-9](https://doi.org/10.1016/0002-9149(90)91053-9)

# Appendix 1 Search strategy

## MEDLINE (via Ovid)

Date range searched: 1946 to present.

Date searched: 4 March 2019.

Records retrieved: 1087.

### Search strategy

1. ATRIAL FIBRILLATION/
2. ATRIAL FLUTTER/
3. SUPRAVENTRICULAR TACHYCARDIA/
4. ("atrial fibrillation\*" or AF).ab,ti.
5. "atrial flutter\*" .ab,ti.
6. "atrial arrhythmia\*" .ab,ti.
7. ("supraventricular tachycardia\*" or SVT).ab,ti.
8. "NOAF\*" .ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. INTENSIVE CARE UNITS/
11. CRITICAL CARE/
12. SEPSIS/
13. SEPTIC SHOCK/
14. "intensive care".ab,ti.
15. "critical care unit\*" .ab,ti.
16. "intensive therapy unit\*" .ab,ti.
17. "high dependenc\*" .ab,ti.
18. (ICU\* or ITU\* or HDU\* or CCU\*).ab,ti.
19. "critically unwell".ab,ti.
20. "critically ill".ab,ti.
21. (sepsis or "septic shock").ab,ti.
22. 10 or 11 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
23. 9 and 22
24. limit 23 to animals
25. limit 23 to ("newborn infant (birth to 1 month)" or "infant (1 to 23 months)" or "preschool child (2 to 5 years)" or "child (6 to 12 years)")
26. "case report\*" .ti.
27. 24 or 25 or 26
28. 23 not 27
29. "atrial fibrillation\*" .ab,ti.
30. (cardiac or cardiothoracic or "cardio thoracic" or cardiopulmonary or "cardio pulmonary").ab,ti.
31. "surg\*" .ab,ti.
32. "coronary care unit\*" .ab,ti.
33. 29 and 30 and 31
34. 29 and 32
35. 33 or 34
36. 28 not 35.

## EMBASE (via Ovid)

Date range searched: inception to 4 March 2019.

Date searched: 4 March 2019.

Records retrieved: 3962.

### Search strategy

1. ATRIAL FIBRILLATION/
2. ATRIAL FLUTTER/
3. SUPRAVENTRICULAR TACHYCARDIA/
4. ("atrial fibrillation\*" or AF).ab,ti.
5. "atrial flutter\* ".ab,ti.
6. "atrial arrhythmia\* ".ab,ti.
7. ("supraventricular tachycardia\*" or SVT).ab,ti.
8. "NOAF\*".ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. INTENSIVE CARE UNITS/
11. CRITICAL CARE/
12. SEPSIS/
13. SEPTIC SHOCK/
14. "intensive care".ab,ti.
15. "critical care unit\* ".ab,ti.
16. "intensive therapy unit\* ".ab,ti.
17. "high dependenc\* ".ab,ti.
18. (ICU\* or ITU\* or HDU\* or CCU\*).ab,ti.
19. "critically unwell".ab,ti.
20. "critically ill".ab,ti.
21. (sepsis or "septic shock").ab,ti.
22. 10 or 11 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
23. 9 and 22
24. limit 23 to animal studies
25. limit 23 to (infant <to one year> or preschool child <1 to 6 years> or school child <7 to 12 years>)
26. "case report\* ".ti.
27. 24 or 25 or 26
28. 23 not 27
29. "atrial fibrillation\* ".ab,ti.
30. (cardiac or cardiothoracic or "cardio thoracic" or cardiopulmonary or "cardio pulmonary").ab,ti.
31. "surg\*".ab,ti.
32. "coronary care unit\* ".ab,ti.
33. 29 and 30 and 31
34. 29 and 32
35. 33 or 34
36. 28 not 35
37. limit 36 to conference abstracts
38. 36 not 37.

## Cumulative Index to Nursing and Allied Health Literature

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 441.

### Search strategy

1. ATRIAL FIBRILLATION/ (20,100)
2. ATRIAL FLUTTER/ (1521)
3. TACHYCARDIA, SUPRAVENTRICULAR/ (2593)
4. ("atrial fibrillation\*" OR AF).ti,ab (24,117)
5. ("atrial flutter\*").ti,ab (1541)
6. ("atrial arrhythmia\*").ti,ab (867)
7. ("supraventricular tachycardia\*" OR SVT).ti,ab (1683)
8. (NOAF\*).ti,ab (9)
9. (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8) (32,813)
10. INTENSIVE CARE UNITS/ (32,253)
11. CRITICAL CARE/ (19,423)
12. SHOCK, SEPTIC/ (4198)
13. ("intensive care").ti,ab (50,295)
14. ("critical care unit\*").ti,ab (1967)
15. ("intensive therapy unit\*").ti,ab (254)
16. ("high dependenc\*").ti,ab (627)
17. (ICU\* OR ITU\* OR HDU\* OR CCU\*).ti,ab (24,659)
18. ("critically unwell").ti,ab (17)
19. ("critically ill").ti,ab (17,286)
20. (10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19) (92,933)
21. (9 AND 20) (480)
22. ("atrial fibrillation\*").ti,ab (21,936)
23. (cardiac OR cardiothoracic OR "cardio thoracic" OR cardiopulmonary OR "cardio pulmonary").ti,ab (114,324)
24. (surg\*).ti,ab (319,271)
25. ("coronary care unit\*").ti,ab (859)
26. ("case report\*").ti (44,822)
27. (22 AND 23 AND 24) (894)
28. (22 AND 25) (20)
29. (26 OR 27 OR 28) (45,731)
30. 21 NOT 29 (361)
31. 30 [Human age groups Infant~Newborn: birth-1 month OR Infant: 1-23 months OR Child~Preschool: 2-5 years OR Child: 6-12 years] (37)
32. ANIMAL STUDIES/ (98,956)
33. (30 AND 32) (1)
34. (31 OR 33) (38)
35. 30 NOT 34 (323).

## Web of Science

Includes Conference Proceedings Citation Index –Science, Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index, Conference Proceedings Citation Index-Science, Conference Proceedings Citation Index- Social Science & Humanities, The Book Citation Index-Science, The Book Citation Index – Social Science & Humanities, Emerging Sources Citation Index, Current chemical reactions-expanded and *Index Chemicus*.

Date ranged searched: 1949 to 2019.

Date searched: 6 March 2019.

Records retrieved: 1772.

Records retrieved after filtering by title: 137.

### Search strategy

“TOPIC: (atrial AND fibrillat\*).

Refined by: TOPIC: ((intensive OR critical) AND (care OR therapy)).

Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC”.

## Cochrane Library

Includes Cochrane Reviews, Cochrane Protocols and Trials.

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved in Cochrane Reviews: 0.

Records retrieved in Cochrane Protocols: 0.

Records retrieved in Trials: 96.

### Search strategy

“atrial fibrillation” AND (“intensive care” OR “critical care” OR “intensive therapy”).

## Database of Abstracts of Reviews of Effects

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 4.

### Search strategy

(“atrial fibrillation” AND (“critical care” OR “intensive care”).

## OpenGrey

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 2.

### Search strategy

“Atrial fibrillation” AND (“Intensive Care” OR “Critical Care” OR “Intensive Therapy”).

## Ongoing, unpublished or grey literature search strategies

### *ClinicalTrials.gov*

URL: <https://clinicaltrials.gov/>.

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 264.

### Search strategy

“Atrial fibrillation” in CONDITION field OR “Atrial flutter” in OTHER TERMS field.

### *International Standard Randomised Controlled Trial Number*

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 292.

### Search strategy

ATRIAL FIBRILLATION” in TEXT field.

### *EU clinical trials register*

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 12.

### Search strategy

“atrial fibrillation” AND (“critical care” OR “intensive care” OR “intensive therapy”).

### *World Health Organization International Clinical Trials Registry Platform*

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 12.

**Search strategy**

“atrial fibrillation” AND (“critical care” OR “intensive care” OR “intensive therapy”).

***National Institute for Health Research UK Clinical Trials Gateway***

Date range searched: inception to 11 March 2019.

Date searched: 11 March 2019.

Records retrieved: 149.

**Search strategy**

“atrial fibrillation”.

## Appendix 2 Risk-of-bias assessment

Reproduced with permission from Sterne *et al.*<sup>25</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others to copy and distribute this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

# Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)

## TEMPLATE FOR COMPLETION

Edited by Julian PT Higgins, Jelena Savović, Matthew J Page, Jonathan AC Sterne  
on behalf of the RoB2 Development Group

Version of 22 August 2019

The development of the RoB 2 tool was supported by the MRC Network of Hubs for Trials Methodology Research (MR/L004933/2- N61), with the support of the host MRC ConDuCT-II Hub (Collaboration and innovation for Difficult and Complex randomised controlled Trials In Invasive procedures - MR/K025643/1), by MRC research grant MR/M025209/1, and by a grant from The Cochrane Collaboration.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

<b>Study details</b>	
<b>Reference</b>	Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149-53. <a href="http://dx.doi.org/10.1097/00003246-200106000-00011">http://dx.doi.org/10.1097/00003246-200106000-00011</a>
<b>Study design</b>	
<input checked="" type="checkbox"/> Individually-randomized parallel-group trial	
<input type="checkbox"/> Cluster-randomized parallel-group trial	
<input type="checkbox"/> Individually randomized cross-over (or other matched) trial	
<b>For the purposes of this assessment, the interventions being compared are defined as</b>	

Experimental:	Amiodarone	Comparator:	Diltiazem
<b>Specify which outcome is being assessed for risk of bias</b>		Rate control	
<b>Specify the numerical result being assessed.</b> In case of multiple alternative analyses being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph) that uniquely defines the result being assessed.			
<b>Is the review team's aim for this result...?</b> <input checked="" type="checkbox"/> to assess the effect of <i>assignment to intervention</i> (the 'intention-to-treat' effect) <input type="checkbox"/> to assess the effect of <i>adhering to intervention</i> (the 'per-protocol' effect)			
<b>If the aim is to assess the effect of <i>adhering to intervention</i>, select the deviations from intended intervention that should be addressed (at least one must be checked):</b> <input type="checkbox"/> occurrence of non-protocol interventions <input type="checkbox"/> failures in implementing the intervention that could have affected the outcome <input type="checkbox"/> non-adherence to their assigned intervention by trial participants			
<b>Which of the following sources were <u>obtained</u> to help inform the risk-of-bias assessment? (tick as many as apply)</b> <input checked="" type="checkbox"/> Journal article(s) with results of the trial <input type="checkbox"/> Trial protocol <input type="checkbox"/> Statistical analysis plan (SAP) <input type="checkbox"/> Non-commercial trial registry record (e.g. ClinicalTrials.gov record) <input type="checkbox"/> Company-owned trial registry record (e.g. GSK Clinical Study Register record) <input type="checkbox"/> "Grey literature" (e.g. unpublished thesis) <input type="checkbox"/> Conference abstract(s) about the trial <input type="checkbox"/> Regulatory document (e.g. Clinical Study Report, Drug Approval Package) <input type="checkbox"/> Research ethics application <input type="checkbox"/> Grant database summary (e.g. NIH RePORTER or Research Councils UK Gateway to Research) <input type="checkbox"/> Personal communication with trialist <input type="checkbox"/> Personal communication with the sponsor			

Risk of bias assessment

Responses underlined in green are potential markers for low risk of bias, and responses in **red** are potential markers for a risk of bias. Where questions relate only to sign posts to other questions, no formatting is used.

Domain 1: Risk of bias arising from the randomization process

Signalling questions	Comments	Response options
1.1 Was the allocation sequence random?	Patients were "randomly assigned" to treatments	NI
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?		NI
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	Important baseline differences in sex and age (though could also be due to the play of chance).	<b>PY</b>
Risk-of-bias judgement		High
Optional: What is the predicted direction of bias arising from the randomization process?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

## Domain 2: Risk of bias due to deviations from the intended interventions (*effect of assignment to intervention*)

Signalling questions	Comments	Response options
2.1. Were participants aware of their assigned intervention during the trial?	Participants in intensive care. No blinding of interventions given.	<a href="#">PN</a>
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		<a href="#">Y</a>
2.3. If <a href="#">Y/PY/NI</a> to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the trial context?		NI
2.4. If <a href="#">Y/PY</a> to 2.3: Were these deviations likely to have affected the outcome?		NA
2.5. If <a href="#">Y/PY/NI</a> to 2.4: Were these deviations from intended intervention balanced between groups?		NA
2.6. Was an appropriate analysis used to estimate the effect of assignment to intervention?	Full ITT analysis	<a href="#">Y</a>
2.7. If <a href="#">N/PN/NI</a> to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?		NA
<b>Risk-of-bias judgement</b>		Some concerns
Optional: What is the predicted direction of bias due to deviations from intended interventions?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

**Domain 2: Risk of bias due to deviations from the intended interventions (*effect of adhering to intervention*)**

Signalling questions	Comments	Response options
2.1. Were participants aware of their assigned intervention during the trial?		Y / PY / <u>PN</u> / <u>N</u> / NI
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		Y / PY / <u>PN</u> / <u>N</u> / NI
2.3. [If applicable:] If <u>Y</u> / <u>PY</u> /NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups?		NA / <u>Y</u> / <u>PY</u> / <u>PN</u> / <u>N</u> / NI
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?		NA / Y / PY / <u>PN</u> / <u>N</u> / NI
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants' outcomes?		NA / Y / PY / <u>PN</u> / <u>N</u> / NI
2.6. If <u>N</u> / <u>PN</u> /NI to 2.3, or <u>Y</u> / <u>PY</u> /NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?		NA / <u>Y</u> / <u>PY</u> / <u>PN</u> / <u>N</u> / NI
Risk-of-bias judgement		Low / High / Some concerns
Optional: What is the predicted direction of bias due to deviations from intended interventions?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

**Domain 3: Missing outcome data**

Signalling questions	Comments	Response options
3.1 Were data for this outcome available for all, or nearly all, participants randomized?		<u>PY</u>
3.2 <b>If <u>N/PN/NI</u> to 3.1:</b> Is there evidence that the result was not biased by missing outcome data?		NA
3.3 <b>If <u>N/PN</u> to 3.2:</b> Could missingness in the outcome depend on its true value?		NA
3.4 <b>If <u>Y/PY/NI</u> to 3.3:</b> Is it likely that missingness in the outcome depended on its true value?		NA
<b>Risk-of-bias judgement</b>		Low
Optional: What is the predicted direction of bias due to missing outcome data?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

### Domain 4: Risk of bias in measurement of the outcome

Signalling questions	Comments	Response options
4.1 Was the method of measuring the outcome inappropriate?		<u>N</u>
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?		<u>PN</u>
4.3 <u>If <u>N/PN/NI</u> to 4.1 and 4.2:</u> Were outcome assessors aware of the intervention received by study participants?		<u>PY</u>
4.4 <u>If <u>Y/PY/NI</u> to 4.3:</u> Could assessment of the outcome have been influenced by knowledge of intervention received?	Sustained rate reduction of 30% is an objective outcome	<u>PN</u>
4.5 <u>If <u>Y/PY/NI</u> to 4.4:</u> Is it likely that assessment of the outcome was influenced by knowledge of intervention received?		NA
Risk-of-bias judgement		Low
Optional: What is the predicted direction of bias in measurement of the outcome?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

**Domain 5: Risk of bias in selection of the reported result**

Signalling questions	Comments	Response options
<b>5.1</b> Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?		NI
<b>Is the numerical result being assessed likely to have been selected, on the basis of the results, from...</b>		
<b>5.2.</b> ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?		NI
<b>5.3</b> ... multiple eligible analyses of the data?		NI
<b>Risk-of-bias judgement</b>		Some concerns
Optional: What is the predicted direction of bias due to selection of the reported result?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

Overall risk of bias

Risk-of-bias judgement		High
Optional: What is the overall predicted direction of bias for this outcome?		NA / Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable

<b>Study details</b>	
<b>Reference</b>	Balser JR, Martinez EA, Winters BD, Perdue PW, Clarke AW, Huang W, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. <i>Anesthesiology</i> 1998;89:1052-9. <a href="http://dx.doi.org/10.1097/00000542-199811000-00004">http://dx.doi.org/10.1097/00000542-199811000-00004</a>
<b>Study design</b>	
<input checked="" type="checkbox"/>	Individually-randomized parallel-group trial
<input type="checkbox"/>	Cluster-randomized parallel-group trial
<input type="checkbox"/>	Individually randomized cross-over (or other matched) trial
<b>For the purposes of this assessment, the interventions being compared are defined as</b>	
Experimental:	Diltiazem
Comparator:	Esmolol
<b>Specify which outcome is being assessed for risk of bias</b>	Rhythm control
<b>Specify the numerical result being assessed.</b> In case of multiple alternative analyses being presented, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph) that uniquely defines the result being assessed.	2hr conversion subgroup of AFib patients
<b>Is the review team's aim for this result...?</b>	
<input checked="" type="checkbox"/>	to assess the effect of <i>assignment to intervention</i> (the 'intention-to-treat' effect)
<input type="checkbox"/>	to assess the effect of <i>adhering to intervention</i> (the 'per-protocol' effect)
<b>If the aim is to assess the effect of <i>adhering to intervention</i>, select the deviations from intended intervention that should be addressed (at least one must be checked):</b>	
<input type="checkbox"/>	occurrence of non-protocol interventions
<input type="checkbox"/>	failures in implementing the intervention that could have affected the outcome
<input type="checkbox"/>	non-adherence to their assigned intervention by trial participants
<b>Which of the following sources were <u>obtained</u> to help inform the risk-of-bias assessment? (tick as many as apply)</b>	
<input checked="" type="checkbox"/>	Journal article(s) with results of the trial
<input type="checkbox"/>	Trial protocol

- ☐ Statistical analysis plan (SAP)
- ☐ Non-commercial trial registry record (e.g. ClinicalTrials.gov record)
- ☐ Company-owned trial registry record (e.g. GSK Clinical Study Register record)
- ☐ “Grey literature” (e.g. unpublished thesis)
- ☐ Conference abstract(s) about the trial
- ☐ Regulatory document (e.g. Clinical Study Report, Drug Approval Package)
- ☐ Research ethics application
- ☐ Grant database summary (e.g. NIH RePORTER or Research Councils UK Gateway to Research)
- ☐ Personal communication with trialist
- ☐ Personal communication with the sponsor

## Risk of bias assessment

Responses underlined in green are potential markers for low risk of bias, and responses in **red** are potential markers for a risk of bias. Where questions relate only to sign posts to other questions, no formatting is used.

### Domain 1: Risk of bias arising from the randomization process

Signalling questions	Comments	Response options
1.1 Was the allocation sequence random?	Patients "were randomized"	NI
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?		NI
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?		<u>PN</u>
Risk-of-bias judgement		Some concerns
Optional: What is the predicted direction of bias arising from the randomization process?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

## Domain 2: Risk of bias due to deviations from the intended interventions (*effect of assignment to intervention*)

Signalling questions	Comments	Response options
2.1. Were participants aware of their assigned intervention during the trial?	Patients were in an ICU. Abstract says study was "unblinded"	<u>PN</u>
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		<u>Y</u>
2.3. <u>If Y/PY/Ni to 2.1 or 2.2</u> : Were there deviations from the intended intervention that arose because of the trial context?	Similar proportions of post-randomisation use of digoxin but no reporting on the use of "DC cardioversion implemented at the discretion of physician staff"	NI
2.4 <u>If Y/PY to 2.3</u> : Were these deviations likely to have affected the outcome?		NA
2.5. <u>If Y/PY/Ni to 2.4</u> : Were these deviations from intended intervention balanced between groups?		NA
2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?		<u>Y</u>
2.7 <u>If N/PN/Ni to 2.6</u> : Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?		NA
<b>Risk-of-bias judgement</b>		Some concerns
Optional: What is the predicted direction of bias due to deviations from intended interventions?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

## Domain 2: Risk of bias due to deviations from the intended interventions (*effect of adhering to intervention*)

Signalling questions	Comments	Response options
2.1. Were participants aware of their assigned intervention during the trial?		Y / PY / <u>PN</u> / N / NI
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?		Y / PY / <u>PN</u> / N / NI
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups?		NA / <u>Y</u> / PY / PN / N / NI
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?		NA / Y / PY / <u>PN</u> / N / NI
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants' outcomes?		NA / Y / PY / <u>PN</u> / N / NI
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?		NA / <u>Y</u> / PY / PN / N / NI
Risk-of-bias judgement		Low / High / Some concerns
Optional: What is the predicted direction of bias due to deviations from intended interventions?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

### Domain 3: Missing outcome data

Signalling questions	Comments	Response options
3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Data for all 44 patients with atrial fibrillation were reported	<u>Y</u>
3.2 <u>If N/PN/Ni to 3.1</u> : Is there evidence that the result was not biased by missing outcome data?		NA
3.3 <u>If N/PN to 3.2</u> : Could missingness in the outcome depend on its true value?		NA
3.4 <u>If Y/PY/Ni to 3.3</u> : Is it likely that missingness in the outcome depended on its true value?		NA
Risk-of-bias judgement		Low
Optional: What is the predicted direction of bias due to missing outcome data?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

**Domain 4: Risk of bias in measurement of the outcome**

Signalling questions	Comments	Response options
4.1 Was the method of measuring the outcome inappropriate?		<u>N</u>
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?		<u>N</u>
4.3 <u>If N/PN/Ni to 4.1 and 4.2</u> : Were outcome assessors aware of the intervention received by study participants?	Electrocardiograms and rhythm strips reviewed by a cardiologist who was blinded to treatment	<u>N</u>
4.4 <u>If Y/PY/Ni to 4.3</u> : Could assessment of the outcome have been influenced by knowledge of intervention received?		NA
4.5 <u>If Y/PY/Ni to 4.4</u> : Is it likely that assessment of the outcome was influenced by knowledge of intervention received?		NA
Risk-of-bias judgement		Low
Optional: What is the predicted direction of bias in measurement of the outcome?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

### Domain 5: Risk of bias in selection of the reported result

Signalling questions	Comments	Response options
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?		NI
Is the numerical result being assessed likely to have been selected, on the basis of the results, from...		
5.2. ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	Likely that there is only one way in which the outcome can be measured	<a href="#">PN</a>
5.3 ... multiple eligible analyses of the data?	Outcome likely to be analysable in only one way	<a href="#">PN</a>
Risk-of-bias judgement		Some concerns
Optional: What is the predicted direction of bias due to selection of the reported result?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable

**Overall risk of bias**

<b>Risk-of-bias judgement</b>		Some concerns
Optional: What is the overall predicted direction of bias for this outcome?		NA / Favours experimental / Favours comparator / Towards null / Away from null / Unpredictable



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



## Appendix 3 Data extraction tables for single-group studies

TABLE 15 Methods and characteristics of prospective single-group studies

Study details	Population characteristics	Intervention
First author and year: Delle Karth 2005 <sup>47</sup>	Primary diagnosis: perspiratory failure (17.6%), heart failure (35%), sepsis (17.6%) and cardiopulmonary resuscitation (11.7%)	Ibutilide: patients received up to two 10-minute i.v. infusions of 1.0 mg of ibutilide, with an interval of 10 minutes. If AF did not terminate during or within 10 minutes after the end of the first infusion, the second infusion was administered. If AF persisted at minute 60, ibutilide treatment was considered unsuccessful and further treatment (beyond minute 60) was started at the discretion of the treating physician
Setting: cardiologic ICU	Median (range) age reported: 63 (56.5–73) years	
Note: medical patients included in the study	Male: $n = 11$ (64.7%)	
Country: Austria	Severity of illness: median (range) SAPS II reported 53 (44.5–63)	
Sample size: $n = 17$ (data extracted for medical patients only; the study also includes cardiac-surgical patients)	Patients on vasopressors: $n = 15$ (88.2%)	Line of NOAF treatment: not specified
NOAF patients: $n = 15$ (88.2%)	Patients with CVD: $n = 6$ (35%) (heart failure)	
	Patients with acute renal failure: $n = 3$ (17.6%)	
	Patients with acute respiratory failure: NR	
	Mechanical ventilation at NOAF onset: $n = 13$ (76.5%)	
	Serum potassium: NR	
	Definition of NOAF: 'recent-onset (< 1 hour) tachycardic (> 100 beats per minute) sustained (> 10 minutes) atrial fibrillation'	
First author and year: Hennersdorf 2002 <sup>46</sup>	Primary diagnosis: hypertension (31%), hypertrophic obstructive cardiomyopathy (8%), dilative cardiomyopathy (12%), cor pulmonale (15%), coronary artery disease (19%), sepsis with cardiac involvement (15%) and reduced left ventricular ejection fraction (15%)	Ibutilide was administered as an infusion over a period of 10 minutes. The dose of ibutilide was 1 mg i.v.; in the case of persisting arrhythmia and body weight of > 70 kg, a second infusion of 1 mg of ibutilide was administered after 30 minutes. Before the ibutilide infusion was started, all patients were given magnesium (1 g, i.v.) and potassium (if the potassium serum level was < 4.5 mmol/l). Magnesium and potassium were administered to prevent proarrhythmic effects (torsade de pointes tachycardia)
Setting: university hospital ICU	Mean age: $68 \pm 11$ years	
Country: Germany	Male: $n = 21$ (80.7%)	
Sample size: $n = 26$	Severity of illness: APACHE II score, median (range) 8 (5–24)	
NOAF patients: $n = 7$ (27%)		All patients received heparin i.v. during the stay on the ICU

Study details	Population characteristics	Intervention
Note: results reported separately for NOAF group	<p>Patients on vasopressors: NR</p> <p>Patients with CVD: hypertrophic obstructive cardiomyopathy (8%), dilative cardiomyopathy (12%), cor pulmonale (15%), coronary artery disease (19%) and reduced left ventricular ejection fraction (15%)</p> <p>Patients with acute renal failure: NR</p> <p>Patients with acute respiratory failure: NR</p> <p>Mechanical ventilation at NOAF onset: <math>n = 19</math> (73%) (not specified if at the onset)</p> <p>Serum potassium: NR</p> <p>Definition of NOAF: NR</p>	<p>Line of NOAF treatment: second line</p> <p>All patients received amiodarone (150 mg, i.v.) as the first-line drug. If patients failed to convert back to sinus rhythm, ibutilide was given i.v. 2 hours after the administration of amiodarone</p>
First author and year: Mayr 2003 <sup>49</sup>	Surgery type: abdominal (35.1%), cardiac (35.1%), vascular (2.7%), trauma (10.81%), orthopaedic (8.1%) and thoracic (5.4%)	
Setting: Surgical ICU	Pneumonia after surgery: 2.7%	
Country: Austria	Median age (range): all patients, 72 years (34–94 years); primary responders, 67 years (34–82 years); non-responders, 73.5 years (51–94 years)	
Sample size: $n = 37$	Male: all patients, $n = 16/37$ (43.2%); primary responders, $n = 7/13$ (53.8%); non-responders, $n = 9/24$ (37.5%)	
NOAF patients: $n = 31$ (84%)	Severity of illness: median (range) SAPS reported – all patients, 13 (5–29); primary responders, 14 (5–29); non-responders, 13 (9–26)	
	Patients on vasopressors: all patients, $n = 29/37$ (78.37%); primary responders, $n = 10/13$ (76.9%); non-responders, $n = 19/24$ (79.16%)	
continued		

TABLE 15 Methods and characteristics of prospective single-group studies (continued)

Study details	Population characteristics				Intervention
	Patients with CVD:				Electrical cardioversion: if required, patients were sedated with etomidate. A maximum of four consecutive shocks were administered. In patients not responding to electrical cardioversion or in recurrent arrhythmia, i.v. anti-arrhythmic therapy was started  Line of NOAF treatment: not specified
	Cardiovascular disease	All patients (N = 37), n (%)	Primary responders (N = 13), n (%)	Non-responders (N = 24), n (%)	
	Coronary artery disease	22 (59.45)	7 (53.8)	15 (62.5)	
	Heart failure	13 (35)	4 (30.76)	9 (37.5)	
	Patients with acute renal failure: NR				
	Patients with acute respiratory failure: NR				
	Mechanical ventilation at NOAF onset: NR				
	Serum potassium (mmol/l): all patients, 4.2 (IQR 3.5–5); primary responders, 4.2 (IQR 3.5–5); non-responders, 4.2 (IQR 3.6–4.7)				
	Definition of NOAF: ‘SVT were defined as narrow-complex, non-sinus tachycardias with heart rate > 100 beats/min for at least 15 mins’				
First author and year: Nakamura 2016 <sup>45</sup>	Primary diagnosis: sepsis (50%) and heart failure (56.2%)				Switching therapy from landiolol to a bisoprolol patch: switching occurred where a continuous landiolol infusion was used for AF-related tachycardia, and its administration duration reached 6 days, or where long-term therapy was expected before day 6. A 4 mg/24 hour bisoprolol patch was attached and the landiolol infusion was stopped after 6 hours. Median landiolol administration time before bisoprolol patch use: 88.1 hours. Median landiolol dosage on bisoprolol patch use: 3.1 µg/kg/minute. Median noradrenaline dosage on bisoprolol patch use: 0.20 µg/kg/minute  Line of NOAF treatment: second line
Setting: medical/surgical ICU for in-hospital patients and emergency ICU for emergency outpatients	Mean age: 75.0 ± 13.1 years				
	Male: n = 7 (43.75%)				
Country: Japan	Severity of illness: mean APACHE II score reported, 24.3 ± 6.0; mean SOFA score reported, 8.6 ± 3.1				
Sample size: n = 16	Patients on vasopressors: in 62.5% of patients, noradrenaline had been given with landiolol				
NOAF patients: 100%					

Study details	Population characteristics	Intervention
	Patients with CVD: $n = 9$ (56.2%) (heart failure)	
	Patients with acute renal failure: NR	
	Patients with acute respiratory failure: NR	
	Mechanical ventilation at NOAF onset: NR	
	Serum potassium: NR	
	Definition of NOAF: NR	
First author and year: Slavik 2003 <sup>40</sup> (conference abstract)	Primary diagnosis: NR	For NOAF rate control and conversion: i.v. amiodarone used in 74.5% of episodes
Setting: general ICU	Mean age: NR	
Country: Canada	Male: NR	For stroke prophylaxis: i.v. heparin used in 36.4% of episodes
Sample size: NR	Severity of illness: NR	Line of NOAF treatment: not specified
NOAF patients: 6.6% patients developed NOAF	Patients on vasopressors: NR	
	Patients with CVD: NR	
	Patients with acute renal failure: NR	
	Patients with acute respiratory failure: NR	
	Mechanical ventilation at NOAF onset: NR	
	Serum potassium: NR	
	Definition of NOAF: NR	
continued		

TABLE 15 Methods and characteristics of prospective single-group studies (continued)

Study details	Population characteristics	Intervention
First author and year: Sleswijk 2008 <sup>39</sup>	Primary diagnosis: NR	Magnesium infusion: patients received MgSO <sub>4</sub> bolus followed by continuous infusion. The infusion rate was reduced to half when plasma (Mg <sup>2+</sup> ) was > 2.0 mmol/l and stopped when plasma (Mg <sup>2+</sup> ) was > 3.0 mmol/l. Where sinus rhythm was achieved, the infusion was stopped at the discretion of the treating clinician
Setting: tertiary ICU, 12 bed	Medical patients: magnesium responders, <i>n</i> = 11; magnesium non-responders, <i>n</i> = 9	
Country: the Netherlands	Surgery patients: magnesium responders, <i>n</i> = 5; magnesium non-responders, <i>n</i> = 4	Line of NOAF treatment: first line. Where no rhythm or rate control (< 110 b.p.m.) was achieved after 1 hour of starting the MgSO <sub>4</sub> infusion, an infusion of amiodarone (loading dose of 300 mg followed by an infusion of 1200 mg/24 hours) was started. Where sinus rhythm was achieved, the amiodarone infusion was stopped at the discretion of the treating clinician
Sample size: <i>n</i> = 29	Mean age: magnesium responders, 64 ± 16 years; magnesium non-responders 69 ± 17 years	
NOAF patients: 100%	Male: <i>n</i> = 14 (48%) (magnesium responders, <i>n</i> = 7; magnesium non-responders, <i>n</i> = 7)	Line of NOAF treatment: second line
	Severity of illness: mean APACHE II score reported – all patients, 19 ± 7 (magnesium responders, 18 ± 7; magnesium non-responders, 21 ± 7)	
	Patients on vasopressors: <i>n</i> = 17 (59%) (all patients) (magnesium responders, <i>n</i> = 8, 50%; magnesium non-responders, <i>n</i> = 9, 69%)	
	Patients with CVD: <i>n</i> = 14 (48%) (all patients) (magnesium responders, <i>n</i> = 5, 31%; magnesium non-responders, <i>n</i> = 9, 69%)	
	Patients with acute renal failure: NR	
	Patients with acute respiratory failure: NR	
	Mechanical ventilation at NOAF onset: NR	
	Serum potassium: NR	
	Definition of NOAF: ‘New-onset AF was defined as newly developed AF during the ICU stay in patients without a previous history of atrial tachyarrhythmias and anti-arrhythmic drug use. Diagnosis was confirmed by a 12-lead electrocardiogram (ECG)’	
APACHE, Acute Physiology and Chronic Health Evaluation; CVD, cardiovascular disease; NR, not reported; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; STVT, supraventricular tachycardia.		

TABLE 16 Results of prospective single-group studies

Study	Results	Adverse effects	Recommendations for/barriers to the future research
Delle Karth 2005 <sup>47</sup>	<ul style="list-style-type: none"> <li>The authors reported that 82.4% of patients converted back to sinus rhythm. The median (range) ICU length of stay was reported as 35 (13–44) days</li> <li>The mean time to termination of the arrhythmia was <math>17.7 \pm 12.5</math> minutes (range 4 to 45 minutes) after start of the first infusion. The total administered dose to those who were successfully converted with ibutilide ranged from 0.5 mg to 2 mg (mean <math>1.20 \pm 47</math> mg)</li> </ul>	<ul style="list-style-type: none"> <li>Sustained polymorphic ventricular tachycardia reported in one patient and this required emergency DCC. Repetitive ventricular salvos was reported in two patients and ibutilide therapy had to be discontinued. Increased ventricular premature complexes were reported in 12 patients but ibutilide infusion did not have to be stopped. One patient experienced a ventricular pause of 3 seconds before conversion to sinus rhythm</li> </ul>	NR
Hennersdorf 2002 <sup>46</sup>	<ul style="list-style-type: none"> <li>Conversion to sinus rhythm was achieved in 71% (<math>n = 5</math>) of patients with recent-onset AF. The remaining patients were converted successfully by external electrical cardioversion</li> </ul>	Torsade de pointes ( $n = 3/26$ , 11.5%)	NR
Mayr 2003 <sup>49</sup>	<ul style="list-style-type: none"> <li>A total of 13 patients (35%, 95% CI 20% to 53%) primarily responded to DCC with restoration of sinus rhythm, of whom eight patients remained in sinus rhythm (24%, 95% CI 12% to 41%) at 1 hour. At 24 and 48 hours, six (16%, 95% CI 6% to 32%) and five (13.5%, 95% CI 5% to 29%) patients remained in sinus rhythm, respectively</li> <li>Eight patients converted back to sinus rhythm in response to the first DCC shock and four patients to the second DCC shock. One out of 22 patients returned to sinus rhythm after three DCC shocks, whereas no patient responded to a fourth DCC shock</li> </ul>	NR	<i>The optimal therapeutic regimen for effective and rapid termination of new-onset SVT in surgical ICU patients still remains to be established</i>
Nakamura 2016 <sup>45</sup>	<ul style="list-style-type: none"> <li>Survival was achieved in 81.3% of the patients for whom switching therapy was administered. The authors reported that three patients (18.75%) died of primary diseases after &gt; 3 days from switching therapy. In all patients who survived, bisoprolol patch therapy was continued on the ward</li> </ul>	<ul style="list-style-type: none"> <li>The authors reported that there were no obvious adverse events in any patient and switching therapy was successfully completed in all the patients</li> </ul>	<i>It would be worth to conduct the further study investigating the efficacy of this switching therapy in the future</i>

continued

TABLE 16 Results of prospective single-group studies (continued)

Study	Results	Adverse effects	Recommendations for/barriers to the future research
Slavik 2003 <sup>40</sup> (abstract)	<ul style="list-style-type: none"> <li>Authors reported that optimal rate control and conversion was achieved in 47% of NOAF episodes</li> <li>Authors reported that optimal stroke prophylaxis was achieved in 91% of NOAF episodes</li> <li>Note: appropriateness of therapy assessed as optimal, appropriate and inappropriate; however, definitions not reported in the abstract</li> </ul>	<ul style="list-style-type: none"> <li>i.v. amiodarone: hypotension (35.6%)</li> <li>i.v. heparin: major bleeding (5%)</li> </ul>	NR
Sleeswijk 2008 <sup>39</sup>	<ul style="list-style-type: none"> <li>Seven patients converted to sinus rhythm within 1 hour after the start of the MgSO<sub>4</sub> infusion, whereas nine patients had a decrease in ventricular rate of &lt; 110 b.p.m. All patients achieved cardioversion after the start of the MgSO<sub>4</sub> infusion without any additional therapy. Mean (SD) and median (range) time until conversion in the magnesium responders was 7 (± 11) hours and 2 (1–45) hours, respectively. The addition of amiodarone after 1 hour of the MgSO<sub>4</sub> infusion was required for 13 patients (magnesium non-responders). Of these 13 patients, 11 achieved cardioversion within 24 hours. Mean (SD) and median (range) conversion time in magnesium non-responders was 13 (± 21) hours and 4 (2–78) hours, respectively. The total mean (SD) and median (range) conversion time was 9.3 (± 16.3) hours and 3 (1–78) hours, respectively. The 24-hour conversion rate in the whole study group was 90%. Magnesium responders and non-responders were analysed separately</li> </ul>	<ul style="list-style-type: none"> <li>Authors reported that no serious events that would cause the discontinuation of the treatment were observed during the study</li> </ul>	<i>A randomized controlled trial is needed to investigate whether this strategy is superior to other treatment regimes</i>
NR, not reported; SD, standard deviation; SVT, supraventricular tachycardia.			

TABLE 17 Methods and characteristics of retrospective single-group studies

Study details	Population characteristics	Intervention
First author and year: Burris 2010 <sup>44</sup>	Primary diagnosis: general surgery (60%), vascular surgery (33%), orthopaedics (3.3%) and neurosurgery (3.3%)	Amiodarone (63%), metoprolol (26%), esmolol (13.3%), diltiazem (6.7%), digoxin (3.3%), multiple drug regimens (10%). Electrical cardioversion (only in combination with pharmacological treatment), <i>n</i> = 4 (13.3%)
Setting: surgical ICU	Mean age: 66.2 ± 7.3 years	Line of NOAF treatment: not specified for each treatment
Country: USA	Male: NR	
Sample size: <i>n</i> = 30	Severity of illness: NR	
Note: data extracted only for patients with atrial arrhythmias (total study <i>n</i> = 120: this includes controls that did not develop arrhythmias)	Patients on vasopressors: <i>n</i> = 14 (46.6%) (intraoperative)	
	Patients with CVD: coronary artery disease, 40%; chronic heart failure 16.7%	
	Patients with acute renal failure: NR	
	Patients with acute respiratory failure: NR	
NOAF patients: NR	Mechanical ventilation at NOAF onset: NR	
	Serum potassium: 3.9 ± 66 mmol/l (preoperative)	
	Definition of NOAF: NR	
First author and year: Kanji 2012 <sup>8</sup>	Primary diagnosis: admission diagnosis reported – sepsis (18%), respiratory failure/pneumonia (19%), cardiogenic shock/cardiac arrest (4%), cerebrovascular accident (1%), rapid AF (4%), postoperative care (48%) and other (6%)	Rhythm control attempted ( <i>n</i> = 105) by administering i.v. amiodarone. Rate control attempted ( <i>n</i> = 28) by administering beta-blockers, calcium channel blockers or digoxin, alone or in combination
Setting: three academic mixed medical/surgical ICUs		Line of NOAF treatment: not specified
Country: Canada	Mean age: 71.6 ± 12.5 years	
Sample size: <i>n</i> = 139	Male: <i>n</i> = 83 (60%)	
NOAF patients: 100%	Severity of illness: mean APACHE II score reported: 22.6 ± 9.0	
	Patients on vasopressors: NR	
	Patients with CVD: coronary artery disease (29%), valvular heart disease (1%), congestive heart failure (6%) and cardiomyopathy (dilated, hypertrophic) (2%)	

continued

TABLE 17 Methods and characteristics of retrospective single-group studies (continued)

Study details	Population characteristics				Intervention																																
First author and year: Kyo 2019 <sup>50</sup>  Setting: two mixed ICUs (emergency and medicosurgical ICU)  Country: Japan  Sample size: n = 85  NOAF patients: 100%	Patients with acute renal failure: NR				Electrical cardioversion: the 85 electrical cardioversion sessions included 142 shocks, with a median of one (IQR 1–2) shock per electrical cardioversion session. The delivered electrical cardioversion energy was ≤ 100 J in 91% of first shocks and 83% of second shocks in all patients  Line of NOAF treatment: not specified																																
	Patients with acute respiratory failure: n = 27 (19%)																																				
	Mechanical ventilation at NOAF onset: NR																																				
	Serum potassium: < 3.5 mmol/l, n = 15 (11%)																																				
	Definition of NOAF: ‘Definition for NOAF cases reported as “defined as those with no previous documented history of any atrial arrhythmia documented in the physical or electronic medical record”’																																				
	Primary diagnosis:																																				
	<table><thead><tr><th>Type of primary diagnosis</th><th>All patients (N = 85), n (%)</th><th>Successful electrical cardioversion (N = 41), n (%)</th><th>Unsuccessful electrical cardioversion (N = 44), n (%)</th></tr></thead><tbody><tr><td>Cardiovascular</td><td>33 (38)</td><td>14 (34)</td><td>19 (43)</td></tr><tr><td>Pulmonary</td><td>26 (31)</td><td>15 (37)</td><td>11 (25)</td></tr><tr><td>Gastrointestinal</td><td>10 (12)</td><td>4 (10)</td><td>6 (14)</td></tr><tr><td>Neurology</td><td>4 (5)</td><td>1 (2)</td><td>3 (7)</td></tr><tr><td>Trauma</td><td>3 (4)</td><td>3 (7)</td><td>–</td></tr><tr><td>Skin and soft tissue</td><td>5 (6)</td><td>2 (5)</td><td>3 (7)</td></tr><tr><td>Other</td><td>4 (5)</td><td>2 (5)</td><td>2 (5)</td></tr></tbody></table>					Type of primary diagnosis	All patients (N = 85), n (%)	Successful electrical cardioversion (N = 41), n (%)	Unsuccessful electrical cardioversion (N = 44), n (%)	Cardiovascular	33 (38)	14 (34)	19 (43)	Pulmonary	26 (31)	15 (37)	11 (25)	Gastrointestinal	10 (12)	4 (10)	6 (14)	Neurology	4 (5)	1 (2)	3 (7)	Trauma	3 (4)	3 (7)	–	Skin and soft tissue	5 (6)	2 (5)	3 (7)	Other	4 (5)	2 (5)	2 (5)
	Type of primary diagnosis	All patients (N = 85), n (%)	Successful electrical cardioversion (N = 41), n (%)	Unsuccessful electrical cardioversion (N = 44), n (%)																																	
	Cardiovascular	33 (38)	14 (34)	19 (43)																																	
	Pulmonary	26 (31)	15 (37)	11 (25)																																	
Gastrointestinal	10 (12)	4 (10)	6 (14)																																		
Neurology	4 (5)	1 (2)	3 (7)																																		
Trauma	3 (4)	3 (7)	–																																		
Skin and soft tissue	5 (6)	2 (5)	3 (7)																																		
Other	4 (5)	2 (5)	2 (5)																																		
Median age (range): all patients, 71 (64–78) years, successful electrical cardioversion, 71 (64–79) years; unsuccessful electrical cardioversion, 71 (62–77) years																																					
Male: all patients, n = 58 (68%) (successful electrical cardioversion, n = 30, 73%; unsuccessful electrical cardioversion, n = 28, 64%)																																					

Study details	Population characteristics	Intervention																
	<p>Severity of illness: APACHE II score at ICU admission, median (range) – all patients, 26 (17–34); successful electrical cardioversion, 26 (18–35); unsuccessful electrical cardioversion, 26 (16–31)</p> <p>SOFA score at the onset of AF, median (range): all patients 8 (5–11); successful electrical cardioversion, 8 (5–12); unsuccessful electrical cardioversion, 8 (5–9)</p> <p>Patients on vasopressors:</p> <table><tr><th>Vasopressor</th><th>All patients (N = 85), n (%)</th><th>Successful electrical cardioversion (N = 41), n (%)</th><th>Unsuccessful electrical cardioversion (N = 44), n (%)</th></tr><tr><td>Noradrenaline</td><td>24 (28)</td><td>12 (29)</td><td>12 (27)</td></tr><tr><td>Dopamine</td><td>21 (25)</td><td>10 (24)</td><td>11 (25)</td></tr><tr><td>Dobutamine</td><td>25 (29)</td><td>14 (34)</td><td>11 (25)</td></tr></table> <p>Patients with CVD: NR</p> <p>Patients with acute renal failure: NR</p> <p>Patients with acute respiratory failure: NR</p> <p>Mechanical ventilation at NOAF onset: not specified whether at the time of onset – all patients, n = 71 (84%); successful electrical cardioversion, n = 37 (90%); unsuccessful electrical cardioversion, n = 34 (77%)</p> <p>Serum potassium (mmol/l), median (range): all patients, 4.0 (3.7–4.6); successful electrical cardioversion, 4.2 (3.9–4.8); unsuccessful electrical cardioversion, 3.9 (3.6–4.3)</p> <p>Definition of NOAF: ‘New-onset AF was defined as the first AF rhythm on ECG occurring during an ICU stay’</p>	Vasopressor	All patients (N = 85), n (%)	Successful electrical cardioversion (N = 41), n (%)	Unsuccessful electrical cardioversion (N = 44), n (%)	Noradrenaline	24 (28)	12 (29)	12 (27)	Dopamine	21 (25)	10 (24)	11 (25)	Dobutamine	25 (29)	14 (34)	11 (25)	
Vasopressor	All patients (N = 85), n (%)	Successful electrical cardioversion (N = 41), n (%)	Unsuccessful electrical cardioversion (N = 44), n (%)															
Noradrenaline	24 (28)	12 (29)	12 (27)															
Dopamine	21 (25)	10 (24)	11 (25)															
Dobutamine	25 (29)	14 (34)	11 (25)															
		continued																

TABLE 17 Methods and characteristics of retrospective single-group studies (continued)

Study details	Population characteristics		Intervention
First author and year: Liu 2016 <sup>41</sup>	Primary diagnosis: sepsis		
Setting: medical ICU	Infection site:		
Country: Taiwan (Province of China)			
Sample size: $n = 240$			
NOAF patients: 100%			
	<b>Infection site</b>	<b>NOAF to sinus rhythm (<math>N = 165</math>), <math>n</math> (%)</b>	<b>NOAF to atrial fibrillation (AF) (<math>N = 75</math>), <math>n</math> (%)</b>
	Respiratory tract	112 (67.9)	48 (64)
	Urinary tract	35 (21.2)	14 (18.7)
	Gastrointestinal	9 (5.5)	5 (6.7)
	Other	9 (5.5)	8 (10.7)
	Mean age: NOAF to sinus rhythm, $77.8 \pm 10.3$ years; NOAF to AF, $76.2 \pm 11.0$ years		
	Male: NOAF to sinus rhythm, $n = 90$ (54.5%); NOAF to AF, $n = 46$ (61.3%)		
	Severity of illness: mean SOFA score reported – NOAF to sinus rhythm, $7.6 \pm 3.0$ ; NOAF to AF, $9.3 \pm 3.2$ . Mean APACHE II score: NOAF to sinus rhythm, $22.8 \pm 5.8$ ; NOAF to AF, $24.6 \pm 6.1$		
	Patients on vasopressors:		
	<b>Vasopressor</b>	<b>NOAF to sinus rhythm (<math>N = 165</math>), <math>n</math> (%)</b>	<b>NOAF to AF (<math>N = 75</math>), <math>n</math> (%)</b>
	Dopamine	64 (38.8)	49 (65.3)
	Noradrenaline	58 (35.2)	48 (64)

continued

Study details	Population characteristics	Intervention																								
	Patients with CVD:	Amiodarone (n = 80, 33.3%), beta-blockers (n = 88, 36.7%), non-dihydropyridine calcium channel blockers (n = 66, 27.5%), digoxin glycosides (n = 27, 11.3%), electrical cardioversion (n = 8, 3.3%)																								
	<table><tr><th>Cardiovascular disease</th><th>NOAF to sinus rhythm (N = 165), n (%)</th><th>NOAF to AF (N = 75), n (%)</th></tr><tr><td>Heart failure</td><td>35 (21.2)</td><td>15 (20)</td></tr><tr><td>Coronary artery disease</td><td>70 (42.4)</td><td>37 (49.3)</td></tr></table>	Cardiovascular disease	NOAF to sinus rhythm (N = 165), n (%)	NOAF to AF (N = 75), n (%)	Heart failure	35 (21.2)	15 (20)	Coronary artery disease	70 (42.4)	37 (49.3)	Line of NOAF treatment: not specified for each treatment															
Cardiovascular disease	NOAF to sinus rhythm (N = 165), n (%)	NOAF to AF (N = 75), n (%)																								
Heart failure	35 (21.2)	15 (20)																								
Coronary artery disease	70 (42.4)	37 (49.3)																								
	Patients with acute renal failure: NOAF to sinus rhythm, n = 65 (39.4%); NOAF to AF, n = 39 (52.0%)																									
	Patients with acute respiratory failure: NOAF to sinus rhythm n = 150 (90.9%); NOAF to AF, n = 71 (94.7%)																									
	Mechanical ventilation at NOAF onset: NOAF to sinus rhythm, n = 143 (86.7%); NOAF to AF, n = 69 (92.0%)																									
	Serum potassium (mmol/l): NOAF to AF, 4.2 ± 1.0; NOAF to sinus rhythm, 4.1 ± 0.9																									
	Definition of NOAF: 'The absence of P waves and irregular ventricular activity lasting for more than 30 seconds'. NOAF to AF defined as 'persistent or recurrent AF 7 days after the onset of NOAF'																									
First author and year: Mayr 2004 <sup>43</sup>	Primary diagnosis: type of surgery	Amiodarone infusion: amiodarone was infused via central venous catheter at 90 mg/hour for a maximum of 12 hours, followed by a weaning regimen (initially 40–60 mg/hour for a maximum of 3 days, then 20 mg/hour for another 5–7 days). Amiodarone was continued orally (200 mg TDS) in some patients. The amiodarone infusion was stopped when the heart rate dropped below 60 b.p.m.																								
Setting: 12-bed general and surgical ICU in a university teaching hospital	<table><tr><th>Type of surgery</th><th>All patients (N = 131), n (%)</th><th>Responders (N = 98), n (%)</th><th>Non-responders (N = 33), n (%)</th></tr><tr><td>Cardiac</td><td>61 (46.56)</td><td>46 (46.9)</td><td>15 (45.45)</td></tr><tr><td>General</td><td>53 (40.45)</td><td>41 (41.8)</td><td>12 (36.36)</td></tr><tr><td>Vascular</td><td>7 (5.3)</td><td>5 (5.1)</td><td>2 (6.2)</td></tr><tr><td>Trauma</td><td>5 (3.8)</td><td>2 (2)</td><td>3 (9.1)</td></tr><tr><td>Orthopaedic</td><td>5 (3.8)</td><td>4 (4.1)</td><td>1 (3)</td></tr></table>	Type of surgery	All patients (N = 131), n (%)	Responders (N = 98), n (%)	Non-responders (N = 33), n (%)	Cardiac	61 (46.56)	46 (46.9)	15 (45.45)	General	53 (40.45)	41 (41.8)	12 (36.36)	Vascular	7 (5.3)	5 (5.1)	2 (6.2)	Trauma	5 (3.8)	2 (2)	3 (9.1)	Orthopaedic	5 (3.8)	4 (4.1)	1 (3)	Line of NOAF treatment: first line
Type of surgery	All patients (N = 131), n (%)	Responders (N = 98), n (%)	Non-responders (N = 33), n (%)																							
Cardiac	61 (46.56)	46 (46.9)	15 (45.45)																							
General	53 (40.45)	41 (41.8)	12 (36.36)																							
Vascular	7 (5.3)	5 (5.1)	2 (6.2)																							
Trauma	5 (3.8)	2 (2)	3 (9.1)																							
Orthopaedic	5 (3.8)	4 (4.1)	1 (3)																							
Country: Austria																										
Sample size: n = 131																										
NOAF patients: 93%																										

continued

TABLE 17 Methods and characteristics of retrospective single-group studies (continued)

Study details	Population characteristics	Intervention
	Sepsis: all patients, 23.9%; responders, 24%; non-responders, 23.6%	
	Mean age: all patients, $68 \pm 12$ years (responders, $68 \pm 12$ years; non-responders, $67 \pm 14$ years)	
	Male: all patients, $n = 82$ (62.6%) (responders, $n = 58$ , 59.2%; non-responders, $n = 24$ , 72.7%)	
	Severity of illness: mean MODS reported: all patients, $7.5 \pm 3.4$ (responders, $7.4 \pm 3.4$ ; non-responders, $7.9 \pm 3.5$ )	
	Patients on vasopressors: NR	
	Patients with CVD: NR	
	Patients with acute renal failure: NR	
	Patients with acute respiratory failure: NR	
	Mechanical ventilation at NOAF onset: NR	
	Serum potassium: NR	
	Definition of NOAF: 'New-onset supraventricular tachyarrhythmias were defined as "narrow-complex non-sinus tachyarrhythmias with heart rates $\geq 100$ bpm lasting for longer than 30 minutes"'	
First author and year: Mitrić 2016 <sup>42</sup>	Primary diagnosis: NR	Amiodarone: a bolus dose was defined as a fixed dose of $> 150$ mg given over 20 minutes to an hour, a continuous infusion was a fixed dose of amiodarone delivered hourly by a syringe pump for $> 2$ hours and delay to an infusion was a gap of 1 hour in the fluid administration record for the administration of a bolus and the start of an infusion
Setting: medical-surgical trauma ICU	Mean age, median (range): all patients, 69 (60–75) years [no recurrence of AF, 65 (57–75) years; recurrence of AF, 71 (61–76)]	
Country: Australia	Male: all patients, $n = 113$ (64%) (no recurrence of AF, $n = 53$ , 61%; recurrence of AF, $n = 60$ , 66%)	
Sample size: $n = 177$ (no recurrence of AF, $n = 86$ ; recurrence of AF, $n = 91$ )	Severity of illness, median (range): APACHE II score reported – all patients, 22 (17–28) [no recurrence of AF, 21 (17–26); recurrence of AF, 23 (17–29)]. SAPS II reported: all patients, 41 (31–53) [no recurrence of AF, 39 (30–49); recurrence of AF, 44 (31–58)]. Charlson Comorbidity Index Score reported: all patients, 2 (1–4) [no recurrence of AF, 2 (1–4); recurrence of AF, 3 (2–5)]	
NOAF patients: 100%		

Study details	Population characteristics			Intervention				
	Patients on vasopressors: NR							
	Patients with CVD:							
	<b>Cardiovascular disease</b>	<b>All patients (N = 177), n (%)</b>	<b>No recurrent AF (N = 86), n (%)</b>	<b>Recurrent AF (N = 91), n (%)</b>	<b>Parameter</b>	<b>All patients (N = 177)</b>	<b>No AF recurrence (N = 86)</b>	<b>AF recurrence (N = 91)</b>
	Myocardial infarction	43 (24)	17 (20)	26 (29)	No. of amiodarone boluses, n (%)			
	Congestive cardiac failure	22 (12)	6 (7)	16 (18)	0	62 (35)	43 (42)	19 (25)
	Ischaemic heart disease	58 (33)	23 (27)	35 (38)	1	98 (55)	51 (50)	47 (61)
	Rheumatic heart disease	2 (1)	2 (2)	0 (0)	2	12 (7)	5 (5)	7 (9)
	Mitral valve disease	9 (5)	7 (8)	2 (2)	3	5 (3)	2 (2)	3 (4)
	Patients with acute renal failure: NR			Amiodarone dosing, n (%)				
	Patients with acute respiratory failure: NR			Bolus only				
	Mechanical ventilation at NOAF onset: NR			Infusion only				
	Serum potassium (mmol/l): reported as median (IQR) for the recurrent AF group only			Bolus and infusion				
	<b>Parameter</b>	<b>On the day AF initially reverted (n = 81)<sup>a</sup></b>	<b>On day AF recurred (n = 73)<sup>a</sup></b>		Delay to infusion after bolus, hours, median (IQR); n	2 (1–4); 74	2 (1–3); 29	2 (1–6); 45
	K <sub>min</sub>	4.2 (3.8–4.5)	4.2 (4.0–4.6)		Total dose (mg), median (IQR)	905 (488–1651)	702 (300–1117)	1366 (752–2711)
	K <sub>max</sub>	4.3 (4.1–4.7)	4.4 (4.1–4.7)		Infusion time (hours), median (IQR)	24 (16–40)	20 (12–28)	31 (20–58)
	<sup>a</sup> Differing patient numbers owing to missing data.			Line of NOAF treatment: first line				
	Definition of NOAF: ‘a rhythm on the electrocardiogram (ECG) with replacement of P waves with rapid oscillations or fibrillatory waves that vary in size, shape and timing, associated with an irregular, frequently rapid, ventricular response when atrioventricular conduction is intact’							
APACHE, Acute Physiology and Chronic Health Evaluation; CVD, cardiovascular disease; ECG, electrocardiography; MODS, Multiple Organ Dysfunction Score; NR, not reported; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TDS, ter die sumendus (three times a day).								

TABLE 18 Results of retrospective single-group studies

Study	Results	Adverse effects	Recommendations for/barriers to the future research
Burris 2010 <sup>44</sup>	<ul style="list-style-type: none"> <li>Authors reported that 33% of patients treated with amiodarone achieved successful conversion to sinus rhythm</li> <li>In total, 10% of all patients did not convert to sinus rhythm and 6.7% of those who converted later reverted to arrhythmia</li> </ul>	NR	<i>Randomized prospective studies are required to determine the success of alternative treatments and should provide the evidence needed to streamline management of this problem</i>
Kanji 2012 <sup>8</sup>	<ul style="list-style-type: none"> <li>Rhythm control alone was attempted in 105 patients (103 patients were administered i.v. amiodarone and two patients were administered sotalol). Successful rhythm conversion was achieved in 90 (87%) patients at some time while receiving amiodarone. In total, 38 (42%) out of 90 patients reverted to AF during their ICU stay after maintaining normal sinus rhythm for at least 24 hours after cardioversion. Authors reported that of the patients with successful rhythm conversion (<math>n = 90</math>), 51 (57%) converted within 6 hours and 66 (73%) converted within 24 hours. Of the 74 patients in this group who were discharged from ICU, 13 (18%) left the ICU in AF. Two patients treated with sotalol converted to sinus rhythm, but one patient reverted to AF after being in sinus rhythm for 24 hours. Both patients (who received sotalol) were discharged from the ICU in normal sinus rhythm</li> <li>Twenty-eight (20%) patients were treated with rate-controlling agents alone (beta-blockers, calcium channel blockers or digoxin, alone or in combination). Twenty-one (75%) patients converted to sinus rhythm while receiving rate-control therapy alone, and five (19%) out of 27 ICU survivors were discharged from the ICU in AF</li> </ul>	NR	In the general adult critically ill population, more research is required to determine (1) whether or not attempting rhythm control is more effective at restoring sinus rhythm than attempting rate control alone, (2) whether or not attempting rhythm control improves clinical outcomes, and (3) what is the optimal anticoagulation strategy in patients who develop NOAF
Kyo 2019 <sup>50</sup>	<ul style="list-style-type: none"> <li>Electrical cardioversion was successful in 41 (48%) patients. Of these patients, 11 (13%) maintained sinus rhythm until ICU discharge and 30 (35%) had recurrent AF. Among the 44 (52%) patients with unsuccessful electrical cardioversion, seven (8%) did not convert back to sinus rhythm until after ICU discharge, whereas 37 (44%) converted to sinus rhythm during their ICU stay</li> </ul>	NR	<i>Further studies are needed to investigate the potential factors associated with the maintenance of SR [sinus rhythm] to establish a better understanding of new-onset AF in critically ill patients</i>

TABLE 18 Results of retrospective single-group studies (continued)

Study	Results	Adverse effects	Recommendations for/barriers to the future research
	<ul style="list-style-type: none"> <li>• Authors reported no difference in median length of ICU stay (days) between the patients who had successful electrical cardioversion and those who had unsuccessful electrical cardioversion [16 (11–17) vs. 15 (7–23), respectively]</li> <li>• No difference in the number of ICU deaths was observed between groups [<math>n = 16</math> (39%) in the successful electrical cardioversion group vs. 14 (32%) in the unsuccessful electrical cardioversion group]</li> <li>• Similarly, no difference in median length of hospital stay (days) was found between the patient groups [28 (16–62) in the successful electrical cardioversion group vs. 31 (19–60) in the unsuccessful electrical cardioversion group]</li> <li>• Authors also did not find any difference in hospital death between the patients with successful electrical cardioversion and the patients with unsuccessful electrical cardioversion [21 (51%) vs. 17 (39%), respectively]</li> </ul>		
Liu 2016 <sup>41</sup>	<ul style="list-style-type: none"> <li>• Fifty-two out of 80 patients (65%) who received amiodarone converted to sinus rhythm</li> <li>• Sixty-seven out of 88 patients (76.1%) who were treated with beta-blockers converted back to sinus rhythm</li> <li>• Forty-seven out of 66 patients (71.21%) who were treated with non-dihydropyridine calcium channel blockers converted to sinus rhythm</li> <li>• Fifteen out of 27 patients (55.55%) treated with digoxin glycosides converted back to sinus rhythm</li> <li>• Fifty per cent of patients who were treated with electrical cardioversion converted back to sinus rhythm</li> </ul>	NR	<i>A larger, prospective comparative study is needed to elucidate the clinical implications between a rate control and a rhythm control strategy in patients with sepsis and NOAF</i>
Mayr 2004 <sup>43</sup>	<ul style="list-style-type: none"> <li>• Sinus rhythm was achieved in 54.2% of patients within the first 12 hours, in 64% within 24 hours and in 74.8% within 48 hours. Heart rate decreased significantly in all patients (–37%) during the observation period, but the decrease was more pronounced in responders than in non-responders</li> </ul>	Increases in serum concentrations of creatinine and bilirubin were observed	NR

continued

TABLE 18 Results of retrospective single-group studies (continued)

Study	Results	Adverse effects	Recommendations for/barriers to the future research
Mitrić 2016 <sup>42</sup>	<ul style="list-style-type: none"> <li>The authors reported no differences in the length of surgical ICU stay between responders and non-responders (<math>13 \pm 10</math> days vs. <math>14 \pm 11</math> days, respectively). It was reported that there was a trend of higher surgical ICU mortality in non-responders (39.4%) than in responders (24.5%) (<math>p = 0.1</math>; 28.2% in all patients)</li> <li>Eighty-six (49%) patients were successfully treated with amiodarone, without recurrence of AF until discharge from ICU. AF recurred in 91 patients (51%) at least once during the ICU stay, after initial successful conversion to normal sinus rhythm</li> <li>The median ICU length of stay was reported as 7 (IQR 4–13) days in all patients, 6 (IQR 3–12) days in patients who had no recurrence of AF and 8 (IQR 4–16) days in patients who had recurrence of AF</li> <li>The median hospital length of stay was reported as 25 (IQR 13–58) days, 21 (IQR 12–46) days and 31 (IQR 18–70) days for all patients, patients who had no recurrence of AF and patients who had recurrence of AF, respectively</li> <li>In total, 23 (13%) patients died in an ICU: 10 (12%) who had no recurrence of AF and 13 (14%) patients who did</li> <li>Forty-seven (17%) of all patients died in the hospital: 22 (26%) patients who had no recurrent AF and 25 (27%) patients who had recurrent AF</li> </ul>	NR	<i>A clear dosing guide is not available and further research is required to elicit the best dosing strategy</i>
NR, not reported.			

## Appendix 4 Excluded studies

TABLE 19 Excluded studies on full text with reason for exclusion

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
American Association of Critical Care Nurses (AACN). Preventing new-onset atrial fibrillation in the ICU. <i>AACN Bold Voices</i> 2018; <b>10</b> :20		X		
Agnihotri K, Patel P, Charilou P, Patel NJ, Badheka A, Noseworthy P, et al. <i>Impact of Atrial Fibrillation on Mortality, Length of Stay and Cost in Patients with Sepsis</i> . Proceedings of the 38th Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm, 10–13 May 2017, Chicago, IL, USA	X			
Akella K, Akella S, Akella SL, Chendrasekhar A. <i>Atrial Fibrillation in Elderly (Age &gt; 65 Years) Trauma Patients is Associated with Increased Mortality and Morbidity</i> . Paper presented at the CHEST 2017 Annual Meeting, Canada, 2017. <i>Cardiovasc Dis</i> 2017; <b>152</b> :A66	X			
Akhtar MI, Ullah H, Hamid M. Magnesium, a drug of diverse use. <i>J Pak Med Assoc</i> 2011; <b>61</b> :1220–5	X			
Al-Hashimi M, Thompson JP. Drugs acting on the heart: anti-arrhythmics. <i>Anaesth and Intensive Care Med</i> 2012; <b>13</b> :374–7	X			
Al-Khafaji A, Cho Su M. Atrial fibrillation in critical care. (Comment on: <i>Intensive Care Med</i> 2006 Mar; <b>32</b> :398–404) 2006; <b>32</b> :1099–100		X		
Ambrus DB, Benjamin EJ, Bajwa EK, Hibbert KA, Walkey AJ. Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. <i>J Crit Care</i> 2015; <b>30</b> :994–7				X
Anane C, Owusu IK, Attakorah J. Monitoring amiodarone therapy in cardiac arrhythmias in the intensive care unit of a teaching hospital in Ghana. <i>Int J Cardiol</i> 2011; <b>10</b>			X	
Ando G, Di Rosa S, Rizzo F, Carerj S, Bramanti O, Giannetto M, et al. Ibutilide for cardioversion of atrial flutter: efficacy of a single dose in recent-onset arrhythmias. <i>Minerva Cardioangiologica</i> 2004; <b>52</b> :37–42	X			
Arita Y, Segawa T, Yamamoto S, Hasegawa S. Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy. <i>BMJ Case Rep</i> 2017; <b>2017</b> :bcr-2017-222268		X		
Arnautovic J, Mazhar A, Souther B, Mikhjian G, Huda N. <i>New-Onset Atrial Fibrillation in Patients with Septic Shock</i> . Proceedings of the 47th Society of Critical Care Medicine Critical Care Congress (SCCM), 25–28 February 2018, San Antonio, TX, USA, abstract number 184	X			
Arrigo M, Bettex D, Rudiger A. Management of atrial fibrillation in critically ill patients. <i>Crit Care Res Pract</i> 2014; <b>2014</b> :840615		X		

continued

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Arrigo M, Bettex D, Rudiger A. [Treatment of atrial fibrillation in intensive care units and emergency departments.] <i>Med Klin Intensivmed Notfmed</i> 2015; <b>110</b> :614–20	X			
Arrigo M, Bettex D, Rudiger A. Response to: comment on 'Management of Atrial Fibrillation in Critically Ill Patients'. <i>Crit Care Res Pract</i> 2016; <b>2016</b> :9724504		X		
Arrigo M, Feliot E, Gayat E, Mebazaa A. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: a report from the FROG-ICU study. <i>Int J Cardiol</i> 2018; <b>270</b> :203				X
Arrigo M, Ishihara S, Feliot E, Rudiger A, Deye N, Cariou A, et al. New-onset atrial fibrillation in critically ill patients and its association with mortality: a report from the FROG-ICU study. <i>Int J Cardiol</i> 2018; <b>266</b> :95–9				X
Arsura EL, Solar M, Lefkin AS, Scher DL, Tessler S. Metoprolol in the treatment of multifocal atrial tachycardia. <i>Crit Care Med</i> 1987; <b>15</b> :591–4	X			
Aydogdu M, Hanazay C, Aldag Y, Baha A, Bilgin S, Gursel G. Effects of atrial fibrillation on intensive care unit outcomes in patients with respiratory failure. <i>J Med Surg Intensive Care Med</i> 2017; <b>8</b> :32–8	X			
Badheka AO, Tuliani T, Rathod A, Shenoy M, Afonso L, Jacob S. Role of lipid lowering therapy and renin angiotensin blockade in outcomes of patients with atrial fibrillation. <i>Am J Cardiol</i> 2012; <b>109</b> :1238	X			
Balik M. New-onset atrial fibrillation in critically ill patients – implications for rhythm rather than rate control therapy? <i>Int J Cardiol</i> 2018; <b>266</b> :147–8	X			
Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. <i>Antiarrhythmic Therapy for Supraventricular Arrhythmias in Septic Shock</i> . Proceedings of the 29th Annual Congress of the European Society of Intensive Care Medicine (ESICM), 1–5 October 2016, Milan, Italy, abstract number A793			X	
Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. <i>Intensive Care Med</i> 1994; <b>20</b> :42–4	X			
Bender JS. Supraventricular tachyarrhythmias in the surgical intensive care unit: an under-recognized event. <i>Am Surg</i> 1996; <b>62</b> :73–5			X	
Bernal E, Wolf S, Cripps M. New-onset, postoperative tachyarrhythmias in critically ill surgical patients. <i>Burns</i> 2018; <b>44</b> :249–55				X
Bernard EO, Schmid ER, Schmidlin D, Scharf C, Candinas R, Germann R. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. <i>Crit Care Med</i> 2003; <b>31</b> :1031–4	X			
Bowles HF, Thangathurai D, Morgan GE, Mikhail M. Management of supraventricular tachycardia in septic patients. <i>Anaesthesia</i> 1990; <b>45</b> :787–8	X			

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Carrera P, Thongprayoon C, Cheungpasitporn W, Iyer VN, Moua T. Epidemiology and outcome of new-onset atrial fibrillation in the medical intensive care unit. <i>J Crit Care</i> 2016; <b>36</b> :102–6				X
Champion S. Comment on 'management of atrial fibrillation in critically ill patients'. <i>Crit Care Res Pract</i> 2015; <b>2015</b> :732598	X			
Champion S. An overlook of new-onset atrial fibrillation in the critically ill using automated detection: have we over looked at it? <i>Crit Care Med</i> 2017; <b>45</b> :e1195		X		
Champion S, Gaüzère BA, Vandroux D, Lefort Y. [Is it worth delivering Direct-Current Counter shock to critically ill patients with supra-ventricular tachyarrhythmia?] <i>Ann Cardiol Angeiol</i> 2018; <b>67</b> :260–3	X			
Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. <i>Intensive Care Med</i> 1993; <b>19</b> :48–52	X			
Clayton B, Ball S, Read J, Waddy S. Risk of thromboembolism in patients developing critical illness-associated atrial fibrillation. <i>Clin Med</i> 2018; <b>18</b> :282–7				X
Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. <i>Am J Cardiol</i> 1998; <b>81</b> :594–8	X			
Crawford TC, Oral H. Cardiac arrhythmias: management of atrial fibrillation in the critically ill patient. <i>Crit Care Clin</i> 2007; <b>23</b> :855–72, vii	X			
Darwish OS, Strube S, Phan A, Tanios M. <i>The Safety and Efficacy of Anticoagulation for Atrial Fibrillation in Patients with Severe Sepsis in the Medical Intensive Care Unit</i> . Proceedings of the American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, 19–21 May 2010, Washington, DC, USA	X			
Darwish OS, Strube S, Nguyen HM, Tanios MA. Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis. <i>Ann Pharmacother</i> 2013; <b>47</b> :1266–71	X			
Davies GE, Cudworth P, Lawler PG. Intravenous magnesium therapy in critically ill patients. <i>Anaesthesia</i> 1992; <b>47</b> :1104	X			
Delle Karth G, Reinelt P, Buberl A, Geppert A, Huelsmann M, Berger R, Heinz G. Circadian variation in ventricular tachycardia and atrial fibrillation in a medical-cardiological ICU. <i>Intensive Care Med</i> 2003; <b>29</b> :963–8				X
Duarte PAD, Leichtweis GE, Andriolo L, Delevatti YA, Jorge AC, Fumagalli AC, et al. Factors associated with the incidence and severity of new-onset atrial fibrillation in adult critically ill patients. <i>Crit Care Res Pract</i> 2017; <b>2017</b> :8046240				X
continued				

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Duarte PAD, Leichtweis GE, Andriolo L, Delevatti YA, Jorge AC, Fumagalli AC, <i>et al.</i> Corrigendum to 'Factors Associated with the Incidence and Severity of New-Onset Atrial Fibrillation in Adult Critically Ill Patients'. <i>Crit Care Res Pract</i> 2019; <b>2019</b> :5710734		X		
Duby JJ, Heintz SJ, Bajorek SA, Heintz BH, Durbin-Johnson BP, Cocanour CS. Prevalence and course of atrial fibrillation in critically ill trauma patients. <i>J Intensive Care Med</i> 2017; <b>32</b> :140–5				X
Eckardt L. Innovations to the therapy of atrial fibrillations in intensive care medicine. <i>Medizinische Klinik-intensivmedizin Und Notfallmedizin</i> 2014; <b>109</b> :564–5		X		
Edwards JD, Kishen R. Significance and management of intractable supraventricular arrhythmias in critically ill patients. <i>Crit Care Med</i> 1986; <b>14</b> :280–2	X			
Edwards JD, Wilkins RG. Atrial fibrillation precipitated by acute hypovolaemia. <i>BMJ (Clin Res Ed)</i> 1987; <b>294</b> :283–4	X			
Faniel R, Schoenfeld P. Intravenous amiodarone: a successful treatment for rapid atrial fibrillation in intensive care patients. <i>Eur Heart J</i> 1981; <b>2</b> :115	X			
Flato Uri Adrian P, Buhatem T, Merluzzi T, Bianco Antonio Carlos M. New anticoagulants in critical care settings. <i>Rev Bras Ter Intensiva</i> 2011; <b>23</b> :68–77	X			
Friedman HZ, Goldberg SF, Bonema JD, Cragg DR, Hauser AM. Acute complications associated with new-onset atrial fibrillation. <i>Am J Cardiol</i> 1991; <b>67</b> :437–9	X			
Fu J, Bi H, Xia Y, Fang H, Liu X, Tang Y, Wang D. [Risk factors of atrial fibrillation in critical ill patients.] <i>Zhonghua Wei Zhong Bing Ji Jiu Yi Xue</i> 2018; <b>30</b> :337–41				X
Gandhi S, Litt D, Narula N. New-onset atrial fibrillation in sepsis is associated with increased morbidity and mortality. <i>Neth Heart J</i> 2015; <b>23</b> :82–8			X	
Ganguly S, Brown T, Pritchett C, Edie S, Allan P, Spivey M. Atrial fibrillation in intensive care. <i>Intensive Care Med Exp</i> 2015; <b>3</b> :A209				X
Gibb S, Rehberg S. The role of the ultra short-acting beta1-adrenoreceptor antagonist Landiolol in the treatment of atrial fibrillation: pharmacology, clinical application and current evidence in anaesthesiology, intensive care and emergency medicine. <i>Clinical Anaesthesia</i> 2018; <b>59</b> :407–21		X		
Goodman S, Weiss Y, Weissman C. Update on cardiac arrhythmias in the ICU. <i>Curr Opin Crit Care</i> 2008; <b>14</b> :549–54	X			
Gray RJ. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker. <i>Chest</i> 1988; <b>93</b> :398–403	X			
Gray J, Haydock P, Wong A, Pierce JMT. Cardiac arrhythmias in the critically ill. <i>Anaesth Intensive Care</i> 2016; <b>17</b> :38–47	X			
Guenancia C, Laurent G, Bruyère R, Quenot JP. New-onset atrial fibrillation in sepsis: so common, but so different. <i>Crit Care Med</i> 2016; <b>44</b> :e306–7				X

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Guenancia C, Dargent A, Large A, Andreu P, Quenot JP. New-onset atrial fibrillation in ICU: a FROG in the throat. <i>Int J Cardiol</i> 2018; <b>270</b> :189				X
Guha K. Atrial fibrillation. <i>Clin Med (Lond)</i> 2019; <b>19</b> :90				X
Guillot M, Diouf M, Harlay ML, Janssen-Langenstein R, Lutun P, Schenck M, <i>et al.</i> [Supraventricular rhythm disorders of the rate/rhythm in critically ill patients.] <i>Réanimation</i> 2009; <b>18</b> :246–53		X		
Hadjizacharia P, O'Keeffe T, Brown CV, Inaba K, Salim A, Chan LS, <i>et al.</i> Incidence, risk factors, and outcomes for atrial arrhythmias in trauma patients. <i>Am Surg</i> 2011; <b>77</b> :634–9	X			
Hampden-Martin A, Miller N, Johnston B, Welters I. A Retrospective Observational Cohort Study of Patients Admitted to a Mixed Medical and Surgical Intensive Care Unit in the United Kingdom with Atrial Fibrillation: Incidence, Risk Factors and Treatment Efficacy. Proceedings of the 31st European Society of Intensive Care Medicine Annual Congress (ESICM), 20–24 October 2018, Paris, France			X	
Harazim M, Karvunidis T, Radej J, Horak J, Novak I, Matejovic M. [Atrial fibrillation in critically ill patients.] <i>Anesteziol Intenzivní Med</i> 2017; <b>28</b> :248–54		X		
Hayashi M, Tanaka K, Kato T, Morita N, Sato N, Yasutake M, <i>et al.</i> Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment. <i>J Cardiovasc Electrophysiol</i> 2005; <b>16</b> :740–7	X			
Heinz G. Atrial fibrillation in the intensive care unit. <i>Intensive Care Med</i> 2006; <b>32</b> :345–8	X			
Heinz G. Arrhythmias in the ICU: what do we know? <i>Am J Respir Crit Care Med</i> 2008; <b>178</b> :1–2				X
Heinz G. [Atrial fibrillation in the ICU. Distinct entity–special treatment?] <i>Leitthema</i> 2013; <b>108</b> :549–54		X		
Hilkens M, Pickkers P, Peters WH, van der Hoeven JG. No elevation of glutathione S-transferase-a1-1 by amiodarone loading in intensive care unit patients with atrial fibrillation. <i>Anaesth Intensive Care</i> 2009; <b>37</b> :281–5			X	
Holt AW. Hemodynamic responses to amiodarone in critically ill patients receiving catecholamine infusions. <i>Crit Care Med</i> 1989; <b>17</b> :1270–6	X			
Hughes M, Binning A. Intravenous amiodarone in intensive care. Time for a reappraisal? <i>Intensive Care Med</i> 2000; <b>26</b> :1730–9	X			
Iberti TJ, Benjamin E, Paluch TA, Gentili DR, Gabrielson GV. Use of constant-infusion verapamil for the treatment of postoperative supraventricular tachycardia. <i>Crit Care Med</i> 1986; <b>14</b> :283–4	X			

continued

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Ito H, Sobue K, So M, Hirate H, Sugiura T, Azami T, <i>et al.</i> Use of landiolol in the perioperative management of supraventricular tachycardia. <i>J Anesth</i> 2006; <b>20</b> :253–4	X			
Jelliffe R. Comment on 'Management of Atrial Fibrillation in Critically Ill Patients'. <i>Crit Care Res Pract</i> 2016:1–2				X
Jenkins SA, Griffin R. <i>New-Onset Atrial Fibrillation in Intensive Care: Incidence, Management and Outcome</i> . Proceedings of the 36th International Symposium on Intensive Care and Emergency Medicine, 15–18 March 2016, Brussels, Belgium		X		
Kanjanahattakij N, Rattanawong P, Krishnamoorthy P, Horn B, Chongsathidkiet P, Garvia V, <i>et al.</i> New-onset atrial fibrillation is associated with increased mortality in critically ill patients: a systematic review and meta-analysis. <i>Acta Cardiol</i> 2019; <b>74</b> :162–9				X
Karth GD, Geppert A, Haumer M, Neunteufl T, Innerhofer P, Priglinger U, <i>et al.</i> Tachycardial atrial fibrillation and atrial flutter in intensive-care patients: comparison of diltiazem and amiodarone for control of heart rate – preliminary results. <i>J Kardiologie</i> 2000; <b>7</b> :50		X		
Kerton M, Wiggins J, Purkiss M. Cardiac arrhythmias in the critically ill. <i>Anaesth Intensive Care</i> 2018; <b>19</b> :298–307	X			
Khoguli SS, Hopkinson RB, Beattie JM, Parmar M, Grant IS. Supraventricular tachydysrhythmias in the ICU. <i>Br J Intensive Care</i> 1994; <b>4</b> :44	X			
Khoury J, Azzam ZS. Propafenone for supraventricular arrhythmias in septic shock – comparison to amiodarone and metoprolol. <i>J Crit Care</i> 2018; <b>45</b> :247		X		
Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, <i>et al.</i> Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. <i>Am J Respir Crit Care Med</i> 2017; <b>195</b> :205–11			X	
Krumpl G, Domanovits H, Stix G, Heinz G, Hasenohrl N. Esmolol in cardiology, emergency and critical-care medicine. <i>J Kardiologie</i> 2012; <b>19</b> :2–8	X			
Kumar A. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. <i>South Med J</i> 1996; <b>89</b> :779–85	X			
Labakis M, Makrygiannis S, Margariti A, Rizikou D, Labakis S, Tselioti P, <i>et al.</i> <i>Prognostic Impact of New-Onset Atrial Fibrillation in Intensive Care Unit Patients</i> . Proceedings from the 26th Annual Congress of the European Society of Intensive Care Medicine (ESICM), 5–9 October 2013, Paris, France				X
Leelathanalerk A, Dongtai W, Huckleberry Y, Kopp B, Bloom J, Alpert J. Evaluation of deprescribing amiodarone after new-onset atrial fibrillation in critical illness. <i>Am J Med</i> 2017; <b>130</b> :864–6			X	

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Lewis O, Ngwa J, Gillum RF, Thomas A, Davis W, Poddar V, <i>et al.</i> Incidence, risk factors and outcomes of new onset supraventricular arrhythmias in African American patients with severe sepsis. <i>Ethn Dis</i> 2016; <b>26</b> :205–12				X
Lim HS, Hamaad A, Lip GY. Clinical review: clinical management of atrial fibrillation – rate control versus rhythm control. <i>Crit Care</i> 2004; <b>8</b> :271–9	X			
Makrygiannis SS, Margariti A, Rizikou D, Lampakis M, Vangelis S, Ampartzidou OS, <i>et al.</i> Incidence and predictors of new-onset atrial fibrillation in noncardiac intensive care unit patients. <i>J Crit Care</i> 2014; <b>29</b> :697.e1–5			X	
Malik A, Candilio L, Hausenloy DJ. Atrial fibrillation in the intensive care setting. <i>J Intensive Care Soc</i> 2013; <b>14</b> :141–9	X			
Marik PE, Zaloga GP. The management of atrial fibrillation in the ICU. <i>J Intensive Care Med</i> 2000; <b>15</b> :181–90	X			
Marinheiro AR, Amador P, Ribeiro R, Alves I, Domingos G, Praxedes V, <i>et al.</i> Incidence, management and impact of atrial fibrillation in septic shock. <i>Acute Cardiovasc Care</i> 2016; <b>5</b> :60–1			X	
Marque S, Launey Y. Traitement de la fibrillation atriale en reanimation (hors anticoagulation). <i>Réanimation</i> 2012; <b>21</b> :180–7		X		
Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bögelein D, <i>et al.</i> Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. <i>Crit Care</i> 2010; <b>14</b> :R108			X	
Miller N, Hampden-Martin A, Johnston B, Welters I. <i>Retrospective Observational Cohort Study of Anticoagulation Practices, Thromboembolic Events and Bleeding Events in Patients that Develop Atrial Fibrillation Admitted to a Mixed Surgical and Medical ICU in the United Kingdom.</i> Proceedings of the 31st European Society of Intensive Care Medicine Annual Congress (ESICM), 20–24 October 2018, Paris, France		X		
Mirhoseini MF, Hamblin SE, Moore WP, Pouliot J, Jenkins JM, Wang W, <i>et al.</i> Antioxidant supplementation and atrial arrhythmias in critically ill trauma patients. <i>J Surg Res</i> 2018; <b>222</b> :10–16	X			
Moran JL, Gallagher J, Peake SL, Cunningham DN, Salazaras M, Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. <i>Crit Care Med</i> 1995; <b>23</b> :1816–24	X			
Moskowitz A, Chen K, Cooper A, Chahin A, Ghassemi M, Celi L. Management of atrial fibrillation with rapid ventricular response in the intensive care unit: a secondary analysis of electronic health record data. <i>Shock</i> 2017; <b>48</b> :436–40	X			

continued

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Moss TJ, Ruminski C, Lake DE, Calland JF, Enfield KB, Moorman JR. <i>The Impact of Incident Atrial Fibrillation in the Intensive Care Unit</i> . Proceedings of the 65th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention (ACC16), 2–4 April 2016, Chicago, IL, USA				X
Murcia Llacer B, Broch Porcar MJ, Olivares Toledo D, Alvarez Cebrian F, Tejeda Adell M, Valentin Segura V. Intravenous amiodarone in the treatment of supraventricular tachyarrhythmias in critically ill patients with different diseases. <i>Medicina Intensiva</i> 1995;19:118–24	X			
Nadler S. What is the best rate control agent for patients with sepsis and atrial fibrillation? <i>Crit Care Alert</i> 2016;24:4–5	X			
Nair GM, Morillo CA. Magnesium in the acute management of atrial fibrillation: noise or music? <i>Pol Arch Med Wewn</i> 2007;117:446–7	X			
Nakos G, Roustanis E, Zikou X, Saranti M, Zylis G, Papathanakos G, et al. <i>Prevalence of Atrial Fibrillation in the Intensive Care Unit (ICU) Setting and Challenges in its Management. An Observational, Prospective, Single-Center Study</i> . Proceedings of the American Thoracic Society International Conference, ATS 2015, May 15–20 2015, Denver, CO, USA	X			
Nallapareddy S, Naik M, Nortje J. Audit on management of new onset atrial fibrillation in general intensive care unit at university teaching hospital. <i>Intensive Care Med</i> 2010;36:S123–S			X	
Needleman JS, Yeh DD, Belcher DM, Quraishi SA. <i>Vitamin D Status is Associated with New-Onset Atrial Fibrillation in Critically Ill Surgical Patients</i> . Proceedings of Clinical Nutrition Week (CNW) 2017, 18–21 February 2017, Orlando, FL, USA				X
Niazi OT, Alkhalil A, Olusanya A, Jain S, Golbari S, Banerjee R, et al. <i>Comparison of In-Hospital Outcomes Of Septic Shock Patients with and Without Atrial Fibrillation: a Retrospective Propensity-Matched Analysis</i> . Proceedings of the 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, ACC17, 17–19 March 2017, Washington, DC, USA				X
Nietupski R, Bellamy C, Miano T, Mikkelsen M, Candeloro C. <i>Continuation of Amiodarone at Discharge For New-Onset Atrial Fibrillation in Critically Ill Patients</i> . Proceedings of the Society of Critical Care Medicine (SCCM) 44th Critical Care Congress, 17–21 January 2015, Phoenix, AZ, USA, abstract no. 178			X	
Nitti C, Falsetti L, Rucco M, Gentili T, Nobili L, Zaccone V, et al. <i>CHA2DS2-VASc and HAS-BLED Scores do not Predict NVAf-related Events in a Population of Critically Ill Patients</i> . Proceedings of 23rd Congresso Nazionale della Societa Scientifica FADOI, 12–15 May 2018, Bologna, Italy	X			
Nowakowski PA. Supraventricular tachyarrhythmias in the intensive care unit. <i>Postgrad Med</i> 1992;92:34	X			

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting $\beta$ 1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. <i>World J Crit Care Med</i> 2015;4:251–7	X			
Papathanasiou A, Roustanis E, Zikou X, Galiatsou E, Papathanakos G, Zilis G, <i>et al.</i> The burden of new onset atrial fibrillation in the intensive care unit (ICU). An observational, prospective, single-center study. <i>Intensive Care Med Exp</i> 2015;3:A212	X			
Personett HA, Smoot DL, Stollings JL, Sawyer M, Oyen LJ. Intravenous metoprolol versus diltiazem for rate control in noncardiac, nonthoracic postoperative atrial fibrillation. <i>Ann Pharmacother</i> 2014;48:314–19	X			
Philip I, Allou N, Mouren S, Bourel P. Atrial fibrillation and anaesthesia-intensive care: an update. Fibrillation auriculaire et anesthésie-reanimation: Mise au point. <i>Sang Thrombose Vaisseaux</i> 2010;22:311–20				X
Pinski SL. Atrial fibrillation in the surgical intensive care unit: common but understudied. <i>Crit Care Med</i> 2004;32:890–1			X	
Poveda-Jaramillo R, Monaco F, Zangrillo A, Landoni G. Ultra-short-acting $\beta$ -blockers (esmolol and landiolol) in the perioperative period and in critically ill patients. <i>J Cardiothorac Vasc Anesth</i> 2018;32:1415–25	X			
Pravinkumar E. Rate and rhythm are important in critically ill patients. <i>BMJ</i> 2003;327:931–2		X		
Pye M, Camm AJ. Use of antiarrhythmic drugs in intensive care. <i>Clin Intensive Care</i> 1994;5:303–10	X			
Quasim T, Riddell L, Kinsella J. Atrial fibrillation in the intensive care unit. <i>Crit Care Med</i> 2010;38:U124–U				X
Quon MJ, Behloul H, Pilote L. Anticoagulant use and risk of ischemic stroke and bleeding in patients with secondary atrial fibrillation associated with acute coronary syndromes, acute pulmonary disease, or sepsis. <i>JACC Clin Electrophysiol</i> 2018;4:386–93	X			
Ratnaparkhi AB, Walton J. The practice of the use of anticoagulation for acute-onset atrial fibrillation in the intensive care units of the north east region of UK; a regional audit. <i>Intensive Care Med</i> 2010;36:S124–S			X	
Richards KJC, Cohen AT. Cardiac arrhythmias in the critically ill. <i>Anaesth Intensive Care Med</i> 2006;7:289–93	X			
Rudiger A, Breitenstein A, Arrigo M, Salzberg S, Bettex D. Suitability, Safety and Efficacy of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Proceedings of the 26th Annual Congress of the European Society of Intensive Care Medicine (ESICM), 5–9 October 2013, Paris, France, abstract no. 0275	X			
Salem JE, El-Aissaoui M, Alazard M, Hulot JS, Aissaoui N, Le-Heuzey JY, <i>et al.</i> Modeling of amiodarone effect on heart rate control in critically ill patients with atrial tachyarrhythmias. <i>Clin Pharmacokinet</i> 2016;55:991–1002	X			

continued

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Salem JE, Dureau P, Funck-Brentano C, Hulot JS, El-Aissaoui M, Aissaoui N, et al. Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. <i>Pharmacol Res</i> 2017; <b>122</b> :118–26	X			
Salerno DM. Supraventricular tachyarrhythmias in the intensive care unit. <i>Postgrad Med</i> 1992; <b>91</b> :293–6, 299–303, 307–10	X			
Salman Salam S, Bajwa Abubakr A, Afessa B. Paroxysmal atrial fibrillation in patients with sepsis admitted to the intensive care unit (ICU). <i>Chest</i> 2006; <b>130</b> :225S			X	
Samarin MJ, Mohrien KM, Oliphant CS. Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide. <i>Crit Care Nurs Q</i> 2015; <b>38</b> :329–44	X			
Sanai L, Armstrong IR. Supraventricular tachydysrhythmias in the critically ill. A review of antidysrhythmic therapy in patients with SVT. <i>J Intensive Care</i> 1993; <b>3</b> :358	X			
Sargent DA. Using ibutilide to convert atrial fibrillation and flutter. <i>Dimens Crit Care Nurs</i> 1999; <b>18</b> :2–12	X			
Schoaps R, Donovan J, Hazard S, Karamchandani K. <i>Anticoagulation on Hospital Discharge in Critically Ill Patients with New-Onset Atrial Fibrillation</i> . Proceedings of the 46th Critical Care Congress of the Society of Critical Care Medicine (SCCM), 21–25 January 2017, Honolulu, HI, USA, abstract no. 204			X	
Seemann A, Boissier F, Razazi K, Carteaux G, de Prost N, Brun-Buisson C, Mekontso Dessap A. New-onset supraventricular arrhythmia during septic shock: prevalence, risk factors and prognosis. <i>Ann Intensive Care</i> 2015; <b>5</b> :27			X	
Seguin P, Laviolle B, Maurice A, Leclercq C, Mallédant Y. Atrial fibrillation in trauma patients requiring intensive care. <i>Intensive Care Med</i> 2006; <b>32</b> :398–404			X	
Sekhri A, Aronow WS, Sekhri V, Palaniswamy C, Chandy D. Treatment of patients with supraventricular tachyarrhythmias in a medical intensive care unit. <i>Compr Ther</i> 2009; <b>35</b> :188–91	X			
Sekhri A, Aronow WS, Sekhri V, Palaniswamy C, Chandy D. <i>Treatment of Supraventricular Tachyarrhythmias in a Medical Intensive Care Unit Supervised by a Pulmonary Critical Care Specialist</i> . Proceedings of the American College of Chest Physicians Annual Meeting, CHEST 2009, 31 October to 5 November 2009, San Diego, CA, USA, abstract number 136	X			
Sen P, Kundu A, Sardar P, Chatterjee S, Nairouz R, Amin H, et al. <i>Outcomes After Cardioversion in Patients Treated with Non Vitamin-K Antagonist Oral Anti Coagulants (NOACS)-Insights from a Meta Analysis</i> . Proceedings of the American Thoracic Society International Conference, ATS 2015, 15–20 May 2015, Denver, CO, USA	X			

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Shah A, Pillai MV, Gandhi U, Eden E, Shapiro J. New-onset atrial fibrillation/atrial flutter in Medical Intensive Care Unit (MICU) Patients with severe sepsis is associated with stroke and increased mortality. <i>Am J Respir Crit Care Med</i> 2014; <b>189</b> :A3114				X
Shaver CM, Chen W, Janz DR, May AK, Darbar D, Bernard GR, <i>et al.</i> Atrial fibrillation is an independent predictor of mortality in critically ill patients. <i>Crit Care Med</i> 2015; <b>43</b> :2104–11				X
Shibata SC, Uchiyama A, Ohta N, Fujino Y. Efficacy and safety of landiolol compared to amiodarone for the management of postoperative atrial fibrillation in intensive care patients. <i>J Cardiothorac Vasc Anesth</i> 2016; <b>30</b> :418–22	X			
Smith H, Yeung C, Gowing S, Sadek M, Maziak D, Gilbert S, <i>et al.</i> A review and analysis of strategies for prediction, prevention and management of post-operative atrial fibrillation after non-cardiac thoracic surgery. <i>J Thorac Dis</i> 2018; <b>10</b> :S3799–S808	X			
Joseph TT, DiMeglio M, Hufferberger A, Laudanski K. Behavioural patterns of electrolyte repletion in intensive care units: lessons from a large electronic dataset. <i>Sci Rep</i> 2018; <b>8</b> :11915			X	
Tober K, Quasim T, Kinsella J. Atrial fibrillation; haemodynamics and mortality in post-operative patients on a general intensive care unit. <i>Intensive Care Med</i> 2012; <b>38</b> :S159–S				X
Tracy C, Boushahri A. Managing arrhythmias in the intensive care unit. <i>Crit Care Clin</i> 2014; <b>30</b> :365–90	X			
Trappe HJ. Treating critical supraventricular and ventricular arrhythmias. <i>J Emerg Trauma Shock</i> 2010; <b>3</b> :143–52	X			
Trappe H-J, Brandts B, Weismueller P. Arrhythmias in the intensive care patient. <i>Curr Opin Crit Care</i> 2003; <b>9</b> :345–55	X			
Trohman RG. Supraventricular tachycardia: implications for the intensivist. <i>Crit Care Med</i> 2000; <b>28</b> (Suppl. 10):N129–35	X			
Trottier S, Bowie D, Stovall M. <i>Acute Atrial Fibrillation in the ICU: Therapeutic Interventions and Hospital Course</i> . Proceedings of the 42nd Critical Care Congress of the Society of Critical Care Medicine, SCCM 2013, 19–23 January 2013, San Juan Puerto Rico			X	
Van der Does WFB, De Groot NMS. Prophylaxis with amiodarone for postoperative atrial fibrillation: when and who? <i>J Thorac Dis</i> 2018; <b>10</b> :S3831–S3	X			
Varriale P, Sedighi A. Acute management of atrial fibrillation and atrial flutter in the critical care unit: should it be ibutilide? <i>Clin Cardiol</i> 2000; <b>23</b> :265–8	X			
Walkey AJ, Benjamin EJ, Lubitz SA. New-onset atrial fibrillation during hospitalization. <i>J Am Coll Cardiol</i> 2014; <b>64</b> :2432–3				X
continued				

TABLE 19 Excluded studies on full text with reason for exclusion (continued)

Study	Excluded based on			
	Population	Study design	Outcome	Intervention
Walkey AJ, Evans SR, Winter M, Benjamin E. <i>Comparative Effectiveness of Heart Rate Control Medications for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study</i> . Proceedings of the American Thoracic Society International Conference, ATS 2015, 15–20 Mar 2015, Denver, CO, USA	X			
Walkey AJ, McManus D. When rhythm changes cause the blues: new-onset atrial fibrillation during sepsis. <i>Am J Respir Crit Care Med</i> 2017; <b>195</b> :152–4				X
Willich T, Hammwöhner M, Goette A. Therapie des Vorhofflimmerns beim kritisch Kranken. <i>Leitthema</i> 2012; <b>107</b> :368–76		X		
Wong A, Pierce T. Cardiac arrhythmias in the critically ill. <i>Anaesth Intensive Care Med</i> 2012; <b>13</b> :360–8	X			
Wood M, Thompson J. Drugs acting on the heart: anti-arrhythmics. <i>Anaesth Intensive Care Med</i> 2009; <b>10</b> :388–91	X			
Yokota T, Uchino S, Yoshida T, Fujii T, Takinami M. Predictors for sustained new-onset atrial fibrillation in critically ill patients: a retrospective observational study. <i>J Anesth</i> 2018; <b>32</b> :681–7				X
Yoshida T, Uchino S, Yokota T, Fujii T, Uezono S, Takinami M. The impact of sustained new-onset atrial fibrillation on mortality and stroke incidence in critically ill patients: a retrospective cohort study. <i>J Crit Care</i> 2018; <b>44</b> :267–72			X	
Yucel E, Hollenberg S. Atrial fibrillation in critical illness: innocent bystander or guilty party? <i>Crit Care Med</i> 2015; <b>43</b> :2254–5				X
Zochios VA, Wilkinson J. Correspondence regarding: atrial fibrillation in the intensive care setting. <i>J Intensive Care Soc</i> 2013; <b>14</b> :276–7		X		

## Appendix 5 RISK-II supplementary material

TABLE 20 Regression model coefficients for mortality after hospital discharge

Independent variable	Coefficient (95% CI) in outcome model for mortality		
	1 to 90 days after discharge	91 days to 1 year after discharge	> 1 year after discharge
NOAF	0.380 (0.231 to 0.529)	-0.005 (-0.148 to 0.138)	0.037 (-0.043 to 0.116)
Age (years) (RCS)			
Spline base variable 1	0.060 (0.039 to 0.081)	0.076 (0.058 to 0.093)	0.060 (0.050 to 0.070)
Spline base variable 2	-0.047 (-0.079 to -0.015)	-0.068 (-0.094 to -0.042)	-0.032 (-0.047 to -0.017)
Spline base variable 3	0.233 (0.069 to 0.397)	0.273 (0.138 to 0.409)	0.151 (0.072 to 0.229)
Male sex (vs. female)	0.080 (-0.035 to 0.196)	0.159 (0.063 to 0.255)	0.108 (0.053 to 0.163)
Hypertension	-0.099 (-0.229 to 0.031)	-0.091 (-0.198 to 0.015)	0.036 (-0.025 to 0.098)
Heart failure	0.303 (0.137 to 0.469)	0.498 (0.359 to 0.637)	0.350 (0.266 to 0.433)
Diabetes mellitus	0.190 (0.054 to 0.326)	0.064 (-0.052 to 0.180)	0.218 (0.154 to 0.283)
Prior thromboembolism	0.326 (0.127 to 0.525)	0.099 (-0.084 to 0.283)	0.219 (0.118 to 0.320)
Pulmonary hypertension	0.604 (0.231 to 0.977)	0.297 (-0.084 to 0.679)	0.458 (0.235 to 0.681)
Valvular heart disease	0.212 (0.017 to 0.407)	-0.015 (-0.196 to 0.166)	0.075 (-0.027 to 0.178)
RCS, restricted cubic spline. Coefficients estimated using Cox proportional hazards regression with dummy variables for all independent variables except age, which was modelled continuously using a RCS with knots at 24, 54, 68 and 84 years.			

TABLE 21 Regression model coefficients for subsequent hospitalisation

Independent variable	Coefficient (95% CI) in model for subsequent hospitalisation with:		
	Atrial fibrillation	Stroke	Heart failure
NOAF	1.767 (1.672 to 1.862)	0.384 (0.112 to 0.656)	0.247 (0.132 to 0.362)
Age (years) (RCS)	0.041 (0.037 to 0.044)	0.028 (0.020 to 0.036)	0.026 (0.022 to 0.030)
Male sex (vs. female)	0.227 (0.134 to 0.320)	0.063 (-0.149 to 0.276)	0.102 (0.010 to 0.194)
Hypertension	0.282 (0.174 to 0.390)	0.483 (0.228 to 0.738)	0.477 (0.360 to 0.594)
Heart failure	0.484 (0.365 to 0.602)	0.160 (-0.154 to 0.475)	2.005 (1.904 to 2.107)
Diabetes mellitus	0.142 (0.036 to 0.248)	0.151 (-0.093 to 0.395)	0.386 (0.287 to 0.485)
Prior thromboembolism	0.202 (0.042 to 0.362)	1.425 (1.173 to 1.677)	0.024 (-0.144 to 0.191)
Pulmonary hypertension	0.236 (-0.100 to 0.572)	0.705 (-0.011 to 1.421)	0.465 (0.214 to 0.716)
Valvular heart disease	0.346 (0.205 to 0.487)	0.255 (-0.104 to 0.613)	0.410 (0.285 to 0.536)
RCS, restricted cubic spline. Coefficients estimated using Cox cause-specific proportional hazards regression with censoring on date of death and dummy variables for all independent variables except age, which was modelled continuously using a restricted cubic spline with knots at 24, 54, 68 and 84 years.			

TABLE 22 Sensitivity analysis: patient characteristics and comorbidities

Variable	NOAF patients (sensitivity) (N = 8145)	Comparator patients (N = 48,870)
<b>Demographics</b>		
Age (years), mean (SD)	71.6 (11.5)	59.0 (17.9)
Sex (male), n (%)	4684 (57.5)	26,445 (54.1)
Ethnicity, n (%)		
White	7634 (93.7)	44,365 (90.8)
Mixed	17 (0.2)	236 (0.5)
Asian	149 (1.8)	1573 (3.2)
Black	92 (1.1)	945 (1.9)
Other	57 (0.7)	534 (1.1)
Not stated	196 (2.4)	1217 (2.5)
<b>Comorbidities, n (%)</b>		
Hypertension	5329 (65.4)	22,917 (46.9)
Heart failure	2049 (25.2)	4999 (10.2)
Diabetes mellitus	1946 (23.9)	9998 (20.5)
Valvular heart disease	1107 (13.6)	3011 (6.2)
Prior thromboembolism	722 (8.9)	3053 (6.2)
Pulmonary hypertension	213 (2.6)	574 (1.2)
Dilating cardiomyopathy	73 (0.9)	229 (0.5)
SD, standard deviation.		

TABLE 23 Sensitivity analysis: outcomes

Outcome	Cumulative incidence of event (95% CI) (%)	
	NOAF patients (sensitivity) (N = 8145)	Comparator patients (N = 48,870)
<b>Mortality</b>		
During hospital admission, n (%)	2774 (34.5)	9595 (19.7)
Time after hospital discharge		
90 days	8.8% (8.0 to 9.6)	4.2% (4.0 to 4.4)
1 year	18.6% (17.6 to 19.7)	11.1% (10.8 to 11.5)
3 years	34.1% (32.8 to 35.4)	22.4% (22.0 to 22.8)
5 years	46.3% (44.9 to 47.8)	30.1% (29.6 to 30.6)
<b>Subsequent hospital admission for<sup>a</sup></b>		
Atrial fibrillation		
1 year	28.2 (26.8 to 29.4)	2.3 (2.2 to 2.5)
3 years	39.8 (38.3 to 41.3)	5.0 (4.7 to 5.3)
5 years	46.2 (44.4 to 47.9)	7.1 (6.7 to 7.5)

TABLE 23 Sensitivity analysis: outcomes (continued)

Outcome	Cumulative incidence of event (95% CI) (%)	
	NOAF patients (sensitivity) (N = 8145)	Comparator patients (N = 48,870)
Stroke		
1 year	1.6 (1.3 to 2.0)	0.6 (0.6 to 0.7)
3 years	3.1 (2.6 to 3.8)	1.4 (1.2 to 1.5)
5 years	4.5 (3.8 to 5.4)	2.0 (1.8 to 2.2)
Heart failure		
1 year	11.1 (10.2 to 12.0)	4.3 (4.0 to 4.5)
3 years	17.4 (16.3 to 18.6)	7.5 (7.2 to 7.8)
5 years	21.8 (20.3 to 23.3)	9.7 (9.3 to 10.0)

a Estimates of risk of hospital admission use a non-parametric method to additionally account for the competing risk of death, i.e. that patients who die are no longer at risk of being admitted to hospital.




FIGURE 11 Sensitivity analysis: mortality from ICU admission.





FIGURE 12 Sensitivity analysis: outcomes after hospital discharge. (a) Mortality after discharge; (b) hospitalisation with AF; (c) hospitalisation with stroke; (d) hospitalisation with heart failure. (continued)



**FIGURE 12** Sensitivity analysis: outcomes after hospital discharge. (a) Mortality after discharge; (b) hospitalisation with AF; (c) hospitalisation with stroke; (d) hospitalisation with heart failure.

TABLE 24 Sensitivity analysis: regression models, main results

Outcome	NOAF group (N = 8145)		Comparator group (N = 48,870)		Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Mortality during hospital admission	2774		9595		2.14 (2.03 to 2.25)	1.51 (1.43 to 1.59)

Outcome	NOAF group (N = 8145)		Comparator group (N = 48,870)		Unadjusted HR (95% CI)	Adjusted HR (95% CI)
	Number of events	Number of person-years at risk	Number of events	Number of person-years at risk		
Death 1–90 days after hospital discharge	456	1247	1614	9497	2.26 (2.05 to 2.49)	1.54 (1.38 to 1.71)
Death 91 days to 1 year after hospital discharge	514	4595	2716	36,352	1.50 (1.37 to 1.65)	1.04 (0.95 to 1.16)
Death > 1 year after hospital discharge	1582	19,351	8054	171,327	1.76 (1.67 to 1.86)	1.07 (1.01 to 1.13)

Outcome	NOAF group (N = 8145)		Comparator group (N = 48,870)		Unadjusted CHR (95% CI)	Adjusted CHR (95% CI)
	Number of events	Number of person-years at risk	Number of events	Number of person-years at risk		
Subsequent hospital admission for atrial fibrillation	1926	8461	1865	96,570	10.67 (10.02 to 11.38)	6.41 (5.99 to 6.85)
Subsequent hospital admission for stroke	157	11,498	520	98,450	2.53 (2.12 to 3.03)	1.59 (1.32 to 1.91)
Subsequent hospital admission for heart failure	857	10,517	2718	95,410	2.71 (2.51 to 2.92)	1.25 (1.15 to 1.35)

Odds ratios estimated using logistic regression  $\pm$  adjustment for age (using a restricted cubic spline with knots at positions 25, 54, 68 and 84 years), sex, diabetes mellitus, hypertension, prior thromboembolism, valvular heart disease, pulmonary hypertension and heart failure. HRs estimated using Cox proportional hazards regression  $\pm$  adjustment for the same factors. Cause-specific hazard ratios estimated using Cox proportional hazards regression with censoring at death  $\pm$  adjustment for the same factors.



## Appendix 6 Intensive care unit databases supplementary material

Parts of this appendix are reproduced or adapted with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The appendix includes minor additions and formatting changes to the original appendix.

TABLE 25 Characteristics of patients with NOAF vs. those without: MIMIC-III database

Characteristic	Never had AF (N = 17,494)	NOAF (N = 1065)
Age (years), median (IQR)	59 (47–73)	75 (64–83)
Sex, n (%)		
Female	8440 (48)	518 (49)
Male	9054 (52)	547 (51)
Weight (kg), median (IQR)	77 (64–91)	77 (65–92)
ICU length of stay (days), median (IQR)	1.8 (1.0–3.5)	5.8 (3.0–11.8)
ICU mortality, n (%)	1260 (7.2)	265 (25)
Hospital length of stay (days), median (IQR)	6 (4–12)	12 (7–21)
Hospital mortality, n (%)	1887 (11)	347 (33)

TABLE 26 Characteristics of patients with NOAF vs. those without: PICRAM database

Characteristic	Never had AF (N = 7415)	NOAF (N = 952)
Age (years), median (IQR)	61 (45–71)	71 (64–78)
Sex, n (%)		
Female	3120 (42)	368 (39)
Male	4295 (58)	584 (61)
Weight (kg), median (IQR)	72 (62–83)	75 (65–85)
ICU length of stay (days), median (IQR)	2.4 (1.5–4.7)	6.1 (3.1–12.8)
ICU mortality, n (%)	628 (8.5)	193 (20)
Hospital length of stay (days), <sup>a</sup> median (IQR)	13 (7–25)	19 (10–40)
Hospital mortality, n (%)	1122 (16)	350 (37)

<sup>a</sup> Thirty-two patients for whom hospital length of stay was unknown are not included.

TABLE 27 Characteristics of included patients by treatment group: MIMIC-III database

Characteristic	Treatment group				Overall (N = 740)
	Amiodarone (N = 94)	Beta-blocker (N = 473)	Calcium channel blocker (N = 144)	DCC (N = 29)	
Age (years), median (IQR)	76 (63–83)	73 (64–83)	73 (65–81)	77 (69–85)	74 (64–82)
Sex, n (%)					
Female	51 (54)	234 (49)	77 (53)	10 (34)	372 (50)
Male	43 (46)	239 (51)	67 (47)	19 (66)	368 (50)
COPD, n (%)	3 (3.2)	28 (5.9)	19 (13)	3 (10)	53 (7.2)
NYHA class III/IV heart failure, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Dialysis-dependent renal failure, n (%)	0 (0)	1 (0.2)	0 (0)	0 (0)	1 (0.1)
Chronic liver disease, n (%)	2 (2.1)	7 (1.5)	2 (1.4)	0 (0)	11 (1.5)
Thyroid disorder, n (%)	2 (2.1)	27 (5.7)	3 (2.1)	1 (3.4)	33 (4.5)
Beta-blocker therapy prior to admission, n (%)	38 (46)	193 (45)	37 (28)	13 (52)	281 (42)
Antipsychotic medication prior to admission, n (%)	4 (4.8)	19 (4.4)	4 (3.1)	0 (0)	27 (4.0)
Highest OASIS at 3 hours, median (IQR)	38 (32–43)	36 (31–40)	36 (30–40)	40 (33–43)	36 (31–41)
Mechanical ventilation at time of NOAF, n (%)	60 (64)	206 (44)	55 (38)	22 (76)	343 (46)
Renal replacement therapy during or < 12 hours prior to NOAF, n (%)	5 (5.3)	38 (8.0)	1 (0.7)	3 (10)	47 (6.4)
i.v. vasoactive medication at time of NOAF, n (%)	34 (36)	45 (9.5)	9 (6.2)	13 (45)	101 (14)
Therapeutic anticoagulation at time of NOAF, n (%)	6 (6.4)	23 (4.9)	5 (3.5)	2 (6.9)	36 (4.9)
Central venous catheter at time of NOAF, n (%)	69 (73)	261 (55)	75 (52)	24 (83)	429 (58)
Bronchodilator therapy on day of, or day preceding, NOAF, n (%)	33 (35)	155 (33)	62 (43)	8 (28)	258 (35)

Characteristic	Treatment group				
	Amiodarone (N = 94)	Beta-blocker (N = 473)	Calcium channel blocker (N = 144)	DCC (N = 29)	Overall (N = 740)
Plasma concentration, median (IQR)					
Sodium (mmol/l)	138 (136–141)	140 (137–143)	140 (137–143)	138 (136–143)	139 (136–143)
Potassium (mmol/l)	4.0 (3.7–4.5)	3.9 (3.6–4.3)	4.0 (3.7–4.3)	4.1 (3.7–4.4)	4.0 (3.7–4.4)
Magnesium (mmol/l)	0.86 (0.78–0.95)	0.82 (0.78–0.95)	0.86 (0.78–0.95)	0.82 (0.78–0.91)	0.82 (0.78–0.95)
Urea (mmol/l)	10.0 (6.4–15.4)	8.9 (5.7–15.7)	8.9 (6.1–15.4)	19.8 (9.5–23.8)	9.3 (6.1–16.1)
Creatinine (µmol/l)	97 (71–168)	97 (62–159)	88 (62–139)	159 (86–270)	97 (62–159)
White cell count ( $\times 10^9/l$ ), median (IQR)	13.6 (8.8–19.7)	11.6 (8.8–15.5)	11.3 (7.5–16.3)	13.1 (10.5–16.3)	11.8 (8.5–16.1)
Haemoglobin concentration (g/l), median (IQR)	100 (88–113)	104 (92–115)	101 (93–116)	99 (91–111)	102 (92–115)
Platelet count ( $\times 10^9/l$ ), median (IQR)	179 (91–258)	190 (129–286)	205 (137–291)	161 (111–219)	190 (123–283)
Prothrombin time (seconds), median (IQR)	15.2 (13.7–17.8)	14.2 (13.1–16.3)	14.0 (12.9–15.6)	15.0 (13.6–17.5)	14.2 (13.1–16.4)
Systolic blood pressure after AF onset (mmHg), median (IQR)	103 (93–122)	119 (104–140)	115 (97–132)	93 (88–111)	116 (100–135)
Mean blood pressure after AF onset (mmHg), median (IQR)	72 (63–81)	80 (69–92)	76 (66–88)	67 (61–78)	78 (67–90)
Heart rate after AF onset (b.p.m.), median (IQR)	124 (110–139)	121 (102–136)	124 (110–141)	123 (98–147)	122 (104–137)
NYHA, New York Heart Association.					

TABLE 28 Characteristics of included patients by treatment group: PICRAM database

Characteristic	Treatment group			Overall (N = 460)
	Amiodarone (N = 344)	Beta-blockers (N = 47)	Digoxin (N = 69)	
Age (years), median (IQR)	69 (63–77)	70 (64–76)	75 (65–81)	70 (63–77)
Sex, n (%)				
Female	141 (41)	20 (43)	25 (36)	186 (40)
Male	203 (59)	27 (57)	44 (64)	274 (60)
COPD, n (%)	51 (15)	1 (2.1)	11 (16)	63 (14)
NYHA class III/IV heart failure, n (%)	2 (0.6)	0 (0)	0 (0)	2 (0.4)
Dialysis-dependent renal failure, n (%)	6 (1.7)	0 (0)	1 (1.4)	7 (1.5)
Chronic liver disease, n (%)	14 (4.1)	1 (2.1)	5 (7.2)	20 (4.3)
Thyroid disorder, n (%)	21 (6.1)	3 (6.4)	4 (5.8)	28 (6.1)
Beta-blocker therapy prior to admission, n (%)	44 (13)	10 (21)	9 (13)	63 (14)
Antipsychotic medication prior to admission, n (%)	5 (1.5)	1 (2.1)	1 (1.4)	7 (1.5)
Highest OASIS at 3 hours, median (IQR)	34 (27–40)	34 (22–38)	30 (25–36)	34 (26–39)
Mechanical ventilation at time of NOAF, n (%)	192 (56)	22 (47)	29 (42)	243 (53)
Renal replacement therapy during or < 12 hours prior to NOAF, n (%)	52 (15)	5 (11)	8 (12)	65 (14)
i.v. vasoactive medication at time of NOAF, n (%)	105 (31)	6 (13)	13 (19)	124 (27)
Therapeutic anticoagulation at time of NOAF, n (%)	37 (11)	5 (11)	6 (8.7)	48 (10)
Central venous catheter at time of NOAF, n (%)	262 (76)	32 (68)	32 (46)	326 (71)
Bronchodilator therapy on day of, or day preceding, NOAF, n (%)	57 (17)	7 (15)	11 (16)	75 (16)
Plasma concentration, median (IQR)				
Sodium (mmol/l)	137 (134–141)	139 (136–144)	138 (135–140)	137 (134–141)
Potassium (mmol/l)	4.2 (3.9–4.5)	4.1 (4.0–4.6)	4.2 (3.9–4.4)	4.2 (3.9–4.5)
Magnesium (mmol/l)	0.95 (0.84–1.14)	1.01 (0.92–1.16)	0.92 (0.82–1.08)	0.96 (0.84–1.12)
Urea (mmol/l)	13.8 (9.5–20.1)	12.1 (7.8–17.7)	13.2 (8.2–18.5)	13.6 (8.8–19.5)
Creatinine concentration (μmol/l)	134 (78–224)	108 (70–151)	112 (84–185)	125 (78–214)
White cell count (× 10 <sup>9</sup> /l), median (IQR)	11.1 (7.5–16.2)	10.6 (7.6–13.4)	12.0 (9.5–16.8)	11.1 (7.7–16.3)
Haemoglobin concentration (g/l), median (IQR)	97 (87–111)	103 (94–112)	101 (90–116)	98 (88–113)
Platelet count (× 10 <sup>9</sup> /l), median (IQR)	163 (105–231)	192 (118–247)	180 (136–237)	166 (109–234)
Prothrombin time (seconds), median (IQR)	16.2 (15.0–19.0)	15.5 (14.4–17.0)	16.6 (15.0–19.4)	16.1 (15.0–19.0)
Systolic blood pressure after AF onset (mmHg), median (IQR)	112 (97–128)	128 (108–156)	119 (103–135)	116 (99–131)
Mean blood pressure after AF onset (mmHg), median (IQR)	74 (67–85)	83 (73–94)	78 (70–88)	75 (67–86)
Heart rate after AF onset (b.p.m.), median (IQR)	128 (107–149)	125 (110–146)	120 (98–140)	127 (107–147)
NYHA, New York Heart Association.				

TABLE 29 Unweighted and weighted covariate means by treatment group: MIMIC-III database

Variable	Unweighted means				Weighted means				Maximum pairwise SMD	
	Amiodarone	Beta-blocker	Calcium channel blocker	DCC	Amiodarone	Beta-blocker	Calcium channel blocker	DCC	Unweighted	Weighted
Age (years)	71.84	71.98	72.56	74.14	72.90	72.56	72.74	72.72	0.17	0.03
Male sex	0.46	0.51	0.47	0.66	0.51	0.51	0.51	0.54	0.20	0.03
OASIS 3-hour score	36.80	35.21	35.22	38.93	35.87	35.89	35.94	36.71	0.48	0.11
Beta-blocker on admission	0.40	0.45	0.31	0.52	0.44	0.44	0.41	0.49	0.21	0.08
Antipsychotic medication on admission	0.05	0.06	0.03	0.00	0.04	0.04	0.04	0.00	0.06	0.04
Thyroid disorder	0.02	0.06	0.02	0.03	0.04	0.04	0.04	0.05	0.04	0.01
COPD	0.03	0.06	0.13	0.10	0.06	0.08	0.08	0.11	0.10	0.05
Liver disease	0.02	0.01	0.01	0.00	0.01	0.01	0.01	0.00	0.02	0.01
Dialysis-dependent renal failure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Plasma sodium concentration (mmol/l)	138.10	139.63	140.04	139.28	139.32	139.48	139.46	139.47	0.35	0.03
Plasma potassium concentration (mmol/l)	4.10	4.02	4.02	4.03	4.01	4.02	4.01	3.97	0.15	0.08
Plasma magnesium concentration (mmol/l)	0.86	0.86	0.87	0.84	0.85	0.85	0.85	0.83	0.20	0.17
Plasma creatinine concentration (mmol/l)	164.16	148.06	125.38	219.54	157.14	152.43	149.86	163.62	0.57	0.08
Plasma urea concentration (µmol/l)	11.97	12.00	12.12	18.48	12.28	13.02	13.32	15.14	0.69	0.30
White cell count ( $\times 10^9/l$ )	14.92	12.68	12.63	15.31	13.52	13.33	12.88	13.81	0.32	0.11
Haemoglobin concentration (g/l)	102.89	104.00	104.82	99.52	102.99	103.07	103.44	101.20	0.30	0.13
										continued

TABLE 29 Unweighted and weighted covariate means by treatment group: MIMIC-III database (continued)

Variable	Unweighted means				Weighted means				Maximum pairwise SMD	
	Amiodarone	Beta-blocker	Calcium channel blocker	DCC	Amiodarone	Beta-blocker	Calcium channel blocker	DCC	Unweighted	Weighted
Platelet count (× 10/l)	207	215	221	184	206	209	209	200	0.29	0.07
Therapeutic anticoagulation at time of NOAF	0.06	0.05	0.03	0.07	0.05	0.04	0.04	0.04	0.03	0.01
Log-prothrombin time	2.76	2.70	2.70	2.74	2.72	2.72	2.72	2.74	0.24	0.10
Systolic blood pressure after AF onset (mmHg)	105.88	119.20	116.69	89.62	113.40	113.60	113.54	108.28	0.83	0.15
Mean blood pressure after AF onset (mmHg)	67.26	74.67	74.45	58.11	71.23	71.37	71.92	67.57	0.76	0.20
Heart rate after AF onset (b.p.m.)	123.68	120.74	123.56	122.14	123.32	122.87	123.09	125.32	0.11	0.09
Temperature (°C)	37.04	37.02	37.06	36.88	37.02	37.02	37.06	37.02	0.23	0.05
i.v. vasoactive medication at time of NOAF	0.36	0.10	0.06	0.45	0.17	0.16	0.15	0.21	0.39	0.06
Noradrenaline dose (µg/kg/minute)	0.12	0.02	0.01	0.08	0.03	0.03	0.02	0.04	0.66	0.09
Vasopressin dose (µg/kg/minute)	0.17	0.05	0.02	0.29	0.07	0.07	0.05	0.10	0.48	0.08
Bronchodilator therapy on day of, or day preceding, NOAF	0.35	0.33	0.43	0.28	0.33	0.33	0.35	0.30	0.15	0.04
Mechanical ventilation at time of NOAF	0.64	0.44	0.38	0.76	0.51	0.50	0.47	0.58	0.38	0.11
Central venous catheter at time of NOAF	0.73	0.55	0.52	0.83	0.63	0.61	0.61	0.68	0.31	0.08
Renal replacement therapy during or < 12 hours prior to NOAF	0.05	0.08	0.01	0.10	0.04	0.05	0.02	0.04	0.10	0.03

TABLE 30 Unweighted and weighted covariate means by treatment group: PICRAM database

Variable	Unweighted means			Weighted means			Maximum pairwise SMD	
	Amiodarone	Beta-blocker	Digoxin	Amiodarone	Beta-blocker	Digoxin	Unweighted	Weighted
Age (years)	68.60	68.94	71.78	69.52	69.23	70.24	0.28	0.09
Male sex	0.59	0.57	0.64	0.60	0.59	0.62	0.06	0.02
OASIS 3-hour	33.77	31.17	29.83	32.75	32.62	31.91	0.43	0.09
Beta-blocker on admission	0.13	0.21	0.13	0.14	0.16	0.15	0.08	0.02
Antipsychotic medication on admission	0.01	0.02	0.01	0.02	0.02	0.01	0.01	0.01
Thyroid disorder	0.06	0.06	0.06	0.06	0.06	0.07	0.01	0.00
COPD	0.15	0.02	0.16	0.12	0.05	0.13	0.14	0.07
Liver disease	0.04	0.02	0.07	0.04	0.03	0.05	0.05	0.02
NYHA class III/IV heart failure	0.01	NA	0.00	0.00	NA	0.00	0.01	0.00
Dialysis-dependent renal failure	0.02	0.00	0.01	0.01	0.00	0.01	0.02	0.01
Plasma sodium concentration (mmol/l)	137.51	139.79	138.05	138.13	138.91	138.31	0.40	0.14
Plasma potassium concentration (mmol/l)	4.24	4.30	4.20	4.24	4.26	4.24	0.19	0.05
Plasma magnesium concentration (mmol/l)	0.99	1.02	0.96	0.99	1.00	0.99	0.29	0.08
Plasma creatinine concentration (mmol/l)	171.42	142.16	156.38	164.82	165.09	164.62	0.25	0.00
Plasma urea concentration (μmol/l)	16.01	13.68	13.88	15.03	14.56	14.27	0.27	0.09
White cell count ( $\times 10^9/l$ )	12.60	11.24	12.88	12.48	11.94	12.52	0.25	0.09
Haemoglobin concentration (g/l)	100.55	104.40	105.42	101.74	102.35	101.98	0.27	0.03
Platelet count ( $\times 10^9/l$ )	179.62	197.59	207.64	190.48	196.85	197.06	0.25	0.06
continued								

TABLE 30 Unweighted and weighted covariate means by treatment group: PICRAM database (continued)

Variable	Unweighted means			Weighted means			Maximum pairwise SMD	
	Amiodarone	Beta-blocker	Digoxin	Amiodarone	Beta-blocker	Digoxin	Unweighted	Weighted
Therapeutic anticoagulation at time of NOAF	0.11	0.11	0.09	0.11	0.13	0.11	0.02	0.02
Log-prothrombin time	2.86	2.80	2.92	2.86	2.82	2.88	0.41	0.18
Systolic blood pressure after AF onset (mmHg)	117.19	123.94	119.54	118.81	120.14	119.19	0.22	0.04
Mean blood pressure after AF onset (mmHg)	75.35	80.36	78.03	76.66	77.66	76.93	0.26	0.05
Heart rate after AF onset (b.p.m.)	125.48	129.06	117.77	124.50	125.74	124.48	0.41	0.05
Temperature (°C)	36.58	36.84	36.54	36.63	36.75	36.60	0.34	0.17
i.v. vasoactive medication at time of NOAF	0.31	0.13	0.19	0.26	0.22	0.24	0.18	0.04
Noradrenaline dose (µg/kg/minute)	0.06	0.04	0.04	0.06	0.05	0.06	0.23	0.05
Vasopressin dose (µg/kg/minute)	0.05	NA	0.00	0.02	NA	0.00	0.29	0.12
Bronchodilator therapy on day of, or day preceding, NOAF	0.17	0.15	0.16	0.17	0.18	0.16	0.02	0.02
Mechanical ventilation at time of NOAF	0.56	0.47	0.42	0.52	0.53	0.49	0.14	0.04
Central venous catheter at time of NOAF	0.76	0.68	0.46	0.69	0.71	0.64	0.30	0.07
Renal replacement therapy during or < 12 hours prior to NOAF	0.15	0.11	0.12	0.14	0.14	0.13	0.04	0.01
NA, not applicable; NYHA, New York Heart Association.								

TABLE 31 Unadjusted and adjusted HRs for each outcome and associated 95% CIs: MIMIC-III database

Treatment	Unadjusted HR	95% CI	Adjusted	HR 95% CI
<b>Rate control</b>				
Beta-blocker	1.03	0.81 to 1.30	1.09	0.78 to 1.51
Calcium channel blocker	0.83	0.62 to 1.12	0.81	0.55 to 1.19
Cardioversion	1.01	0.39 to 2.62	1.59	0.44 to 5.75
<b>Rhythm control</b>				
Beta-blocker	0.91	0.73 to 1.12	0.91	0.61 to 1.35
Calcium channel blocker	0.65	0.50 to 0.84	0.59	0.37 to 0.92
Cardioversion	1.45	0.82 to 2.57	2.00	0.86 to 4.65
<b>Reversion to AF</b>				
Beta-blocker	1.18	0.79 to 1.78	1.37	0.67 to 2.78
Calcium channel blocker	1.44	0.90 to 2.31	1.73	0.78 to 3.84
Cardioversion	1.80	0.83 to 3.90	1.01	0.28 to 3.71
<b>Reversion to heart rate of <math>\geq 110</math> b.p.m.</b>				
Beta-blocker	1.08	0.80 to 1.46	0.95	0.59 to 1.52
Calcium channel blocker	1.44	1.00 to 2.07	1.61	0.93 to 2.79
Cardioversion	0.67	0.30 to 1.53	0.93	0.36 to 2.42
<b>Hospital mortality</b>				
Beta-blocker	0.64	0.44 to 0.93	1.03	0.53 to 2.03
Calcium channel blocker	0.77	0.50 to 1.20	1.30	0.61 to 2.76
Cardioversion	1.56	0.86 to 2.83	0.96	0.31 to 3.01

TABLE 32 Unadjusted and adjusted HRs for each outcome and associated 95% CIs: PICRAM database

Treatment	Unadjusted HR	95% CI	Adjusted HR	95% CI
<b>Rate control</b>				
Beta-blocker	0.85	0.57 to 1.27	0.82	0.48 to 1.42
Digoxin	0.64	0.45 to 0.92	0.56	0.34 to 0.92
<b>Rhythm control</b>				
Beta-blocker	0.95	0.64 to 1.40	0.99	0.57 to 1.72
Digoxin	0.57	0.41 to 0.81	0.67	0.41 to 1.09
<b>Reversion to AF</b>				
Beta-blocker	0.79	0.50 to 1.27	0.84	0.42 to 1.65
Digoxin	1.21	0.78 to 1.89	1.32	0.71 to 2.47
<b>Reversion to heart rate of <math>\geq 110</math> b.p.m.</b>				
Beta-blocker	0.94	0.58 to 1.52	0.88	0.43 to 1.79
Digoxin	1.41	0.91 to 2.19	1.14	0.63 to 2.09
<b>Hospital mortality</b>				
Beta-blocker	0.74	0.40 to 1.38	0.75	0.30 to 1.84
Digoxin	1.21	0.79 to 1.86	1.37	0.75 to 2.50

TABLE 33 Unadjusted and adjusted HRs for each outcome and associated 95% CIs: combined databases

Treatment	Unadjusted HR	95% CI	Adjusted HR	95% CI
<b>Rate control</b>				
Beta-blocker	1.26	1.10 to 1.43	1.14	0.91 to 1.44
Calcium channel blocker	1.06	0.86 to 1.29	0.88	0.63 to 1.23
Digoxin	0.69	0.52 to 0.91	0.52	0.32 to 0.86
Electrical cardioversion	1.74	0.90 to 3.36	2.30	0.87 to 6.06
<b>Rhythm control</b>				
Beta-blocker	0.81	0.71 to 0.93	0.86	0.67 to 1.11
Calcium channel blocker	0.58	0.47 to 0.71	0.56	0.39 to 0.79
Digoxin	0.58	0.41 to 0.83	0.64	0.35 to 1.17
Electrical cardioversion	1.25	0.77 to 2.03	1.58	0.71 to 3.51
<b>Reversion to AF</b>				
Beta-blocker	0.68	0.55 to 0.84	0.72	0.48 to 1.08
Calcium channel blocker	0.81	0.58 to 1.13	0.89	0.48 to 1.64
Digoxin	1.39	0.90 to 2.14	2.22	0.95 to 5.21
Electrical cardioversion	1.02	0.52 to 1.98	0.64	0.20 to 2.02
<b>Reversion to heart rate of <math>\geq 110</math> b.p.m.</b>				
Beta-blocker	1.00	0.85 to 1.17	0.88	0.65 to 1.18
Calcium channel blocker	1.62	1.28 to 2.06	1.54	1.00 to 2.37
Digoxin	1.24	0.92 to 1.66	1.26	0.75 to 2.12
Electrical cardioversion	1.24	0.68 to 2.26	0.90	0.32 to 2.51
<b>Hospital mortality</b>				
Beta-blocker	0.78	0.62 to 0.99	0.97	0.56 to 1.68
Calcium channel blocker	0.95	0.67 to 1.33	1.21	0.62 to 2.39
Digoxin	1.16	0.76 to 1.79	1.77	0.77 to 4.06
Electrical cardioversion	1.92	1.16 to 3.17	0.87	0.25 to 3.00




FIGURE 13 Cumulative incidence plot of time from treatment to heart rate of < 110 b.p.m. for each treatment: MIMIC-III database.




FIGURE 14 Kaplan-Meier curves of time from achieving rate control to reversion to heart rate of  $\geq 110$  b.p.m.: MIMIC-III database.




FIGURE 15 Cumulative incidence plot of time from treatment to heart rate of < 110 b.p.m. for each treatment: PICRAM database.




FIGURE 16 Kaplan-Meier curves of time from achieving rate control to reversion to heart rate of  $\geq 110$  b.p.m.: PICRAM database.




FIGURE 17 Cumulative incidence plot of time from treatment to rhythm control for each treatment: MIMIC-III database.




FIGURE 18 Kaplan-Meier curves for each treatment of time from achieving rhythm control to reversion to AF: MIMIC-III database.




FIGURE 19 Cumulative incidence plot of time from treatment to rhythm control for each treatment: PICRAM database.




FIGURE 20 Kaplan-Meier curves for each treatment of time from achieving rhythm control to reversion to AF: PICRAM database.




FIGURE 21 Kaplan-Meier survival curves for each treatment group: MIMIC-III database.




FIGURE 22 Kaplan–Meier survival curves for each treatment group: PICRAM database.

## Appendix 7 Critical Care Health Informatics Collaborative database analysis

### Aim

The aim of this brief report was to investigate the incidence and characteristics of NOAF in a multicentre UK-based intensive care population. The CCHIC database was not included in the main analysis because it lacks data pertaining to most anti-arrhythmic medications.

This analysis was performed to allow comparison with data extracted for the main analysis to assess consistency and generalisability of our findings in the main report.

### Methods

#### Study design

We carried out a retrospective analysis of patient data collected for the Health Informatics Collaborative (CCHIC) database. The HIC database was created with retrospectively collected detailed data from the ICU clinical information systems relating to patients treated on four general ICUs in London and Cambridge, UK, from 2014 to 2018.

#### Study population

We included data relating to all adult patients during their first ICU admission. We used the eligibility criteria stated in *Chapter 4, Study population*. However, we were unable to exclude patients with documented pre-existing arrhythmias because these data were not available in the CCHIC database. Pre-existing arrhythmia was, therefore, determined only by the presence of arrhythmia during the first 3 hours of ICU admission.

### Results

#### Study population

The CCHIC database included data relating to 33,451 adult first admissions to an ICU. Of these patients, 7889 had an ICU length of stay of < 24 hours. We identified 2713 patients being paced or with another significant arrhythmia during the first 3 hours of ICU admission. Of the remaining 22,849 patients, 1003 had missing hospital mortality data. Of the remaining 21,846 eligible patients, 2618 (12%) developed NOAF. This process is outlined in *Figure 23*. No data were missing in our cohort for baseline demographic variables. Acute Physiology and Chronic Health Evaluation (APACHE) II scores were missing for 3635 patients. Hospital length of stay was missing for 2008 patients. Patients who developed NOAF appeared older and more unwell and more likely to be male and, interestingly, slightly more likely to have had elective surgery than those who did not develop NOAF (*Table 34*).

#### Characteristics of new-onset atrial fibrillation

The median time from ICU admission to the first episode of NOAF was 43 hours (IQR 23.5–73 hours). The median total duration of AF per patient who developed NOAF was 13.5 hours (IQR 4–37 hours).




FIGURE 23 The CCHIC database analysis flow chart.

TABLE 34 The CCHIC database analysis patient characteristics

Characteristic	Never AF (N = 19,228)	NOAF (N = 2618)
Age (years), median (IQR)	60 (45–70)	70 (65–80)
Sex, n (%)		
Female	8266 (43)	885 (34)
Male	10,962 (57)	1733 (66)
APACHE II score, median (IQR)	14 (11–18)	16 (13–21)
Missing, n	3237	398
Elective surgery, n (%)	6513 (34)	991 (38)
ICU length of stay (days), median (IQR)	2 (1–5)	5 (3–11)
ICU mortality, n (%)	845 (4.4)	250 (9.5)
Hospital length of stay (days), median (IQR)	13 (8–26)	18 (10–36)
Missing, n	1729	279
Hospital mortality, n (%)	1673 (8.7)	450 (17)
APACHE, Acute Physiology and Chronic Health Evaluation.		

## Discussion

This analysis demonstrates that the incidence of NOAF and the time to NOAF onset among eligible patients is similar across the PICRAM and CCHIC databases. The association between NOAF and mortality was evident in the CCHIC database. The total duration of AF per patient appeared shorter in the CCHIC database than in the PICRAM database. The CCHIC database analysis included treated and untreated episodes of AF; therefore, the average duration may have been reduced by very brief episodes in which treatment was not felt to be warranted.

## Conclusion

The epidemiology of NOAF identified in the CCHIC database is like that observed in the PICRAM database. Similar incidence and onset times suggest that the NOAF identified by bedside observations is a comparable phenomenon across these databases.



## Appendix 8 Expert panel details

Parts of this appendix are reproduced or adapted with permission from Bedford *et al.*<sup>81</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>. The appendix includes minor additions and formatting changes to the original appendix.

### Expert panel details and research recommendations

TABLE 35 Expert panel members and roles

Name	Role	Institution
Professor Peter Watkinson	Associate professor of intensive care medicine	University of Oxford, Oxford, UK
Dr Jonathan Bedford	Clinical research fellow	University of Oxford, Oxford, UK
Dr Andrew Walden	Consultant in intensive care medicine	Intensive care unit, Royal Berkshire Hospital, Reading, UK
Professor Ben O'Brien	Professor of perioperative medicine	St Bartholomew's Hospital & Barts Heart Centre, London, UK
Dr Kim Rajappan	Consultant in cardiology	Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Dr Ian Taylor	Lay representative	NA
Mrs Cathy Taylor	Lay representative	NA
NA, not applicable.		

### Treatments and confounding variables

The following lists were drawn initially from the scoping review and were then refined and ratified by the expert panel, as outlined in *Chapter 2, Expert panel review*.

#### Treatments of interest

#### Treatments to be included in the analysis

- Amiodarone i.v.
- Beta-blockers i.v.
  - Labetalol.
  - Esmolol.
  - Metoprolol.
- Calcium channel blockers i.v.
  - Diltiazem.
  - Verapamil.
- Digoxin i.v.
- Electrical cardioversion.

**Treatments of interest but not possible with our data**

Propafenone, ibutilide and landiolol were identified as candidate therapies in the scoping review; however, these are not available in our data sets.

*Confounding/matching variables***Demographic/comorbid factors**

- Age.
- Sex.
- Congestive cardiac failure.
- Severe respiratory disease/pulmonary fibrosis.
- COPD (previous or current diagnosis).
- Chronic liver disease (previous or current diagnosis).
- Chronic renal failure.
- Thyroid disorders (previous or current diagnosis, or taking relevant medications).
- Preadmission beta-blockers.
- Preadmission antipsychotic medication.

**Admission factors**

- Illness severity in the first 3 hours (therefore, not influenced by NOAF, as we are excluding patients in AF in the first 3 hours).

**Factors at the time of new-onset atrial fibrillation treatment**

- Heart rate.
- Blood pressure.
- Body temperature.
- Presence and type of vasopressor/inotrope.
- Dose of vasopressor/inotrope.
- White cell count.
- Plasma electrolyte (K, Mg, Na, Ca) concentrations.
- Plasma urea and creatinine concentrations.
- Platelet count.
- Prothrombin time.
- Presence of therapeutic dose anticoagulation.
- Presence of bronchodilator therapy.
- Mechanical ventilation.
- Haemofiltration (current or previous 12 hours).
- Presence of central venous access.

## Research recommendations

### *Amiodarone versus beta-blockers*

TABLE 36 Research recommendation 1: amiodarone vs. beta-blockers

Domain	Description
<b>Step 2: prioritise</b>	
Uncertainty identified	Either amiodarone or beta-blockers are commonly used in critically ill patients to control AF, but there is little evidence to support whether or not one is superior
Reason uncertain (conflicting or lack of evidence)?	Although cohort studies have suggested survival advantages to beta-blockers, the evidence is conflicting and subject to bias
<b>Step 3: two-component research recommendation</b>	
Structured statement	A RCT of amiodarone vs. beta-blockers for management of NOAF in critically ill patients should be undertaken
Structured rationale	NOAF during ICU is associated with substantially increased mortality after correction for associated risk factors. Both amiodarone and beta-blockers are commonly used but have significant side effects. Whether or not one is superior to the other has not been demonstrated
PICOS	<p>Patients: patients who experience NOAF while in an ICU</p> <p>Intervention: amiodarone</p> <p>Control: beta-blocker</p> <p>Outcomes:</p> <ul style="list-style-type: none"> <li>• mortality (30 and 90 days)</li> <li>• length of stay (ICU and hospital)</li> <li>• AF burden post commencing treatment</li> <li>• rate control post commencing treatment</li> <li>• duration of organ support (respiratory, cardiovascular and renal)</li> <li>• thromboembolism</li> <li>• inotrope/vasopressor requirement</li> </ul> <p>Study type: RCT</p>

### Risk stratification tools for anticoagulation

TABLE 37 Research recommendation 2: risk stratification tools for anticoagulation

Domain	Description
<b>Step 2: prioritise</b>	
Uncertainty identified	It is not clear in which patients who develop NOAF while in an ICU anticoagulation following hospital discharge might be beneficial
Reason uncertain (conflicting or lack of evidence)?	There is very little evidence to inform practice, but the risk of thromboembolism is increased in comparison with those who do not develop NOAF even when corrected for known risk factors
<b>Step 3: two-component research recommendation</b>	
Structured statement	Whether or not there are subgroups of patients who develop NOAF while in an ICU who may benefit from long-term anticoagulation is unknown. Studies should be undertaken to create risk stratification tools or investigate whether or not current tools are applicable to the 'NOAF during ICU population' to identify patients sufficiently at risk of future thromboembolism to merit consideration of anticoagulation
Structured rationale	The risk of thromboembolism is increased compared with those who do not develop NOAF, even when corrected for known risk factors. However, current risk stratification tools have not been validated in the 'NOAF during ICU population' and do not take account of ICU treatments that may affect future outcome
PICOS	<p>Patients: patients experiencing an episode of NOAF during an ICU admission</p> <p>Intervention/control: none</p> <p>Outcome: thromboembolism</p> <p>Study type: cohort study with long-term follow-up</p>

### Incidence of atrial fibrillation and left ventricular dysfunction

TABLE 38 Research recommendation 3: incidence of AF and left ventricular dysfunction

Domain	Description
<b>Step 2: prioritise</b>	
Uncertainty identified	The incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following development of NOAF while in an ICU is unknown. However, readmission with heart failure and thromboembolism is increased over the 5 years following an episode of NOAF while in an ICU, particularly in the first year
Reason uncertain (conflicting or lack of evidence)?	Lack of evidence
<b>Step 3: two-component research recommendation</b>	
Structured statement	A prospective cohort study to demonstrate the incidence of AF and/or left ventricular dysfunction at hospital discharge and at 3 months following development of NOAF should be undertaken
Structured rationale	Readmission with heart failure and thromboembolism is increased over the 5 years following an episode of NOAF while in an ICU, particularly in the first year. Whether or not these events are driven by persistent left ventricular dysfunction and/or AF is unknown
PICOS	<p>Patients: patients who experience NOAF while in an ICU</p> <p>Intervention: AF detection and echocardiogram at/near hospital discharge and at 3 months</p> <p>Control: NA</p> <p>Outcomes: AF, left ventricular dysfunction, heart failure, thromboembolism, CHA<sub>2</sub>DS<sub>2</sub>-VASc and anticoagulation</p> <p>Study type: prospective cohort</p>
CHA <sub>2</sub> DS <sub>2</sub> -VASc, congestive heart failure, hypertension, age $\geq 75$ years, diabetes mellitus, stroke or transient ischaemic attack, vascular disease, age 65 to 74 years, sex category; NA, not applicable.	



EME  
HS&DR  
HTA  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***